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CHAPTER 1 
SYNTHESIS, DELIVERY AND REGULATION OF EUKARYOTIC HEME AND FE-S 
CLUSTER COFACTORS 
1.0 Prelude 
Iron plays an important role in all biological systems. Its utility in biology comes 
from its unique electrochemical characteristics that impart the ability of the biomolecule 
for which it binds to mediate complex chemical reactions required to sustain life. Iron 
participates in a myriad of indispensable reactions including oxidation-reduction, 
electron transfer, and substrate activation used in a variety of cellular processes 
including cellular respiration, metabolism, and photosynthesis. In humans, the majority 
of iron is incorporated into heme, but a minority gets stored bound either within the iron 
storage protein ferritin or incorporated into proteins either as metal alone or as a metal 
containing cofactor1. Among the several iron containing cofactors, Fe-S clusters are the 
second prominent class after heme and they can be found ubiquitously in all organisms. 
These inorganic cofactors exist in a number of different configurations but their main 
function is the transfer of electrons for redox reactions. When bound to proteins, the 
range of reduction potentials of Fe-S clusters is expanded and fine-tuned by solvent 
accessibility and by the amino acids in the vicinity of the cluster2,3. Hence Fe-S clusters 
associated with proteins can function as excellent electron carriers in almost all cellular 
processes. As a few examples, they are present in primary and secondary metabolic 
enzymes, some DNA repair enzymes, and iron regulatory proteins (IRPs)4. The list of 
Fe-S proteins is numerous and their function is a thesis by itself, so I will limit my 
description of Fe-S clusters in this chapter to their assembly and steps related to their 
utilization.  
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The remarkable and diverse electronic potentials of Fe-S clusters allow them to 
be exploited in many systems, and this makes their assembly indispensable for cell 
viability. This is best highlighted by the number of human diseases associated with 
defects in Fe-S cluster assembly proteins, disease states of which are outlined in detail 
below. Studying the characteristics of proteins involved in Fe-S cluster assembly has 
been a main focus of research within Stemmler lab. My research was centered on 
uncovering the structural and functional details of cysteine desulfurase, a protein that 
provides sulfur for the Fe-S cluster assembly within the mitochondria. My original project 
in this context proposed to individually characterize Isd11, the accessory protein 
associated with cysteine desulfurase enzyme Nfs1 in yeast mitochondria. But due to 
inherent insolubility of Isd11, an issue described in detail in chapter 4, continuation of 
that project was not feasible. Since then, my research focus deviated to study the 
characteristics of Nfs1-Isd11 as a complex and the effect of frataxin (a proposed iron 
delivery protein) on its function. Chapter 2 and 3 describes what I accomplished in those 
regards.  
This first chapter serves to deliver the required background information on the 
field and it highlights the main characters within the Fe-S cluster bioassembly pathway; 
essential for one to follow the details within the subsequent chapters. It discusses two 
major iron cofactor assembly pathways: heme and Fe-S cluster synthesis. This report 
has already been published as a review article which I was the primary author: 
“Barupala, D. P., Dzul, S. P., Riggs-Gelasco, P. J., & Stemmler, T. L. (2016). Synthesis, 
delivery and regulation of eukaryotic heme and Fe–S cluster cofactors. Archives of 
biochemistry and biophysics, 592, 60-75”. My role in writing this review included 
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organizing the entire content and submitting the article for review in addition to writing 
the text within the introduction and heme assembly sections. Although the discussion 
about heme cofactor assembly is far from my research interest, it is included here to 
emphasize the significant amount of time and effort spent to draft that section solely by 
myself.  
1.1 Abstract 
In humans, the bulk of iron in the body (over 75%) is directed towards heme- or 
Fe-S cluster cofactor synthesis, and the complex, highly regulated pathways in place to 
accomplish biosynthesis have evolved to safely assemble and load these cofactors into 
apoprotein partners. In eukaryotes, heme biosynthesis is both initiated and finalized 
within the mitochondria, while cellular Fe-S cluster assembly is controlled by correlated 
pathways both within the mitochondria and within the cytosol. Iron plays a vital role in a 
wide array of metabolic processes and defects in iron cofactor assembly leads to 
human diseases. This review describes progress towards our molecular-level 
understanding of cellular heme and Fe-S cluster biosynthesis, focusing on the 
regulation and mechanistic details that are essential for understanding human disorders 
related to the breakdown in these essential pathways. 
1.2 The role of iron in biology 
Iron’s abundance and unique chemical characteristics are often exploited by 
nature to drive the complex chemistry required by cells to maintain life. Iron is the fourth 
most abundant element on the earth’s crust5, so its high prevalence during early 
evolution is certainly a factor for its current ubiquitous presence in nature. The human 
body contains 3 to 4 grams of the metal and absorbs 1 to 2 mg of it each day6. The 
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reactivity and ability of the metal to cycle between the Fe(II), (III) and (IV) oxidation 
states makes it extremely useful for driving intricate reactions in biology that include 
substrate activation, electron transfer, and oxidation-reduction reactions. Because of 
this chemical versatility, iron plays a role in nearly every biological pathway. While its 
utility within biology is apparent, the Achilles heel of this essential metal is its tendency 
to precipitate in aqueous solutions7. Through coordination to biomolecules, however, 
the solubility of the metal can be controlled and its reactivity attenuated. At the 
elemental level, first coordination sphere ligands stabilize the solubility of the metal 
while at the same time tune its chemical properties for selective participation in only 
desired reactions 8. Ligand variability in this first coordination sphere helps control how 
the metal behaves, however at the cellular level a complex network of proteins, 
controlled at the genetic level, helps ensure metal availability to specific protein partners 
in the cell1.   
Pathways related to eukaryotic iron homeostasis are shown in Figure 1.19. Iron is 
brought into cells either via the transferrin Fe uptake pathway or through direct 
membrane transporter (ex. the DMT1 pathway)10. Once in the cell, imported iron can 
bind to iron regulatory proteins where it serves to control concentration, it can be stored 
within the ferritin complex, it can be exported, or it can be incorporated as cofactors into 
apoprotein partners. In humans, the bulk of iron in the body (over 75%) is directed 
towards heme-6 or Fe-S cluster cofactor11 biosynthesis. Assembly of the Fe-cofactors 
follows highly regulated pathways that have evolved to safely build and load these 
inorganic Fe-containing cofactors into the apoprotein partners while controlling metal 
reactivity. In eukaryotes, heme biosynthesis is initiated and completed within the 
 5	
mitochondria, while Fe-S cluster assembly is controlled by separate but correlated 
pathways within both the mitochondria and the cytosol. Iron plays a central role in a 
wide array of metabolic processes, so it is not surprising that defects in cofactor 
assembly leads to human diseases. This review details progress towards elucidating 
the molecular details of cellular heme and Fe-S cluster biosynthesis. A focus on both 
regulation and mechanism will be critical for understanding human disorders related to 
the breakdown in these essential pathways.  
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Figure 1.1: Major cellular Fe utilization pathways in humans. Under physiological 
conditions, most Fe is internalized as the Tf-bound form, which undergoes receptor-
mediated endocytosis via binding to TfR1. Decrease in endosomal pH releases Fe(III) 
from Tf, which is then reduced by the endosomal reductase STEAP3 to Fe(II). Fe(II) is 
then transported to the cytosol via DMT1 to join the LIP. Fe in LIP can be utilized for 
storage in ferritin, import to mitochondria for storage and heme and Fe-S cluster 
synthesis, export to the cytosol via ferroportin, cellular Fe regulation via IRPs and 
incorporation into other Fe proteins in the cytosol. Under non-physiological conditions 
Fe(III) can enter the cell after being reduced to Fe(II) and imported by DMT1. Tf: 
Transferrin, TfR1: Transferrin receptor 1, DCYTB: duodenal cytochrome b, DMT1: 
divalent metal transporter 1, STEAP3: six transmembrane epithelial antigen of the 
phosphate 3, LIP: labile iron pool, PCBP: poly (rC)-binding proteins, OMM: outer 
membrane of mitochondria, IMM: inner membrane of mitochondria, MFRN: Mitoferrins, 
FTMT: mitochondrial specific ferritin, ABCB7: transporter for unknown source of sulfur 
X-S from mitochondria to cytoplasm, IRP: iron regulatory proteins, IRE: iron-responsive 
elements of mRNA.  
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1.3 Heme cofactors 
1.3.1 Introduction 
Among the many metalloporphyrins found in nature, heme is one of the most 
abundant. It is utilized in many vital biological processes including photosynthesis, 
oxygen transport, biological oxidation and reduction, and many more. Most of the total 
iron content in human body is incorporated into heme-containing proteins such as 
hemoglobin, myoglobin, catalases, peroxidases, nitric oxide synthases, and 
cytochromes12. The unique structure of heme, which consists of the iron cation 
coordinated to four nitrogen atoms from a tetrapyrrole ring, allows for fine tuning of the 
metal’s reactivity to carry out the function of the biomolecule to which it is attached. 
Here we discuss the different heme types, their biosynthesis and regulation, their 
function in biology, and finally the diseases linked to a loss of heme function.  
1.3.2 Heme structure and types of heme in nature 
Modifications to the basic heme molecule allow for the diverse array of heme 
functions found in nature. The parent heme molecule, also known as heme b, 
protoheme IX or protoporphyrin IX, serves as the platform in each case. The 
tetrapyrrole unit of heme consists of four pyrrole units linked by four methine bridges. A 
nitrogen atom from each pyrrole coordinates the iron atom in the center of the planar 
tetrapyrrole ring. Distortions from planarity can be critical to heme function and reactivity 
(examples include hemoglobin13 and myeloperoxidase, MPO14). Fifth and sixth ligands 
to the Fe can be provided by amino acid side chains from the apoprotein or by small 
inorganic molecules coordinating above and below the plane of the ring. Eight positions 
in the tetrapyrrole carry side chain modifications, particularly methyl groups on carbons 
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2, 7, 12, and 18, vinyl groups on carbons 3 and 8, and propionyl groups on carbons 13 
and 17 (Figure 1.2). Substitutions to the same carbons with various other side chains 
create several biologically important heme types found in nature (Figure 1.3). Heme A, 
B, and C are found in a wide spectrum of organisms and take part in vital biochemical 
processes such as respiration, photosynthesis and oxygen transport. The additional 
cofactor types (Heme D, D1, I, M, and O) are species-specific and carry out highly 
specialized functions. Table 1 summarizes the structural features, occurrences, and 
known functions of each heme type. 
1.3.3 Heme biosynthesis pathway 
Since heme serves as an essential cofactor to several proteins involved in 
central metabolic processes, all organisms have established a conserved biosynthetic 
pathway to synthesize the cofactor. Atomic detail is available for many of the enzymes 
involved in bioassembly of heme, and these enzyme structures have provided key 
insights into reaction mechanisms. The general assembly process consists of four 
stages: the synthesis of a single pyrrole, the assembly of four pyrroles to make the 
tetrapyrrole ring, modification of the side chains, and the insertion of iron into the ring 
(Figure 1.4)15. Specific details for this conserved pathway are outlined below.  
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Figure 1.2: Structure of heme. Standard 1-24 IUPAC numbering system is used to 
number the carbon atoms of the tetrapyrrole16. 
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Figure 1.3: Important types of heme found in nature. Side chain differences with 
respect to the parent heme molecule (heme B) are shown in blue.  
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Table 1.1: Comparison of different heme types in nature. 
 
Type Structure Remarks Organisms Proteins Function Ref. 
Heme A C3= hydroxyethylfarnesyl 
group 
C18= formyl group  
Conversion of heme to heme 
A is catalyzed by Heme A 
synthase. 
Bacteria, archaea, plants 
and animals.  
Cytochrome a containing 
heme-Cu oxidases. 
E.g. Cytochrome c 
oxidase/Complex IV in 
mammalian mitochondria. 
Terminal reaction of aerobic 
respiration. Reduction of oxygen 
to water. 
17 
Heme B Parent heme molecule also 
known as protoheme IX, Fe-
protoporphyrin IX or heme.  
Binds to apoproteins non-
covalently. 
In a variety of organisms. Cytochromes b and 
hemoglobins.  
Diverse array of functions 
associated with heme b such as 
electron transport and oxygen 
carrier. 
 
Heme C C3 and C8= thioether bonds 
with cysteine residues. 
Binds to apoproteins 
covalently. 
In a variety of organisms. Cytochromes c 
E.g. bacterial alcohol 
dehydrogenase, bacterial caa3 
and cbb3 oxidases, 
mitochondrial and bacterial bc1 
complex, and cytochrome cd1 
nitrite reductase. 
Serve as electron carriers to 
perform single electron transfers 
in energy transduction processes 
such as photosynthesis, 
respiration and N and S cycles. 
Other functions include 
apoptosis, detoxification of ROS.  
18 
Heme D C12= hydroxylated, in a trans 
conformation to the γ-
spirolactone. 
C13= hydroxylated, propionyl 
group forms a γ-spirolactone 
with the hydroxyl group. 
In diverse bacteria including 
Azotobacter, Proteus, 
Acetobacter, Salmonella, 
Bacillus, Pseudomonas, 
Haemophilus and E. coli. 
Terminal respiratory oxidases. 
E.g. Cytochrome d oxidase. 
Terminal reaction of aerobic 
respiration. Reduction of oxygen 
to water at low oxygen levels. 
19-21 
Heme D1 C3 and C8= an acetyl group 
and a methyl group on each 
carbon. 
C2 and C7= keto groups on 
each carbon. 
C13 propionyl side chain has 
reduced to incorporate a vinyl 
group between second and 
third carbons. 
In Pseudomonas 
perfectomarinus, 
Alcaligenes faecalis, 
Paracoccus denitrificans, 
Thiobacillus denitrificans, 
and Thiosphaera 
pantotropa. 
Nitrite reductase that functions 
in dissimilatory nitrogen 
metabolism. 
E.g. Cytochrome cd1 nitrite 
reductase. 
Catalyzes the one-electron 
reduction of nitrite to nitric oxide 
and four-electron reduction of 
oxygen to water. 
22,23 
Heme I C2 and C12= hydroxymethyl 
groups, they form ester bonds 
with carboxyl side chains of 
amino acids. 
Binds to apoproteins 
covalently. 
In mammalian secretory 
fluids. 
Peroxidases such as bovine 
milk enzyme lactoperoxidase, 
eosinophil peroxidase and 
thyroid peroxidase 
Peroxide-driven oxidation of 
halide and pseudohalide ions as 
a nonspecific antimicrobial 
defense mechanism for the 
protection of mucosal surfaces.  
24 
Heme M C2 and C12= hydroxymethyl 
groups, they form ester bonds 
with carboxyl side chains of 
amino acids.  
C3= vinyl group on C3 forms a 
sulfonium ion linkage with the 
sulfur of a methionyl residue.  
In mammalian neutrophils Myeloperoxidase  Peroxide-driven oxidation of 
chloride and bromide ions as an 
antimicrobial defense 
mechanism. 
14,24 
Heme O C3= hydroxyethylfarnesyl 
group.  
Bacteria such as E. coli. Cytochrome o containing quinol 
oxidases. 
E.g. Cytochrome bo3 
Terminal reaction of aerobic 
respiration. Reduction of oxygen 
to water. 
25,26 
 12	
 
Figure 1.4: Heme biosynthesis pathway. ALA: 5-aminolevulinic acid, ALAS: ALA 
synthase, PBGS: porphobilinogen synthase, ALAD: ALA dehydratase, PBGD: 
porphobilinogen deaminase, UROS: uroporphyrinogen synthase, UROD: 
uroporphyrinogen decarboxylase, PBR: peripheral-type benzodiazepine receptor, CPO: 
coproporphyrinogen III oxidase, PPO: protoporphyrinogen IX oxidase, FC: 
Ferrochelatase, IMM: inner membrane of mitochondria, IMS: intermembrane space, 
OMM: outer membrane of mitochondria.  
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1.3.3.1 Important steps in heme biosynthesis 
The first step in eukaryotic heme biosynthesis is the mitochondrial formation of 5-
aminolevulinic acid (ALA), which is the precursor that serves as the only source of 
carbon and nitrogen atoms required to build the basic heme unit. Depending on 
species, one of two major pathways directs formation of this precursor leading to 
production of tetrapyrroles. In the Shemin pathway, the enzyme ALA synthase (ALAS) 
that resides on the matrix side of the mitochondrial inner membrane catalyzes the 
condensation of glycine and succinyl-CoA27-30. ALAS is found in animals, fungi, non-
photosynthetic eukaryotes, and α-proteobacteria (organisms that resemble bacterial 
ancestors of mitochondria). Mammals have two ALAS isoforms; the first isoform 
(ALAS1) provides housekeeping functions and a second erythroid specific isoform 
(ALAS2) provides for the more robust heme requirements in erythrocytes31. Both forms 
of ALAS are homodimers and require pyridoxal 5’-phosphate (PLP) bound as a Schiff 
base covalent adduct to a catalytic lysine. During the joining of glycine and succinyl CoA 
on the PLP scaffold, both CO2 and Coenzyme A are released as byproducts32. Upon 
formation, ALA exits the mitochondria to serve as the substrate for the subsequent four-
enzymatic conversions that occur in the cytosol. Little is known about the specifics of 
export, but it has been suggested that SLC25A38, a member of the SLC25 family of 
transporters of the mitochondrial inner membrane, facilitates import of glycine into the 
mitochondria in exchange for ALA transfer across the mitochondrial inner membrane33.  
In the second major pathway for ALA synthesis, also known as the C5 pathway, 
glutamyl-tRNA reductase (GluTR) converts glutamyl-tRNA to glutamate-1-semialdehyde 
(GSA) in the first of the two-step ALA production pathway34. The second step involves 
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the conversion of GSA to ALA by the enzyme glutamate-1-semialdehyde-2, 1-amino 
mutase (GSAM)35-37. This second major pathway is found in plants, archaea and most 
bacteria. 
Once exported to the cytosol, ALA serves as the building block to synthesize 
uroporphyrinogen III following three consecutive steps. The first step involves 
condensation of two ALA molecules to form porphobilinogen (PBG) by porphobilinogen 
synthase (PBGS), also known as ALA dehydratase (ALAD)38,39. PBGS is a 
homooctamer in which each dimer contains one catalytic site40. Each active site binds 
an ALA molecule at two distinct sites and each subunit binds one zinc atom41. Of the 
eight Zn atoms on PBGS, four zinc atoms stabilize the enzyme structure while the other 
four engage in catalytic activity42,43. Four molecules of porphobilinogen undergo 
polymerization to form 1-hydroxymethylbilane in a reaction catalyzed by 
porphobilinogen deaminase (PBGD). PBGD uses a covalently attached dipyrromethane 
cofactor (made of two linked PBG molecules) to prime the polymerization of four PBG 
molecules. Six PBG molecules form a linear hexapyrrole covalently bound to PBGD, 
which is then cleaved to yield 1-hydroxymethylbilane and the protein bound cofactor44. 
This unstable tetrapyrrole serves as the substrate for uroporphyrinogen synthase 
(UROS), the enzyme that synthesizes uroporphyrinogen III. UROS functions as a 
monomer and completes ring inversion and the subsequent closure of the tetrapyrrole, 
yielding uroporphyrinogen III45,46. Spontaneous ring closure is also possible, but the 
resulting product uroporphyrinogen I cannot be converted to heme. Uroporphyrinogen III 
also serves as the branching point for the synthesis of chlorophylls and corrins. In heme 
biosynthesis, this cyclic intermediate is converted to coproporphyrinogen III, a product 
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that lacks four acetic side chains. Subsequent decarboxylation steps are carried out by 
uroporphyrinogen decarboxylase (UROD) within the cytosol to yield four methyl groups 
in place of the acetic side chains47. UROD is a homodimer with each subunit carrying an 
active site cleft that faces the other in the dimer interface48. 
Three enzymes associated with the mitochondrial inner membrane complete the 
terminal steps in the eukaryotic heme biosynthesis. Their arrangement suggests they 
act as a multiprotein complex that facilitates substrate channeling49. 
Coproporphyrinogen III entry into the mitochondria is likely mediated by the peripheral-
type benzodiazepine receptor (PBR), located on the mitochondrial outer membrane50. In 
the first of the three terminal steps, coproporphyrinogen III undergoes oxidative 
decarboxylation of its propionyl side chains on two pyrrole rings to form 
protoporphyrinogen IX. This reaction is completed in higher eukaryotes and in a few 
bacterial species by the oxygen-dependent coproporphyrinogen III oxidase (CPO), an 
enzyme located in mitochondrial intermembrane space51. CPO requires molecular 
oxygen as the terminal electron acceptor52.  
In the next step, protoporphyrinogen IX is oxidized to protoporphyrin IX, following 
the removal of six hydrogen atoms from the porphyrinogen ring, to provide an 
alternating double bond structure to the macrocycle; this reaction is catalyzed by 
protoporphyrinogen IX oxidase (PPO)53. In eukaryotes, the oxygen-dependent PPO is a 
homodimer that utilizes molecular oxygen as the terminal electron acceptor and 
functions as an integral membrane protein located in the mitochondrial inner 
membrane54. The active site of the protein faces the intermembrane space and uses a 
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FAD cofactor for electron transfer. The complete reaction uses three O2 molecules that 
are reduced to three H2O2 molecules.  
Ferrochelatase (FC) is responsible for the insertion of ferrous iron into 
protoporphyrin IX to form Fe-protoporphyrin IX or heme, in the next step of heme 
biosynthesis. FC is a mitochondrial inner membrane protein with its catalytic site located 
on the mitochondrial matrix side. Channeling of protoporphyrin IX from PPO to FC may 
occur via direct interaction between the two proteins that allows efficient substrate 
transfer54. FC functions as a homodimer and each monomer contains a 2Fe-2S cluster 
whose function is unknown55,56. The reaction mechanism involves distortion of the 
planar porphyrin molecule into a saddle conformation to facilitate the insertion of ferrous 
iron57. Once synthesized, heme can undergo side chain modifications (e.g. heme A and 
heme O synthesis) or covalent attachments (e.g. heme C in cytochrome c biogenesis) 
to produce additional heme types depending on cellular needs. 
1.3.3.2  Regulation of heme biosynthesis 
In humans, heme is synthesized at two locations, in erythroid progenitors within 
bone marrow to provide for developing red cells, and in the liver to provide for numerous 
heme-containing enzymes. Liver responds to various metabolic states in the body, 
hence heme synthesis in liver is regulated accordingly. Erythroid progenitors on the 
other hand maintain heme production at a steady pace to meet the demand of red blood 
cells. Mechanisms for regulation of heme synthesis in these two origins therefore differ.  
The first step, catalyzed by two different isoforms of ALAS in liver (ALAS1) and 
bone marrow (ALAS2), is the rate-limiting step of heme synthesis. Both isoforms are 
post-transcriptionally regulated by two different mechanisms. Heme has a negative 
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feedback effect on ALAS1 transcripts and two alternate splice forms of ALAS1 facilitate 
this regulatory mechanism. One splice form is subjected to heme-mediated decay58-60 
but the other is resistant to this effect and requires translation in order to be regulated 
by heme-mediated decay61,62. Heme itself blocks translocation of a precursor form of 
ALAS1 from cytoplasm to mitochondria contributing to its downregulation63. 
Transcription of ALAS1 is upregulated by the peroxisome proliferator activated 
coactivator 1α (PGC-1α) in correlation to cellular glucose levels64. In contrast, erythroid-
specific transcriptional factors such as GATA1 regulate ALAS2 transcription by binding 
to the promoter region65. In translational regulation of ALAS2, iron responsive elements 
(IRE) in ALAS2 transcripts can bind iron regulatory proteins (IRP). This prevents ALAS2 
mRNA translation, allowing heme synthesis in differentiating red cells to be regulated in 
relation to cellular iron availability and mitochondrial function66,67. 
In addition, three enzymes within the heme biosynthesis pathway (PBGS, PBGD, 
and UROS) are transcriptionally regulated, yet they utilize a dual promoter system that 
allows erythroid specific or non-erythroid specific regulation of a single gene. Alternative 
splicing of exons creates two different PBGS transcripts, either with a housekeeping 
promoter or with an erythroid–specific promoter that binds erythroid-specific 
transcription factors including GATA168. Both PBGS transcripts encode identical 
proteins because they share the same translational start site despite their difference in 
lengths. On the contrary, alternative splicing of transcripts of the PBGD gene produces 
proteins of different lengths69,70. Erythroid-specific promoters of PBGD contain several 
specific cis-acting sequences (including GATA1, NF-E2 and CACCC motifs) that are not 
seen in the housekeeping promoter71. Similarly, alternative splicing of UROS gene 
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creates two transcripts. Erythroid-specific promoters of UROS contain eight GATA 
binding sites while the non-erythroid promoter contains NF1, AP1, Oct1, Sp1 and NRF2 
binding sites. Both transcripts produce identical proteins72. The remaining enzymes 
within the pathway have single promoters; regardless, they exhibit erythroid and non-
erythroid expression differences. The UROD gene carries a promoter of non-erythroid 
origin but UROD levels in erythroid tissue are significantly elevated compared to 
ubiquitous tissue and the specific mechanism resulting in this upregulation has yet to be 
determined73. The human CPO gene contains a single active promoter with six Sp1 
sites, four GATA binding sites and a novel regulatory element named CPRE that aids in 
the elevated expression in erythroid tissue74. The PPO gene contains a GATA1 binding 
site in its single promoter, suggesting potential erythroid-specific regulation50. Cis-
elements like NF-E2, GATA1 and the Sp1 binding sites are present in the human FC 
gene promoter and they have been found to induce FC expression during erythroid 
differentiation while the GC box maintains housekeeping expression of the gene75. 
Expression of ferrochelatase is also regulated by iron availability of the cells, related to 
the Fe-S cluster of FC 76. 
It is evident that the heme biogenesis enzymes in the erythroid pathway are 
transcriptionally induced by erythroid-specific transcription factors in coordination with 
iron uptake. Liver on the other hand maintains sufficient heme levels by combining 
synthesis and degradation in response to changes in cellular heme pools. Both systems 
are important however for maintaining cellular iron homeostasis and they are therefore 
areas of interest for understanding heme related diseases. 
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1.3.4 Incorporation of heme into apoprotein recipients 
Although diverse in their function, heme-containing proteins share a structurally 
conserved element, the heme cofactor. Primary factors contributing to the functional 
diversity of heme proteins are the protein ligands coordinating Fe in the proximal/distal 
positions and the covalent linkage of the heme to the biomolecule. Insertion and 
stabilization of the heme unit within a heme containing protein has been studied 
extensively within cytochrome c. Heme C forms two thioether bonds between C3 and 
C8 vinyl groups of heme and the cysteine residues of CXXCH motifs in the 
apocytochrome c. Three systems driving this association have been studied extensively 
(reviewed in77,78). System I/CCM (Cytochrome C Maturation) is most prevalent in α and 
γ proteobacteria, all plant mitochondria, some protozoal mitochondria and red algae, 
and typically involves nine assembly proteins including CcmA through CcmH79. 
Although system II/CCS (Cytochrome C Synthesis) was originally studied in green algae 
Chlamydomonas reinhardtii, it can also be found in chloroplasts, most Gram-positive 
bacteria, cyanobacteria and some β, δ, and ε proteobacteria. Several of the 
components in system II vary in different organisms but the major components include 
CcsA, CcsB and CcsX. System III/CCHL (Cytochrome C Heme Lyase) is mostly 
restricted to fungal, vertebrate and invertebrate mitochondria and some protozoal 
mitochondria. This system employs a cytochrome c heme lyase enzyme, which is now 
known as holocytochrome c synthase (HCCS)80 to convert apocytochrome c to 
holocytochrome c. These three systems carry out a similar function: to keep both Fe in 
heme and sulfur in cysteine residues of the apoproteins in the reduced state to facilitate 
correct covalent attachment. Mechanisms of incorporation of additional heme types into 
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different heme binding proteins can be quite diverse and species specific: hence their 
discussion was eliminated from this review but is discussed in additional sources81-84. 
1.3.5 Heme function 
Heme proteins are ubiquitous in nature and perform a wide variety of functions. 
One abundant class of heme proteins is the photosynthetic and respiratory 
cytochromes. Other classes include globins, catalases, peroxidases, cytochrome 
P450s, oxygenases and others. Here we discuss the versatile chemistry of the heme 
unit in several categories of heme proteins. 
Peroxidases use H2O2 to oxidize substrates without oxygen transfer. Their 
catalytic cycle includes three steps: 1) H2O2 oxidizes Fe3+ and porphyrin to generate a 
porphyrin π cation radical with water as a product; 2) oxidation of substrate reduces the 
porphyrin π cation radical; and 3) a second substrate reduces Fe4+ to Fe3+ 85. Examples 
from mammalian peroxidases include myeloperoxidase (MPO), eosinophil peroxidase 
(EPO), and lactoperoxidase (LPO)86, and these enzymes can oxidize a wide variety of 
substrates due to their high reduction potentials. The covalent vinyl sulfonium heme 
linkage in heme M of MPO enables heme distortion and the resulting reduction in 
electron density in the heme best explains the unusually high reduction potential of 
MPO87. These peroxidases are capable of generating oxidants such as hypohalous 
acids, hypothiocyanous acid, reactive nitrogen species, singlet oxygen, phenoxyl and 
hydroxyl radicals, all which are key components in antimicrobial properties exerted by 
the immune system86. 
Cytochromes P450 represent another subgroup of heme proteins in high 
abundance in nature; humans alone carry more than fifty P450 enzymes. These 
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enzymes are mostly known for xenobiotics detoxification in liver, where drugs and other 
xenobiotics are hydroxylated and made more soluble, facilitating their conversion to 
easily eliminated products. In addition, P450s also participate in the biosynthesis of 
steroids, highlighting their importance in metabolism. 
Additional noteworthy heme enzymes include nitric oxide synthase (NOS) and 
heme oxygenase (HO). NOS catalyzes the oxidation of L-arginine to L-citrulline and 
nitric oxide (NO), a signaling molecule important for regulation of the cardiovascular and 
nervous systems as well as participating in immune response. Heme oxygenase is 
responsible for the degradation of free heme, resulting in its efficient elimination and the 
recycling of iron85. The complete list of heme proteins is extensive and exceeds the 
limits of this review. Instead, we will focus on human disorders that result from loss of 
heme protein function, many of which are severe, and merit detailed discussion.  
1.3.6 Diseases of heme synthesis 
Several human diseases are associated with disruption of the heme biosynthetic 
pathway. Many of these diseases are associated with inherited mutations in heme 
biosynthesis genes, however some are caused by environmental factors affecting their 
enzyme products. Along with nine major porphyrias, we will focus on diseases 
associated with disruption of the heme biosynthesis pathway. 
1.3.6.1 Porphyrias 
The clinical presentation of porphyria includes skin lesions and acute 
neurovisceral attacks which are related to the accumulation of specific intermediates in 
the heme biosynthetic pathway. Nine such diseases have been identified and they are 
categorized as hepatic or erythropoietic, pertaining to the organ in which the 
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intermediates accumulate. However, a more clinical classification of porphyria divides 
these into three groups: acute, cutaneous and rare recessive.  
Even though no disease causing mutations for ALAS1 has ever been found in 
humans, many mutations affecting the function of the ALAS2 isoform have been 
identified. Although not commonly seen as loss of function mutations in the heme 
biosynthesis pathway, gain of function deletions in ALAS2 are found to be causative of 
a cutaneous porphyria called X-linked dominant erythropoietic protoporphyria (XLDPP). 
This disease is characterized by increased ALAS2 activity and excessive protoporphyrin 
production. ALA production is increased such that the final step catalyzed by 
ferrochelatase is rate-limiting, resulting in the accumulation of protoporphyrin. Liver 
damage and photosensitivity are the clinical manifestations of this disease88.  
Deficiency of ALAD causes a rare recessive porphyria named ALAD porphyria, 
for which only less than ten cases have been reported. In this autosomal disorder, loss 
of ALAD activity in liver and erythroid precursors leads to excretion of ALA and 
coproporphyrinogen III into the urine. Patients suffer from intermittent acute 
neurovisceral attacks and/or chronic neuropathy, and onset of this disorder ranges from 
childhood to adulthood89.  
An additional disease related to the first steps in heme biosynthesis is acute 
intermittent porphyria (AIP). As in all acute porphyrias, acute life-threatening 
complications occur mostly in the adulthood, however in rare cases severe attacks can 
occur in the childhood. Urinary excretion of ALA and porphobilinogen is increased due 
to decreased PBGD activity. Activity loss is caused by mutations in the PBGD gene and 
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over 200 mutations have been identified. This disorder is seen in homozygous 
dominants for the trait and a majority of heterozygotes remain disease-free90. 
Congenital erythropoietic porphyria (CEP) is another rare recessive type of 
porphyria caused by the deficiency of UROS. This autosomal recessive disease that is 
a result of loss of UROS function leads to the spontaneous formation of 
uroporphyrinogen I, the isomer of uroporphyrinogen III that cannot be converted to 
heme, so it is accumulated and excreted91. Clinical features of this disease include 
chronic hemolysis and cutaneous photosensitivity caused by diffusion of 
uroporphyrinogen I to plasma, and these conditions begin to manifest in early infancy. 
There have been over twenty UROS mutations that cause this disease identified to 
date92. 
Porphyria cutanea tarda (PCT) is the most common porphyria and it falls under 
the category of cutaneous porphyrias. This disease only shows symptoms in the skin, 
including lesions in areas exposed to sun, skin fragility leading to secondary infections, 
and hypertrichosis. Ocular pain and photophobia have also been reported rarely93. The 
cause of these symptoms is accumulation of excessive porphyrin in the skin. 
Tetrapyrroles are highly photoreactive and hence they absorb energy from the visible 
region of electromagnetic spectrum. Excited ring structures reach ground state by 
transferring energy, which drives peroxidation and oxidation of biological 
macromolecules such as membrane lipids, nucleic acids and proteins. Familial PCT, 
one of the two forms of PCT, is an autosomal dominant trait similar to AIP in that only a 
minority of heterozygotes is affected. In familial PCT, uroporphyrinogen III is 
accumulated and excreted in urine due to UROD mutations. Patients with sporadic 
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PCT, although not associated with UROD mutations, show decreased UROD activity 
and hepatic Fe overload, similar to that seen in familial PCT94. Hepatoerythropoietic 
porphyria (HEP) is a rare porphyria associated with UROD deficiency. Symptoms are 
similar to that seen in PCT (skin lesions, red urine, hypertrichosis and scarring) however 
they can be much more severe. This rare recessive porphyria often onsets in infancy or 
childhood and shows high porphyrin concentrations in erythrocytes and less than 10% 
UROD activity95. 
Hereditary coproporphyria (HCP), another acute porphyria, is caused by 
mutations that destabilize the enzyme CPO. Clinical characteristics are very similar to 
other acute porphyrias (i.e., AIP) and show a high coproporphyrinogen III content in 
urine and feces, as well as increased photosensitivity. Also similar to other acute 
porphyrias, HCP is mostly seen in dominant homozygotes for the trait, with only some 
heterozygotes developing the disease96.  
An additional porphyria caused by mutations in a heme biosynthesis enzyme 
includes variegate porphyria (VP), characterized by dysfunctional PPO. Symptoms are 
again very similar to any acute porphyria, showing acute neurovisceral attacks and 
cutaneous photosensitivity. Onset of the symptoms is in adulthood and over 100 PPO 
gene mutations (including nonsense, missense, deletion, insertion and splice mutations) 
have been identified97. As in AIP, urinary excretion of ALA and porphobilinogen and 
fecal content of protoporphyrinogen IX and coproporphyrinogen III is increased during 
acute attacks. In addition, PPO activity is dramatically reduced (50%) in tissues of VP 
patients98.  
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The last of the nine porphyrias associated with heme synthesis is another 
cutaneous porphyria named erythropoietic protoporphyria (EPP). Mutations in the 
ferrochelatase gene cause a deficiency in mitochondria leading to accumulation of free 
protoporphyrin IX, primarily in erythrocytes. Excess protoporphyrin IX is behind the 
predominant clinical feature of photosensitivity, which begins in childhood99,100.  
1.3.6.2 Additional diseases 
Loss of function mutations of ALAS2 is the cause of the disorder X-linked 
sideroblastic anemia (XLSA). A group of point mutations alter the protein’s ability to bind 
the PLP cofactor, however other mutations affect protein domains outside the cofactor-
binding region. The decrease in heme synthesis efficiency prevents normal erythroblast 
development in the bone marrow. The resulting overload of iron results in characteristic 
iron granules surrounding the nucleus (a sideroblast). This disease is characterized by 
microcytic hyperchromic anemia, the presence of mature but pale and smaller than 
normal erythrocytes and Fe overloaded mitochondria in erythroblasts in the bone 
marrow101.   
ALAD requires Zn for function, and Zn deficiency makes ALAD susceptible to Pb 
inhibition. Pb replaces Zn in ALAD and the inhibited protein leads to high levels of ALA 
in blood, which is responsible for neurological manifestations due to its toxicity at high 
concentrations102. A similar disease, named hepatorenal tyrosinemia, shows 
neurotoxicity due to high ALA levels, with abnormal liver and kidney function. This 
disease is caused by mutations in fumarylacetoacetate hydrolase gene, which 
hydrolyzes fumarylacetoacetate to fumarate and acetoacetate during the tyrosine 
catabolism pathway. In the event of enzyme deficiency, fumarylacetoacetate is 
 26	
metabolized to succinylacetone, which is structurally similar to ALA, hence it acts as a 
potent inhibitor for ALAD103. Excess ALA and succinylacetone can be seen in patients’ 
urine and blood samples. 
1.4 Fe-S clusters 
1.4.1 Introduction 
Iron-sulfur (Fe-S) clusters are the second major form of complex iron cofactors 
found in biology. Due to the high abundance of iron and sulfur on the earth’s surface, 
and the easy association of these atoms under anaerobic conditions, Fe-S clusters 
likely developed early in evolution before the earth’s transition to an aerobic 
atmosphere. Consequently, these cofactors are ubiquitous in all organisms and play a 
role in almost every biological pathway. Here we provide an overview of the structure, 
formation, and function of Fe-S cluster cofactors.  
1.4.2 Fe-S cluster structure 
In many ways, Fe-S clusters are simpler than heme. While heme is a mixture of 
organic (protoporphyrin) and inorganic (iron) components, Fe-S clusters are strictly 
inorganic. Iron atoms in biological Fe-S clusters interact directly with protein residues 
and sulfur atoms bridge neighboring iron atoms. Fe-S clusters exist in a variety of 
configurations depending on their respective number of iron and sulfur atoms. The three 
most common forms (2Fe-2S, 3Fe-4S and 4Fe-4S) are illustrated in Figure 1.5. More 
complex Fe-S clusters have also been observed, including the 7Fe-8S and 8Fe-8S 
clusters identified in ferredoxins from Desulfovibrio africanus104. 
The Fe atoms within the Fe-S cluster can exist in either ferric or ferrous forms 
and cycling between these redox states allows the transfer of electrons for redox 
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reactions. The tendency of the oxidized Fe-S cluster to gain an electron is termed the 
“reduction potential”. By convention, this potential is expressed in comparison to a 
reference standard hydrogen electrode, which is assigned a potential of 0V. Depending 
on Fe-S cluster type, interactions with neighboring amino acids, and solvent 
accessibility, a single Fe-S cluster can take up to two electrons with a reduction 
potential spanning ~1000 mV105. This remarkable range of accessible reduction 
potentials can largely explain the biological utility of the Fe-S cluster.  
Fe-S clusters do not exist freely but are intimately connected to their apoprotein 
partner. Free iron will form an insoluble complex when bound to sulfide, so the protein 
plays a critical role in solubilizing the Fe-S unit. Fe-S proteins usually bind their 
corresponding Fe-S cofactor via ionic interactions between cysteine thiols and iron in 
the Fe-S cofactor. In some cases, Fe-S clusters are alternatively ligated via histidine 
residues. Subsets of 2Fe2S clusters, such as those found in Rieske proteins (see 
section 1.4.5), are coordinated by two cysteine and two histidines (Cys2His2)106 and a 
common coordination theme of proteins involved in Fe-S cluster biogenesis is Cys3His1 
coordination107.  
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Figure 1.5: Structure for the 3 most common forms of Fe-S Cluster: 2Fe-2S, 3Fe-
4S, and 4Fe-4S.	  
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1.4.3 General Fe-S cluster biogenesis pathway 
Production of Fe-S clusters must be highly regulated to prevent unwanted 
reactions of both free iron and sulfur. Similar to heme-proteins, Fe-S proteins are 
synthesized in their apo-state and obtain their Fe-S cluster cofactor from a dedicated 
Fe-S cluster formation pathway. At present, there are three known general pathways for 
Fe-S cluster formation: the iron sulfur cluster (ISC), cytosolic iron sulfur assembly (CIA), 
and sulfur assimilation (SUF) pathways. These three pathways provide Fe-S clusters for 
the majority of Fe-S proteins in almost all organisms. While dedicated Fe-S cluster 
forming pathways can exist for individual Fe-S proteins, such as the nitrogen fixation 
(Nif) pathway that provides an Fe-S cluster for the nitrogenase enzyme in nitrogen-fixing 
bacteria108, this review will focus only on the general Fe-S cluster production pathways. 
1.4.3.1 Iron sulfur cluster (ISC) pathway 
The most robust and best-characterized pathway for Fe-S cluster biosynthesis is 
the iron sulfur cluster (ISC) pathway. A simplified description of this pathway is provided 
in Figure 1.6. The ISC pathway, present in bacteria and in the mitochondria of 
eukaryotes, provides general housekeeping Fe-S clusters to a large number of Fe-S 
proteins. In eukaryotes, this pathway provides Fe-S clusters for several key 
mitochondrial Fe-S proteins. ISC was initially identified in the Azotobacter vinelandii and 
Escherichia coli bacterial species, where ISC genes are arranged in the isc operon. 
Additional early work in eukaryotes (in Saccharomyces cerevisiae and human proteins) 
revealed a highly homologous system localized to the mitochondria. In addition to 
providing for mitochondrial Fe-S proteins, the ISC system provides a component to the 
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cytosolic and nuclear Fe-S cluster formation pathways, thus ISC is essential for the 
maturation of all cellular Fe-S proteins in eukaryotes109,110.  
ISC serves as a template for understanding general Fe-S cluster production. In 
human ISC, de novo 2Fe-2S synthesis occurs on the dedicated scaffold protein 
ISCU111. Sulfur for this reaction is provided by ISC’s dedicated cysteine desulfurase 
enzyme ISCS via a persulfide intermediate that gets transferred to ISCU112 upon 
formation of an ISCU-ISCS complex. In eukaryotes, ISCS has a dedicated protein co-
factor ISD11 that is essential for ISCS function113. Electrons for ISCS persulfide release 
are provided by the 2Fe-2S cluster containing ferredoxin FDX, which in turn gets 
reduced by the ferredoxin reductase FDXR that uses NADPH as its final electron 
source114,115. FDX also interacts with ISCU, providing 2 reducing equivalents for 
assimilation of two 2Fe-2S clusters on an ISCU dimer to form a single 4Fe-4S cluster111. 
An additional Fe-binding protein Frataxin interacts with the ISCS-ISCU complex and 
regulates ISCS activity116. Additionally, there are alternate scaffold proteins (ISCA117 
and NFU1118) that interact with ISC proteins and these are believed to be required for 
the maturation of a specific subset of Fe-S proteins.  
Despite intense study, the physiologic source of iron for ISC remains a subject of 
debate. Several potential iron donors have been investigated and iron delivery to ISCU 
has been demonstrated from several potential sources in vitro within a variety of 
systems. The protein frataxin119,120 interacts with the ISCU-ISCS complex and could be 
the source of iron for the pathway120. In the bacterial system, two additional members of 
the isc operon have been investigated as potential iron donors, IscX and IscA. The 
small acidic protein IscX binds iron and regulates cysteine desulfurase activity in a 
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manner very similar to Frataxin121. The alternative scaffold IscA is also an interesting 
candidate because of its tight (KD~1019) binding affinity for mononuclear iron122 and its 
capability of delivering iron to IscU123,124. An additional interesting hypothesis is that iron 
may come from a glutathione-glutaredoxin complex125. The lack of conclusive evidence 
for a specific iron source suggests that in vivo, there could be multiple iron sources or 
that the mode of iron delivery may be atypical.  
A detailed mechanism for Fe-S cluster delivery from ISCU to downstream targets 
is currently under investigation. The Fe-S cluster bound to ISCU is transferred to the 
glutaredoxin GLRX5126,127. Efficient transfer from ISCU to GLRX5 requires involvement 
of the ATPase SSQ1, which binds to both ISCU and GLRX5128. Binding of SSQ1 to 
ISCU, along with the interaction of a DnaJ-like co-chaperone JAC1129, destabilizes the 
Fe-S cluster on ISCU facilitating its transfer from ISCU to GLRX5130. GLRX5 is 
considered the end of the ISC pathway because it is the last common Fe-S cluster 
carrier for all mitochondrial Fe-S proteins. GLRX5 continues the cluster transfer 
process, however, and it is able to interact with a variety of downstream Fe-S 
proteins131-133. The specific recipient depends on the ultimate destination of the Fe-S 
cluster. For example, 4Fe-4S cluster conversion and delivery is facilitated by GLRX5’s 
interaction with two other Fe-S proteins, ISCA and IBA57134. 
Despite being mostly localized to mitochondria135, ISC is required for maturation 
of all cellular Fe-S proteins110. The mechanism by which cytosolic Fe-S proteins depend 
on mitochondrial ISC is actively being investigated. Because Fe-S clusters are not able 
to cross the mitochondrial inner membrane136, this mechanism likely involves the 
transport of an Fe-S cluster precursor out of the mitochondria and into the cytosol. 
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Recent work has identified an unknown compound produced by mitochondrial ISCS 
(named ‘X-S’) that may provide reduced sulfur for cytosolic Fe-S cluster formation137.  
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Figure 1.6: Diagram depicting de novo Fe-S cluster formation and the main Fe-S 
cluster transfer steps in the ISC, SUF, and CIA systems. Protein names used are 
from the human system for ISC and CIA, and from the bacterial system for SUF. 
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1.4.3.2 Cytosolic iron sulfur assembly (CIA) pathway 
Recent studies have revealed the involvement of another essential and highly 
conserved Fe-S biosynthetic pathway that is present within the cytosol and nucleus of 
eukaryotes. This pathway is called cytosolic iron-sulfur assembly (CIA)138. This pathway 
has been identified in many eukaryotic systems and is essential in almost all cases139. 
CIA is unique among Fe-S maturation pathways in that it does not obtain reduced sulfur 
via a dedicated cysteine desulfurase. A simplified description of the CIA pathway is 
provided in Figure 1.6. Instead of an ISCS analog, CIA relies on mitochondrial export of 
a sulfur-containing compound, ‘X-S’, via the mitochondrial export protein ABCB7140 and 
the intermembrane space protein ALR141. The identity of X-S is currently unknown, but 
may be glutathione-complexed to an Fe-S cluster139. In human CIA, the primary scaffold 
for de novo Fe-S assembly is a tetrameric complex formed between CFD1 and NBP35, 
which binds a bridging 4Fe-4S cluster between the CFD1 and NBP35 subunits142. 
Reducing equivalents for this reaction are provided by an Fe-S containing protein 
CIAPIN1 (similar to FDX in ISC), which in turn gets reduced by the diflavin reductase 
NDOR1 (similar to FDXR in ISC), utilizing reducing equivalents from NADPH143,144.  
The 4Fe-4S clusters from the NBP35-CFD1 complex get transferred to another 
Fe-S protein IOP1, which binds two 4Fe-4S clusters per monomer145,146. IOP1, in turn, 
delivers its Fe-S clusters to a multi-component complex called the CIA targeting 
complex, which consists of at least three proteins CIA1, CIA2B, and MMS19147. The CIA 
targeting complex is able to interact with a variety of recipient Fe-S proteins, likely an 
indication of its function in downstream Fe-S cluster delivery. 
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1.4.3.3 Sulfur assimilation (SUF) pathway 
Of the three Fe-S general cluster formation pathways, the sulfur assimilation 
(SUF) pathway is probably the most ancient. SUF predominantly exists in prokaryotes, 
however it is found in specific locations in eukarya, including the chloroplasts in some 
plants148 and the apicoplasts in some plasmodium species149, and recently proteins 
homologous to bacterial SUF were discovered in the cytosol of a blastocystis 
species150. At present, SUF has been best characterized in the Gram-negative bacteria 
Escherichia coli and Erwynia chrysanthemi where its genes are organized into the suf 
operon (Figure 1.7). 
The SUF pathway is similar to ISC in many ways. Like in ISC, SUF provides 
general Fe-S cluster formation to accommodate a variety of Fe-S proteins. In fact, SUF 
and ISC seem to be redundant in Gram-negative bacteria, as the removal of the entire 
isc or suf operon results in no deleterious effects. Simultaneous suf/isc operon deletion, 
however, is lethal151. While ISC and SUF follow the same general mechanism for Fe-S 
cluster formation (Figure 1.6), SUF seems to be favored under conditions of oxidative 
stress and iron limitation152 and the SUF proteins are correspondingly more stable 
under adverse conditions in vitro153. In E. coli, the SUF pathway centers around two 
heteromeric complexes called SufBC and SufSE. 
The primary scaffold SufB requires a binding partner SufC for activity, forming 
the SufBC complex in a SufB2C2 arrangement. The SufBC complex can form a 4Fe-4S 
cluster on SufB that can be transferred to recipient proteins154. The exact role of SufC in 
this process is unknown, but it has ATPase activity that is essential for Fe-S cluster 
formation on SufB155. SufB, on its own is relatively unstable and prone to spontaneous 
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oligomerization. There is also a paralogue of SufB, named SufD that is able to replace a 
SufB in the SufBC complex, resulting in the SufBCD complex156. However, SufBC is 
likely the most active form157. The SUF cysteine desulfurase SufS functions in a similar 
manner to ISCS, accepting sulfur from cysteine via a persulfide intermediate. SufS has 
an essential binding partner SufE, which is required for activity, forming the SufSE 
complex158. While it may seem SufE is similar to ISD11 from eukaryotic ISC, SufE 
functions differently from ISD11 in that it accepts the persulfide from SufS and allows 
the SufS enzyme to complete its turnover159. 
Details of SUF’s downstream cluster delivery are not as well established as in the 
ISC pathway. The 4Fe-4S cluster formed by SufBC can be transferred to the A-type 
carrier protein SufA in vitro154,157, but SufBC also may be able to transfer directly to 
recipient apo-proteins. In vivo, SufA is functionally redundant with the ISCA bacterial 
homologue160 and possibly acts as an intermediate carrier of the 4Fe-4S cluster from 
SufB, passing it off to downstream apoproteins161,162. Another protein involved in this 
process (ErpA) has redundant function with SufA but is necessary for the development 
of active Fe-S proteins163.  
Several important details of the SUF pathway remain to be identified. As in ISC, 
the in vivo source of iron is unknown. Also of interest is SufD’s incorporation in the 
SufBCD complex, which allows SufB to accept iron in vivo155 and facilitates binding of a 
FADH2 cofactor156. This cofactor may be able to reduce ferric iron, facilitating potential 
Fe3+ sources such as ferritins or ferric citrate164. While SufA can deliver mononuclear 
iron to SufBC in vitro123, it is currently believed to function downstream of de novo Fe-S 
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formation (Figure 1.6). The source of electrons for SufS turnover and for Fe-S formation 
remains in question3. 
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Figure 1.7: Illustration of suf and isc operons, with corresponding promoters (Pisc 
and Psuf), which play a central role in regulation of SUF and ISC at the genetic 
level in bacteria. Operons depicted are from the E. coli model system. Steps are 
colored based on the encoded protein’s function as follows: red (regulatory), yellow 
(sulfur delivery), green (primary scaffold), blue (downstream Fe-S cluster delivery), cyan 
(electron transfer), and gray (unknown). 
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1.4.4 Fe-S cluster biogenesis regulation 
The best-developed model for Fe-S biogenesis pathway regulation comes from 
work done in Gram-negative bacterial systems, where both the ISC and SUF pathways 
are present. This work reveals a fascinating interplay between ISC and SUF, where the 
necessary ISC and SUF genes are organized into their respective isc and suf operons 
(Figure 1.7). While this review has focused on eukaryotic systems, regulatory 
mechanisms in bacteria may provide insight into how this regulation occurs in 
eukaryotes. At the center of E. coli Fe-S cluster biogenesis regulation is a DNA-binding 
protein IscR, the first member of the isc operon, which directly regulates both the ISC 
and SUF systems.  
Under non-stressed conditions, ISC is favored over SUF for general 
housekeeping of Fe-S cluster biosynthesis165. The transcriptional regulator IscR can 
bind a 2Fe-2S cluster (forming holo-IscR), obtaining its Fe-S cluster from the same ISC 
machinery utilized by other Fe-S proteins166. In the holo configuration, IscR binds to the 
isc promoter and prevents binding of RNA polymerase167. Thus, holo-IscR acts as a 
feedback regulator, inhibiting transcription of the entire isc operon when ISC activity is 
sufficient168. IscR is a relatively poor substrate for ISC-mediated Fe-S cluster loading169 
and holo-IscR can only form after the ISC proteins have exhausted their interactions 
with other apo-Fe-S proteins. In addition to being a weak ISC substrate, IscR does not 
bind its Fe-S cluster tightly and effectively acts as a sensor of cellular iron and oxygen 
conditions170. Under high-oxygen or low-iron conditions, holo-IscR quickly reverts to 
apo-IscR. Therefore under typical aerobic conditions, high oxygen levels cause holo-
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IscR to revert to apo-IscR. Apo-IscR dissociates from the isc promoter and isc is 
uninhibited.  
In the apo configuration, IscR does not bind to the isc promoter but instead 
favors binding to the suf promoter, activating transcription of SUF genes171. Appropriate 
interaction of apo-IscR with the suf promoter involves two additional transcription 
factors: the ferric uptake regulator (Fur) and the peroxide responsive regulator (OxyR). 
Suf expression is constitutively repressed by Fur, which binds Fe2+ under non-stressed 
conditions when iron levels are sufficient and oxidative stress is low. With its Fe2+ 
cofactor, Fur binds to the suf promoter at the same site as apo-IscR, inhibiting suf 
expression172. When the cell faces iron deficiency, Fur loses its iron cofactor, 
dissociates from the suf promoter, thus triggering transcription of suf. The cell’s 
preference for SUF over ISC in the presence of oxidative stress also reveals the 
involvement of another transcription factor (OxyR), as oxidized OxyR recruits RNA 
polymerase to the suf promoter. 
There are additional regulatory mechanisms for cluster bioassembly beyond the 
level of gene expression. The small non-coding RNA RyhB, for example, is encoded 
just upstream of the SUF promoter and can bind to the iscRSUA mRNA to prevents its 
translation173. RyhB expression, however, is constitutively repressed by Fur-Fe2+, so 
RyhB effectively inhibits ISC when conditions favor SUF174. 
1.4.5 Fe-S cluster function 
Fe-S clusters are versatile biological cofactors found in the most fundamental 
biochemical pathways, including aconitase and succinate dehydrogenase of the citric 
acid cycle and respiratory complexes I-III of the electron transport chain135. Nuclear Fe-
 41	
S proteins also have a unique role in DNA damage recognition and repair. Several 
forms of DNA polymerase, helicase, glycosylase, and primase all contain Fe-S 
clusters139. Considering their remarkable range of functions, a thorough summary of 
various Fe-S proteins is well beyond the limited scope of this review. New Fe-S proteins 
continue to be discovered but in many cases, the role of the Fe-S cluster within the Fe-
S protein remains unknown, even if the cluster’s presence is essential for proper protein 
function. 
Fe-S clusters can be found in the active site of many essential enzymes and 
usually are involved directly in catalysis. Being stable in a variety of redox states, Fe-S 
clusters are best known for their role as electron carriers. Fe-S clusters can carry 
usually one, but sometimes two electrons and are, subsequently, stable in various 
reduced states. 2Fe-2S clusters, for example, can exist in oxidized (Fe3+/Fe3+) or 
reduced (Fe3+/Fe2+) forms while 4Fe-4S clusters are stable in oxidized 
(Fe3+/Fe3+/Fe3+/Fe2+), intermediate (Fe3+/Fe3+/Fe2+/Fe2+), and reduced 
(Fe3+/Fe2+/Fe2+/Fe2+) forms175. The reduction potential of an Fe-S cluster is often 
modulated by interactions with nearest neighbor protein residues and by access to 
solvent, allowing for a large range of biological functions. Ferredoxins are considered 
the archetypical Fe-S cluster electron carriers and were the earliest Fe-S proteins to be 
functionally characterized176. Ferredoxins are involved in many essential biochemical 
pathways, transferring electrons for cellular respiration, photosynthesis, and nitrogen 
fixation177. A ferredoxin is even involved in the ISC iron sulfur cluster biogenesis 
pathway, as discussed previously (see section 3.3.1)178.  
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But Fe-S cluster-mediated electron transfer is not limited to ferredoxins. In fact, 
one of the most the fundamental electron transfer processes, the electron transport 
chain (ETC), utilizes numerous Fe-S clusters. Respiratory complexes I, II, and III of the 
ETC all contain Fe-S clusters. Respiratory complex I uses a network of 8 Fe-S clusters 
for step-wise electron transfer179. Similarly, complex II contains an Fe-S protein 
component called SDHB with a 2Fe-2S, 3Fe-4S, and 4Fe-4S cluster180. Lastly, complex 
III utilizes a unique Fe-S cluster called a “Rieske center”181. The Rieske center is a 2Fe-
2S cluster where one of the iron atoms is coordinated by histidines instead of cysteines, 
resulting in a Cys2His2 coordination182.  
Fe-S clusters can also be involved in non-redox reactions. The 4Fe-4S cluster in 
aconitase, for example, catalyzes a hydration-dehydration reaction, ligating directly to 
the citrate substrate183. In some cases, Fe-S clusters appear to only serve a structural 
function and not participate in chemistry directly, as is the case in endonuclease III184.  
1.4.6 Fe-S clusters in human disease 
Unlike in Gram-negative bacteria, where ISC/SUF redundancy allows for removal 
of an entire pathway, in humans the absence or mutation of a single component is often 
incompatible with life. In select cases there are human diseases that have been linked 
to defective Fe-S cluster biogenesis pathways. Below we describe several diseases 
directly linked to dysfunctional Fe-S cluster formation. 
1.4.6.1 Friedreich’s ataxia 
With an incidence of 1 in 50,000185,186, and a carrier prevalence of 1 in 100187, 
Friedreich’s ataxia (FRDA) is by far the most prevalent disease linked to defective Fe-S 
cluster formation. FRDA is an autosomal recessive genetic disease caused by a GAA-
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trinucleotide repeat expansion in an intron of the frataxin gene, a protein involved in the 
ISC pathway188. This trinucleotide repeat expansion leads to under-expression of the 
frataxin gene and subsequently, low levels of frataxin189. These insufficient frataxin 
levels are responsible for the pathophysiology of FRDA, but the precise role of frataxin 
is still unknown190. Frataxin may deliver iron to the ISC pathway191, be an allosteric 
activator of the ISCU-ISCS complex116, or may have a combination of roles. FRDA 
tissues demonstrate increased mitochondrial iron deposits192 which leads to increased 
oxidative stress and cell death in metabolically active tissues such as cardiomyocytes 
and neurons of the dorsal root ganglia. FRDA presents early in adolescence with 
progressive ataxia, or difficulty coordinating movement, sensory loss, weakness, and 
dysarthria. FRDA patients are usually wheelchair bound in their teens with a 
significantly reduced quality of life and life expectancy193. Median age of survival is 35 
years with cardiac dysfunction usually being the cause of death194.  
1.4.6.2 ISCU myopathy 
ISCU myopathy (IM) is an additional condition related to a defect in Fe-S cluster 
biogenesis. It is the 2nd most common disorder linked to defective Fe-S cluster synthesis 
but is much less common than FRDA with only 25 known cases. To date, all patients 
identified with IM have come from families of Swedish ancestry135. Similar to FRDA, the 
IM phenotype is inherited in an autosomal recessive pattern. IM is caused by a splicing 
defect during ISCU post-transcriptional processing that leads to defective ISCU 
protein195,196. Loss of ISCU leads to lower ISC activity and a resulting deficiency of 
essential Fe-S proteins, including succinate dehydrogenase and aconitase of the citric 
acid cycle197. Symptoms are exacerbated in cells that are metabolically active, such as 
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the myocytes of skeletal muscle during exercise, and patients with IM experience 
exercise intolerance198. Prolonged activity can lead to tachycardia, tachypnea, and 
muscle pain199. Unlike FRDA, IM is not progressive and most cases have a normal life 
expectancy. 
1.4.6.3 GLRX5 sideroblastic anemia 
GLRX5 Sideroblastic Anemia (GSA), a disease caused by mutated GLRX5, has 
only been identified in a single patient to date. While GSA is exceedingly rare, this 
particular case study has revealed a unique mechanism linking Fe-S cluster production 
to general iron homeostasis66,200. GLRX5, involved in the last step of the ISC pathway, 
directs Fe-S cluster delivery from ISCU to downstream targets. One target is the iron-
responsive protein IRP1, an Fe-S protein activated when its Fe-S cluster is absent200. 
Defective GLRX5, therefore, leads to constitutively active IRP1. IRP1 regulates several 
proteins involved in iron homeostasis201, including those involved in heme production. In 
particular, apo-IRP1 inhibits expression of the final enzyme in heme synthesis, 
aminolevulinate synthase (ALAS2). Defective GLRX5, therefore, leads to insufficient 
heme and impaired erythropoiesis, resulting in anemia. Iron that would be directed 
towards heme production accumulates in the cytosol of erythroblasts, creating the 
characteristic ringed-sideroblasts3.  
1.4.6.4 Additional diseases 
Succinate Dehydrogenase (SDH) subunit B, the Fe-S cluster containing protein 
of the succinate dehydrogenase complex, is a known tumor suppressor. Succinate, the 
substrate for SDH, stabilizes hypoxia-inducible factor (HIF), which regulates key 
processes in cell division and blood vessel growth under hypoxic conditions. Mutations 
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in SDHB or in fact any of the other main subunits of SDH (SDHA, SDHC, and SDHD) 
cause susceptibility to tumor formations known as paragangliomas or 
phaeochromocytomas in a disorder called Hereditary Paraganglioma-
Pheochromocytoma202, stemming from the accumulation of succinate and stabilization 
of HIF. SDHAF2, an assembly protein that flavinates SDH, is also implicated in 
paragangliomas. Recently, two additional Fe-S assembly proteins, SDHAF1 and 
SDHAF3, were found to stabilize Fe-S cluster assembly in SDH203. The later two 
proteins have LYR-motifs (Leu-Tyr-Arg) common to proteins involved in Fe-S cluster 
assembly. SDHAF1 deficiency is known to cause leukoencephalopathy204. 
Lastly, mutations in either NFU1 or BOLA3, two different genes involved in Fe-S 
cluster biogenesis, leads to multiple mitochondrial dysfunction syndrome, a condition 
characterized by defects in Complexes I, II, and III and pyruvate/a-ketoglutarate 
dehydrogenases. NFU1 is thought to be an alternative to ISCU as a scaffold for Fe-S 
assembly. Both BOLA3 and NFU1 appear to be involved in lipoate synthesis, possibly 
related to a role in assembling Fe-S clusters in lipoic acid synthase (LIAS), thus 
providing an explanation for the reduced PDH and a-KGDH activities characteristic of 
this syndrome. The impaired energy production results in lactic acidosis, 
encephalopathy205 and early death. 
1.5 Summary 
The utilization of complex Fe cofactors in biology requires a tightly controlled 
process of cofactor assembly and of delivery to the correct apoprotein partner. 
Numerous ailments, some of which outlined within this review, result when there is a 
breakdown in the assembly process or in delivery of the cofactor. The development of 
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treatment strategies for these disorders will require a more advanced molecular 
understanding of each protein malfunction outlined above. Therefore cooperation of 
bioinorganic chemists with the cell biologists alike will be essential to provide the 
broader understanding of how these complex pathways harness the power of iron in 
complex cofactors within the biological milieu. 
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CHAPTER 2 
COOPERATIVITY BETWEEN CYSTEINE DESULFURASE “NFS1” AND ITS 
ACCESSORY PROTEIN “ISD11” PROMOTES STABILITY AND ACTIVITY OF THE 
YEAST PROTEIN COMPLEX 
2.0 Prelude 
During eukaryotic de novo Fe-S cluster biogenesis within mitochondria, the Nfs1-
Isd11 protein pair serves as the functional cysteine desulfurase complex. Isd11 does 
not have any prokaryotic orthologs, and was reported to have an activation function on 
the eukaryotic Nfs1. Lack of association between them leads to deficient sulfur 
mobilization in vivo, reduced Fe-S protein levels and retarded cell growth. However, 
molecular and atomic level understanding of how complexation occurs, and how Isd11 
exerts its effect is still lacking. This chapter describes the work I have done to provide 
comprehensive molecular level information on the Nfs1-Isd11 structure and function. 
The subunit composition and molecular weight of the complex was elucidated as a part 
of biophysical characterization. Extensive thermal stability imparted by Isd11 on the 
Nfs1 was discovered as a significant factor in activating Nfs1 within Fe-S cluster 
assembly while substrate binding affinity was only minimally affected by Isd11. Taken 
together these results provide comprehensive knowledge on the level of cooperativity 
between yeast Nfs1 and Isd11. This work is being prepared for publication at the 
moment and will be referred as: Barupala, D. P., Murugesan, Y., Dancis, A., Pain, D., & 
Stemmler, T. L. (2016). “Cooperativity between cysteine desulfurase Nfs1 and its 
accessory protein Isd11 promotes stability and activity of the yeast protein complex”. 
Biochemistry.” 
 
 
 48	
2.1 Abstract 
The versatility of oxidation states in Fe-S clusters is a key reason for their 
extensive prevalence in biology, serving as electron reaction centers in several 
functionally indispensable proteins. Due to their essential nature, it is not surprising that 
Fe-S cluster synthesis is so carefully controlled by a dedicated set of proteins that work 
in an orchestrated manner. Cluster synthesis and proteins that utilize these cofactors 
have been studied extensively. During Fe-S cluster biosynthesis, cysteine desulfurases 
function as the sulfur source and they operate by enzymatically obtaining sulfane sulfur 
from L-cysteine and subsequently delivering it to the assembly scaffold protein via 
transfer of a persulfide intermediate. In yeast, the function of the cysteine desulfurase 
“Nfs1” is supported by an accessory protein “Isd11”. Although several functional studies 
support the physiological activity of Nfs1 and Isd11 working as a complex, less attention 
has been given on studying the molecular properties of this complex and also on 
elucidating the biophysical basis of their activity. Here we report that the isolated Nfs1-
Isd11 complex posses higher thermal stability as a protein complex, and that an Isd11 
induced conformational change on Nfs1 is the key to this profound stabilization. We find 
that the Nfs1-Isd11 complex has a millimolar affinity towards its substrate L-cysteine, 
and that the substrate binding is facilitated by a conformational change on Nfs1. 
Combined with previously published data, these molecular details assist in helping us 
understand the role of the Nfs1-Isd11 complex and its role in Fe-S cluster synthesis. 
2.2 Introduction 
Fe-S clusters are found ubiquitously in nature and their function is indispensable 
within almost every cell. As the second most prominent iron cofactor (after heme), Fe-S 
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clusters play a role in nearly every cellular pathway2. Their utility is centered on their 
capability to direct redox chemistry by transferring electrons in a modulated manner. 
Key factors that allow for their varied activity is their unique protein bound architecture 
and their evolutionarily adapted coordination environment, which are optimized for their 
individual activity. Fe-S clusters can fluctuate between oxidized (Fe3+ based) and 
reduced (Fe2+ based) states and contain a wide distribution of iron and sulfur 
stoichiometries (different types of clusters include 2Fe-2S, 3Fe-4S, 4Fe-4S, etc.). Their 
redox versatility, coupled with their structural diversity, allows these clusters to drive 
several distinctive chemical processes, including mitochondrial respiration (complexes I, 
II, and III), gene regulation (SoxR) and product catalysis (radical SAM enzymes)3. Given 
the importance of these clusters in all of biology, it is not surprising that their 
bioassembly is tightly regulated, a process that is highly conserved between 
prokaryotes and eukaryotes. 
In all cells, Fe-S cluster assembly is driven by a dedicated set of proteins that 
function in a coordinated manner to produce the iron containing cofactor. In eukaryotes, 
cluster assembly is performed by two major pathways: 1) the iron sulfur cluster (ISC) 
pathway, which operates within the mitochondria, and 2) the cytosolic iron sulfur 
assembly (CIA) pathway, which operates within the cytosol but is dependent on sulfur 
from the ISC3,109,110. The eukaryotic ISC pathway provides Fe-S clusters to meet most 
of the cellular demand, and proteins within this pathway are generally conserved 
between eukaryotes and prokaryotes. In Saccharomyces cerevisiae, 2Fe-2S clusters 
are assembled within the mitochondria de novo on Isu1, the assembly scaffold protein, 
using sulfur provided by the cysteine desulfurase Nfs1 working together with its 
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accessory protein Isd113. Electrons are provided by the ferredoxin Yah1 which is 
recharged in an NADPH driven manner by the ferredoxin reductase Arh1126. While the 
iron source for the process is unclear, yeast frataxin homolog Yfh1 has been shown to 
serve as an iron chaperone in vitro as well as serving as a regulator of Nfs1 activity3,206-
208. Assembly of Fe-S clusters is accomplished through the coordinated assembly 
activity of these proteins, and downstream cluster delivery and utilization proteins drive 
the targeted transfer of these clusters to recipient proteins3,209. During cluster assembly 
however, the protein complex constructed in yeast of Isu1, Nfs1, Isd11, Yah1 and Yfh1 
accomplish Fe cofactor biosynthesis with assistance from additional proteins including 
the acyl carrier protein (ACP)210; exact details of how these proteins work together to 
accomplish product formation are however lacking. Deficiency of activity in even a 
single protein within this complex has a disastrous effect on cell (and in the case of 
humans, patient) viability.  
Several diseases states related to insufficient Fe-S cluster synthesis have been 
identified, however the neurodegenerative disorder Friedreich’s ataxia (FRDA) is the 
archetypal disease. GAA- triplet repeat expansions of variable length found in the first 
intron of the human frataxin (FXN) gene lead to a stark reduction in protein levels, and 
this is at the heart of the disorder. Frataxin deficiency gives rise to mitochondrial iron 
deposits, a reduction in Fe-S cluster bioassembly, and reduced activity for Fe-S 
containing proteins. FRDA patients suffer from progressive spinocerebellar and sensory 
ataxia with hypertrophic cardiomyopathy as well as an increased risk of developing 
diabetes211. While diseases associated with deficits in the other ISC proteins, including 
the human cysteine desulfurase (NFS1) and its binding partner (ISD11) are rare, NFS1 
 51	
deficiency and a compromised NFS1-ISD11 complex are suspected to cause infantile 
mitochondrial II/III deficiency, which is an autosomal recessive disorder characterized 
by lactic acidemia, hypotonia, and a deficiency in respiratory complex II and III212. A 
mutation in the LYRM4 gene encoding for ISD11 in humans causes combined oxidative 
phosphorylation deficiency (COXPD), a disease that impairs activity of respiratory 
complexes I, II, and III213. As a result, ISD11 is unable to form a stable complex with 
NFS1214. These severe human deficiencies related to reduced activity of the ISC 
proteins underscore the point that understanding the molecular activity of these proteins 
is fundamental for understanding the pathophysiology and biochemistry underlying 
crucial events in these disease states. This molecular and atomic level characterization 
of two of the yeast ISC proteins, Nfs1 and Isd11, is the goal of this study. 
In cells, cysteine desulfurase provides sulfur for Fe-S cluster assembly by 
liberating sulfide from L-cysteine in a pyridoxal 5’-phosphate (PLP) assisted manner. 
Cysteine desulfurases generally exist as homodimers215,216. Eukaryotic cysteine 
desulfurases require the accessory protein Isd11 for activity, however interestingly 
Isd11 is absent in prokaryotes113,217. The reaction mechanism of cysteine desulfurase 
was first elucidated using the bacterial NifS ortholog from Azotobacter vinelandii218,219. 
Characterization studies on the yeast Nfs1 protein solidified this enzyme’s role in iron 
homeostasis220 and Fe-S cluster assembly221. Unfortunately, structural details for the 
eukaryotic enzyme, and an understanding of how it interacts with its Isd11 accessory 
protein, are lacking. Structural studies on this topic have had a reliance on modeling of 
the Nfs1 architecture from using the bacterial orthologs222,223. While the exact function of 
Isd11 is unknown, yeast Isd11 was shown to promote persulfide formation on Nfs1 by 
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bringing the bound substrate in close proximity to the Nfs1 active site cysteine 
residue116,224. 
In order to provide a molecular and atomic level understanding of how the Nfs1-
Isd11 complex is formed, and to provide a basis for understanding the effect of Isd11 on 
Nfs1 activity, we isolated yeast Nfs1 and Isd11, both individually and as a co-expressed 
Nfs1-Isd11 complex. The optimal Isd11 to Nfs1 protein stoichiometry related to complex 
activity was characterized. The thermal stability that Isd11 imparts on Nfs1 during 
complex formation is shown to be a contributing factor in Nfs1 activity related to Fe-S 
cluster formation. An Isd11 induced conformational change on Nfs1 produces a 
profound stabilization effect of the enzyme that leads to activity. Finally, the affinity of 
the substrate L-cysteine for the Nfs1-Isd11 complex is only moderately altered by Isd11 
binding. Combined, these studies paint a picture for how Nfs1 and Isd11 work together 
to produce and deliver the sulfur required for Fe-S cluster biosynthesis within the 
eukaryotic ISC pathway. 
2.3 Materials and methods 
2.3.1 Expression of yeast Fe-S cluster synthesis proteins 
Nfs1(and C421A)-Isd11 co-expression: The pST39 co-expression vector 
containing Δ1-33 Nfs1-6xHis-Isd11 or Δ1-36 Nfs1(C421A)-6xHis-Isd11 was transformed 
into BL21 (DE3) cells. In both these constructs Nfs1 lacks the mitochondrial targeting 
sequence but Isd11 remains full length. Starter cultures were made by inoculating a 
transformed colony in Luria Bertani (LB) broth supplemented with 100 µg/ml ampicillin; 
These cultures were incubated in a rotating shaker for 16 hours (overnight) at 230 rpm 
and 37 °C. Starting OD of the growth cultures (1 L) supplemented with 100 µg/ml 
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ampicillin were set to 0.075 by adding the appropriate amount of starter culture and the 
cells were grown until cell density reached 0.4 OD600. Growth temperature was then 
switched to 18 °C and cells were induced at 0.7 OD600 using 0.8 mM IPTG 
supplemented with 10 µM PLP. Cells grew for 18 hours before harvesting by 
centrifugation at 7900 x g for 30 min. 
Nfs1 expression: The pET21b vector containing Δ1-33 Nfs1-6xHis was 
transformed into BL21 (DE3) codon plus cells. Starter cultures and growth cultures were 
treated exactly as mentioned above except they were supplemented with 34 µg/ml 
chloramphenicol in addition to 100 µg/ml ampicillin. Cells were grown at 37 °C in LB 
broth (1 L) until cell density reached 0.4-0.5 OD600. Growth temperature was then 
switched to 25 °C and cells were induced at 0.7 OD600 with of 1 mM IPTG, 
supplemented with 10 µM PLP. Cells were continued to grow at 25 °C for 3 hours 
before harvesting by centrifugation. 
Isd11 Expression: Expression and purification of Isd11-6xHis followed the 
protocol that was previously published225. Briefly the pET21b vector containing Isd11-
6xHis tag was transformed into BL21 (DE3) codon plus cells. A starter culture was 
made by inoculating a transformed colony in LB broth, supplemented with 100 µg/ml 
ampicillin and 34 µg/ml chloramphenicol and it was incubated in a rotating shaker for 16 
hours (overnight) at 200 rpm and 37 °C. Growth cultures (200 ml) were also 
supplemented with 100 µg/ml ampicillin and 34 µg/ml chloramphenicol and the starter 
culture was diluted in LB to a 1:40 ratio. Cells were grown at 37 °C in LB broth until cell 
density reached 0.7-0.8 OD600 and then these samples were induced with 0.5 mM 
IPTG. Cells were grown at 37 °C for 3 hours before harvesting by centrifugation.  
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2.3.2 Purification of yeast Fe-S cluster synthesis proteins 
Purification of Nfs1 and Nfs1(and C421A)-Isd11 Complexes: Frozen cell pellets 
were resuspended in pH 7.5 lysis buffer containing 50 mM Sodium Phosphate, 150 mM 
NaCl for Nfs1(and C421A)-Isd11 complexes/300 mM NaCl for Nfs1 alone, 5% Glycerol, 
20 mM Imidazole, and 5 mM β–ME (4 ml/g of cells). In addition, cOmplete™ EDTA-free 
protease inhibitor cocktail (Roche), lysozyme (10 mg/ml), and DNase (10 µg/ml) 
supplemented with 5 mM MgCl2 were also included in the lysis buffer. Protein 
purification was performed at 4 °C. Cell suspensions were incubated at 4 °C for 30 min 
while stirring at a slow pace before passing through the Emulsiflex cell homogenizer 
three times for cell lysing. Cell lysate was then centrifuged at 53300 x g for 1 hour. 
Crude soluble fraction was filtered (0.20 µm) before passing through His-Trap HP 5 ml 
Ni column (GE Healthcare) using an AKTA FPLC chromatography system (Amersham 
Biosciences/GE Healthcare); Nfs1 or Nfs1(C421A)-Isd11 was passed through high 
density Nickel Agarose Beads (GoldBio) manually packed in a bench-top column. Ni 
columns were first washed with 20 column volumes of binding buffer to eliminate any 
residual unbound proteins. Bound proteins were then eluted by flowing an imidazole 
gradient of 20-500 mM across the columns and fractions containing Nfs1 or Nfs1(and 
C421A)-Isd11 complexes were identified using SDS-PAGE. Active fractions were 
pooled and concentrated to ~ 1 ml using 10 kDa molecular weight cutoff Amicon 
centrifugal filter devices (Millipore). All proteins were incubated with excess PLP to 
ensure 100 % loading of PLP to all Nfs1 units. Concentrated protein(s) was passed 
through a Superdex 200 size exclusion column to further remove impurities and to 
transfer to the final buffer at pH 7.5 comprised of 20 mM HEPES and 5mM β–ME plus 
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150 mM NaCl for the Nfs1(and C421A)-Isd11 complexes and 300 mM NaCl for Nfs1 
alone. Fractions containing Nfs1 or Nfs1(and C421A)-Isd11 complexes were pooled and 
concentrated to store at -80 °C in aliquots until further use for experiments. These 
purification protocols yielded >95% pure proteins (Figure 1). 
Purification of Isd11: The majority of overexpressed Isd11 was found in bacterial 
inclusion bodies. Cell pellets were resuspended in a buffer containing 50 mM Tris HCl 
(pH 8.0), and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were lysed by passing 
through the Emulsiflex cell homogenizer three times followed by six rounds of sonication 
(20 s each round and 2 min intervals). The lysate was spun at 53300 x g for 30 min and 
crude soluble fraction was removed. Pellet containing insoluble Isd11 was dissolved 
with a buffer at containing 50 mM Tris HCl (pH 8.0), 8M urea, and 1 mM PMSF, and the 
resulting suspension was spun at 65000 x g at 20 °C for 30 min. Supernatant was 
mixed with a His-select Ni affinity gel (Sigma P6611), pre-washed with water and 50 
mM Tris HCl (pH 8.0) with 1 mM PMSF buffer, for 1 hour at room temperature on a 
rocking platform to allow end-to-end mixing. After removing unbound protein, the resin 
was further washed with a 50 mM Tris HCl (pH 8.0) and 1 mM PMSF binding buffer to 
eliminate any residual unbound protein. Bound protein was then eluted using an elution 
buffer containing 50 mM Tris HCl (pH 8.0), 8M urea, 400 mM imidazole, and 1 mM 
PMSF. Fractions containing denatured Isd11 identified using SDS-PAGE were pooled 
and stored at room temperature until further use. This purification protocol yielded 
approximately completely pure protein (see Figure 1). 
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2.3.3 Protein size and stoichiometry characterization 
Size exclusion chromatography: Concentrated and purified proteins were passed 
again through Superdex 200 (120 ml column bed volume) column using AKTA FPLC 
system (GE Healthcare) to identify the molecular size and oligomeric states of 
protein(s). The Superdex 200 column was pre-equilibrated with 20 mM HEPES, 300 
mM NaCl, and 5 mM β-ME running buffer at pH 7.5, and concentrated protein at a 1 ml 
volume was injected onto the column. The separation flow rate at 4 °C was set at 0.5 
ml/min. BioRad gel filtration standards containing Thyroglobulin (670 kDa), γ-globulin 
(158 kDa), Ovalbumin (44 kDa), Myoglobin (17 kDa), and Vitamin B12 (1.35 kDa) were 
passed across the column in the same manner to calibrate the molecular size of the 
target proteins.  
Gel densitometry: Gel densitometric analysis was used to identify the relative 
oligomeric stoichiometry of protein samples. Purified Nfs1-Isd11 complex was subjected 
to denaturing SDS-PAGE to separate Nfs1 and Isd11 based on their molecular weight. 
Several samples of Nfs1-Isd11 complex were run across multiple lanes to reduce 
uncertainty in the measurement. Each lane carried a total of 2-5 µg of protein, as 
measured by Direct Detect Infrared Spectrometer for protein quantification. After 
staining/destaining, gels were imaged using Bio-Rad Gel Doc EZ Imaging System and 
analyzed using Bio-Rad Image Lab software. Bio-Rad gel imaging system provides a 
tool to measure the volume of a protein band, and then calculates the sum of all 
intensities within the band boundaries. The band % is the calculated percentage of a 
particular band’s volume compared to the total of all band volumes in a lane, and this 
measurement was used to calculate the ratio between Nfs1 and Isd11. Gel signals 
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corresponding to Nfs1 and Isd11 was divided by the expected molecular weight of the 
respective protein to calculate the molar band % and the ratio between molar band % 
values from Nfs1 and Isd11 (per Nfs1 monomer) provided the stoichiometry of Nfs1 and 
Isd11 in the protein complex. Stoichiometry between Nfs1 and Isd11 in the Nfs1-Isd11 
complex obtained here was then compared to the size of the protein complex obtained 
from size exclusion chromatography. 
2.3.4 Biophysical properties of proteins 
Differential scanning calorimetry: The thermal stability of Nfs1 and Nfs1(and 
C421A)-Isd11 complexes was assessed using differential scanning calorimetry (DSC). 
Purified and concentrated proteins were diluted to 2-3 mg/ml, using 20 mM HEPES, 300 
mM NaCl, 5 mM β-ME at pH 7.5 buffer degassed to remove dissolved air. Protein 
samples were loaded in the sample cell of a TA Instruments Nano-DSC calorimeter; the 
reference cell was filled with matched buffer. The total volume for the capillary cell is 0.3 
ml, however an excess of solution (~0.6 ml) is used for loading to prevent trapping air 
bubbles. Both capillary cells were manually pressurized to maintain a constant pressure 
of 3 atm during the scan. Each protein sample was scanned at a rate of 1 °C/min from 
10 °C to 90 °C and the melting curves for Nfs1 and Nfs1-Isd11 were compared to 
assess differences in thermal stability resulting in complex formation. In addition, 
melting curves for Nfs1-Isd11 and Nfs1(C421A)-Isd11 were compared to assess any 
difference in thermal stability between wild type and mutant protein complexes. 
Experiments were done in duplicate on independently isolated proteins to ensure data 
reproducibility. The thermal profiles were simulated using the TA instruments 
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NanoAnalyze software package to identify the best-fit values for melting temperatures 
(Tm). 
ANS fluorescence spectroscopy: Fluorescence spectroscopy was used to 
identify protein structural changes due to complexation and substrate binding. Binding 
with 1,8-Anilinonaphthalenesulfonate (ANS), a fluorophore which selectively binds to 
solvent exposed hydrophobic regions in molten globule proteins226, was used to 
determine structural differences between Nfs1 and Nfs1-Isd11. ANS binding 
experiments were carried out using 40 µM samples of either purified Nfs1 or Nfs1-Isd11 
diluted in 20 mM HEPES, 300 mM NaCl, and 5 mM β-ME at pH 7.5. All buffers were 
initially degassed to remove dissolved air. Samples were incubated for 10 min after 
addition of 50 µM ANS. The ANS probe was excited at 371 nm and the fluorescence 
emission spectra were measured using a Horiba Scientific Spectrofluorometer at 5 nm 
intervals with 1 s spectral integration time and 1 mm slit width. A fluorescence cuvette 
(Starna), with 1 ml capacity and 1 cm path length was used to collect fluorescence 
emission spectra at 25 °C. Spectra were collected in triplicate using different protein 
preparations to ensure spectral reproducibility. Similarly ANS fluorescence 
measurements were used to assess the changes in protein fold upon addition of L-
cysteine to Nfs1(C421A)-Isd11. Duplicated 20 µM Nfs1(C421A)-Isd11 samples in 20 
mM HEPES and 300 mM NaCl buffer at pH 7.5 were incubated with 20 equivalents of L-
cysteine for 10 min and then with 50 µM ANS for another 10 min before acquisition of 
spectra using same experimental parameters as above. 
Tryptophan fluorescence spectroscopy: Tryptophan fluorescence spectroscopy 
was used to measure structural changes in Nfs1(C421A)-Isd11 that occur upon binding 
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of substrate L-cysteine. Freshly made L-cysteine was titrated consecutively to 20 µM 
Nfs1(C421A)-Isd11 in 20 mM HEPES and 300 mM NaCl buffer at pH 7.5. Protein 
samples were carefully mixed and incubated for 10 min after each addition of L-
cysteine; emission spectra were measured at 25 °C following excitation of the samples 
at 300 nm as above. Each addition was timed 1 min after the start of spectra acquisition 
to maintain consistency between data points. All spectra were corrected for dilution. 
Experiments were performed in duplicate using independently prepared protein samples 
to ensure spectral reproducibility. The change in fluorescence intensity at 340 nm was 
plotted against respective L-cysteine concentrations to calculate the binding affinity of 
Nfs1(C421A)-Isd11 to L-cysteine. Best-fit simulation to data was obtained using the 
DynaFit curve fitting software227. 
2.3.5 Functional properties of proteins 
UV-visible spectroscopy: UV-visible spectroscopy was used to measure the 
affinity of Nfs1(C421A)-Isd11 to its substrate L-cysteine. In this experiment, 50 µM 
purified Nfs1(C421A)-Isd11 in 20 mM HEPES and 300 mM NaCl at pH 7.5 was titrated 
consecutively with freshly made L-cysteine. Protein samples were carefully mixed and 
incubated for 10 min after each addition of L-cysteine; spectra were measured at a 1.0 
nm scan pitch using Shimadzu UV-1800 Spectrophotometer. Each addition was timed 1 
min after the start of spectra acquisition to maintain consistency between data points. 
All spectra were collected at 25 °C under anaerobic conditions and corrected for 
dilution. Experiments were performed in duplicate using independently prepared protein 
samples to ensure spectral reproducibility. The change in spectral intensity at 340 nm 
was plotted against respective L-cysteine concentrations to calculate the binding affinity 
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of Nfs1(C421A)-Isd11 to L-cysteine. Best-fit simulation to data was obtained using 
DynaFit curve fitting software227.  
Cysteine desulfurase activity assay: An acid labile sulfide detection assay was 
performed to calculate the Michaelis-Menten kinetics parameters for the Nfs1-Isd11 
complex. In this assay, Fe3+ with sulfide liberated from the enzyme aids the conversion 
of N, N-dimethyl-p-phenylenediamine sulfate (DPD) to methylene blue. Its characteristic 
visible absorption feature at ~750 nm is used to quantify sulfide production with the use 
of a calibration curve. Nfs1-Isd11 complex was incubated with a series of L-cysteine 
concentrations ranging from 100 µM to 2 mM. Each reaction was handled separately to 
maintain accuracy of timing and measurements. Assay mixture contained 100 mM 
HEPES (pH 7.5), 150 mM MaCl, 50 µM PLP, 12 µM purified Nfs1-Isd11 and distilled 
water and the total reaction volume was 100 µl. Each reaction was prepared by first 
mixing the assay components together in an eppendorf tube covered with rubber septa 
(Sigma-Aldrich-Z565717) to prevent air escaping. Respective L-cysteine amounts were 
then introduced to each tube using a gas-tight Hamilton syringe. After a 5 min 
incubation at 30 °C, the reaction was stalled by adding 100 µl of 20 mM DPD in 7.2 N 
HCl and 30 mM FeCl3 in 1.2 N HCl also using gas-tight Hamilton syringes and each 
addition was timed 45 s apart to maintain the consistency between each reaction. 
Distilled water was added up to 800 µl. Each tube was then vortexed for 10 s before 
incubating for 20 min at 30 °C for efficient color development. All tubes were spun at 
14000 x g for 2 min to remove protein precipitation before measuring the absorbance at 
750 nm using a 1 ml cuvette with Varian Cary-50 Bio UV-Visible Spectrophotometer. 
The amount of persulfide liberated at each concentration was determined using a 
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standard plot constructed using known Na2S concentrations. Measurements were 
corrected for dilution and the initial rate of reaction (µM/min) was plotted against L-
cysteine concentration (µM) to calculate enzyme kinetics parameters. 
2.3.6 Structural studies of Nfs1 
Homology modeling: Homology modeling was used as a tool to model the three-
dimensional structure of Nfs1. Published X-ray crystal structure of bacterial IscS (PDB: 
1P3W) was used as the input model for the SWISS-MODEL workspace228 
(https://swissmodel.expasy.org) provided by the SIB ExPASy Bioinformatics Resource 
Portal. Modeled Nfs1 structure was viewed using the PyMOL Molecular Graphics 
System (Version 1.8.2.2 Schrödinger, LLC) to inspect the overall structure and identify 
the residue configuration of the active site. 
2.4 Results 
2.4.1 Co-expression of Nfs1 with Isd11 leads to stable complex formation 
The solution stability of Nfs1 in complex with Isd11 is enhanced relative to pure 
homogeneous protein.  Purified Nfs1-Isd11 complex exhibited a characteristic neon 
yellow color indicative of PLP bound to the cysteine desulfurase. This complex was 
soluble at 4 °C for 2-3 days at salt conditions as low as 150 mM. In contrast, Nfs1 and 
Isd11 purified separately have poor solubility following isolation, as was previously 
observed with other eukaryotic proteins229,230. When expressed in E. coli individually, 
Isd11 is predominately contained within inclusion bodies. Isd11 could be resolubilized 
using 8 M urea, and the protein could be purified in its denatured form (Figure 2.1). 
However, as expected, Isd11 precipitated upon removal of urea below 2 M 
concentrations (data not shown)231. Similarly, in a previous study, Isd11 purified from a 
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soluble fraction of bacterial lysate aggregated and formed a polydisperse mixture of 
oligomers in the absence of Nfs1231,232. When overexpressed alone, Nfs1 exhibited the 
characteristic neon yellow color highlighted above.  The protein was comparatively 
soluble, in contrast to Isd11 alone, and it could be purified from soluble fractions from 
the bacterial cell lysate. It was, however, extremely important to maintain high salt 
concentrations (300 mM NaCl) and low temperatures (< 20 °C) to keep Nfs1 in a 
soluble unaggregated state. It was previously reported that Nfs1, from yeast 
mitochondria, is prone to aggregation in the absence of its binding partner 
Isd11113,233,234. These results are consistent with Isd11 coordination to cysteine 
desulfurase contributing to the solubility and stability of the enzyme, which helps both 
proteins maintain solubility.  
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Figure 2.1: SDS-PAGE gel of purified proteins. Lanes represent 1: molecular weight 
marker, 2: purified yeast Nfs1-Isd11 complex, 3: Nfs1, and 4: Isd11. Nfs1-Isd11 and 
Nfs1 are present in non-denaturing media whereas Isd11 is present in 8 M urea.  
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2.4.2 Molecular weight and protein stoichiometry of the Nfs1-Isd11 complex 
Co-expressed Nfs1-Isd11 provided a stable protein complex that could easily be 
characterized for overall size and protein stoichiometry. Purified Nfs1 and Isd11 
migrated individually at ~50 kDa and ~12 kDa, respectively, on an SDS-PAGE gel 
(Figure 2.1). These results are consistent with the predicted molecular weights of the 
proteins derived from gene sequences, at 52,196.2 Da and 12331.1 Da for Nfs1-6xHis 
and Isd11-6xHis, respectively. Nfs1 expressed alone appears to run mostly between 
158,000 Da (γ-globulin) and 44,000 Da (Ovalbumin) (Figure 2.2, Line B), as judged by 
size exclusion chromatography. The predicted molecular weight for a Nfs1 homodimer 
from the gene sequence is 104,392.4 Da, consistent with the bulk of the protein 
migrating as a homodimer. This is not unique since a homodimer has been seen for 
other cysteine desulfurases216. A larger molecular weight species at > 600,000 Da is 
also seen in our data, suggesting Nfs1 alone is prone to higher order oligomerization. 
The Nfs1-Isd11 complex peak overlaps at a size of ca. 158,000 Da, as judged by size 
exclusion chromatography (Figure 2.2, Line A).  
Gel densitometric analysis of the Nfs1-Isd11 complex revealed a ratio of Nfs1 to 
Isd11 of 1:2 (Figure 2.3). Since cysteine desulfurase runs as a stable dimer (as judged 
by the size exclusion chromatography listed above), the Nfs1-Isd11 complex would be 
consistent with 2 Nfs1 molecules and 4 Isd11 molecules producing the composite 
protein complex structure. The predicted total molecular weight for this combination, 
obtained from gene sequence data, adds up to 149,456.4 Da, which is close within error 
bars of the technique, to the molecular weight deduced from this complex at 158,000 
kDa from size exclusion chromatography. This combination is also in close agreement 
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with results obtained from the human proteins, which also suggest a NFS1:ISD11 
stoichiometry of 1:2213,229. Murine proteins have shown a ternary complex with NFS1-
ISD11-ISCU at a 1:2:1 ratio, and a quaternary complex with NFS1-ISD11-ISCU-FXN in 
1:2:1:1 ratio235, again in close agreement with results from our yeast Nfs1-Isd11 
complex, and from our Nfs1-Isd11-Isu1-Yfh1 multiprotein complex recently reported 
(Stephen Dzul (2016) “Insights into de novo Fe-S cluster biogenesis via the eukaryotic 
Fe-S cluster pathway (ISC) in vitro”, PhD dissertation). In combination, these results are 
consistent with yeast Nfs1 existing as a stable homodimer, and it associates with four 
Isd11 monomers to form a Nfs12-Isd114 protein complex when co-expressed.  
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Figure 2.2: Size exclusion chromatograms of purified Nfs1 and Nfs1-Isd11 
complex compared to the gel filtration standard proteins. Solid, dotted, and dashed 
lines represent chromatograms for 1) gel filtration standard proteins, 2) Nfs1-Isd11 
complex, and 3) Nfs1 expressed alone, respectively. Lines A and B indicate that Nfs1-
Isd11 and Nfs1 oligomeric structures correspond to molecular weights of ~150 kDa and 
~100 kDa, respectively. Gel filtration standard proteins include 1: Thyroglobulin 
(670,000 Da), 2: γ-globulin (158,000 Da), 3: Ovalbumin (44,000 Da), 4: Myoglobin 
(17,000 Da), and 5: Vitamin B12 (1,350 Da). *Nfs1-Isd11 and Nfs1 chromatograms also 
include additional peaks that correspond to higher order oligomeric forms of Nfs1-Isd11 
and Nfs1, which elute at a smaller retention volume. Nfs1-Isd11 and Nfs1 
chromatograms are offset for clarity.  
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Figure 2.3: Gel densitometric analysis of the Nfs1-Isd11 complex. Molar band 
volume is equivalent to percentage band volume (quantified using the Bio-Rad Image 
Lab software) divided by expected molecular weight of each protein in the complex. The 
ratio between molar band volumes corresponds to the ratio between Nfs1 and Isd11 in 
the complex.  
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2.4.3 Stabilization energetics of the Nfs1-Isd11 complex 
Thermodynamic factors that impact the stability of the Nfs1-Isd11 complex have 
also been characterized in detail within this report. Comparisons of energetic profiles 
using Differential Scanning Calorimetry (DSC) revealed the Nfs1-Isd11 complex 
possesses a thermal stability much greater than Nfs1 alone. An average melting 
temperature for Nfs1 was measured to be 40.70 ± 0.24 °C (Figure 2.4). The raw melting 
data for the molecule by itself was best simulated using two individual denaturation 
events, possibly pertaining to the unfolding of two individual domains. In contrast, the 
average melting profile from the Nfs1-Isd11 complex was 61.75 ± 0.05 °C, indicating a 
thermal stability of over ~20 °C higher for the assembled complex compared to Nfs1 
alone (Figure 2.4). Interestingly, the raw melting data for the Nfs1-Isd11 complex was 
best simulated using three individual denaturation events, the additional peak likely 
pertaining to the unfolding of Isd11 (Table 2.1). Our results are in good agreement with 
the observation that the two proteins within the complex are more stable when co-
expressed. Due to the limited solubility, we were unable to reach concentrations 
required to measure the thermal stability of Isd11 alone. However, it can be concluded 
from our data that complexation causes an enhancement in the thermal stability of the 
Nfs1 enzyme.  
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Figure 2.4: Differential Scanning Calorimetric thermal profiles for purified Nfs1 
and the Nfs1-Isd11 complex. Solid black and dotted gray lines represent sum of best-
fit simulations and raw data respectively. Dotted black lines represent simulated peaks 
corresponding to domains and/or individual unfolding events in each structure. Melting 
temperatures for simulated peaks are depicted in Table 2.1. The thermal profile for 
Nfs1-Isd11 is offset for clarity.  
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Table 2.1: Melting temperatures (°C) for each domain/unfolding event obtained 
from Differential Scanning Calorimetry data for Nfs1 and Nfs1-Isd11. 
 
Domain/unfolding event  Melting Temperature (°C) 
Nfs1 
1 39.05 ± 0.6 
2 41.95 ± 0.2 
Nfs1-Isd11 
1 56.9 ± 0.8 
2 60.25 ± 0.4 
3 62.05 ± 0.4 
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2.4.4 Nfs1-Isd11 complex is more folded than Nfs1 itself 
Structural changes that occur upon protein complexation may contribute to the 
higher thermal stability seen for the Nfs1-Isd11 complex. ANS fluorescence 
spectroscopy was used to test the hypothesis that Isd11 imparts stability on Nfs1 by 
inducing a conformational change on the protein that allows Nfs1 to adopt a more 
stable, more compact fold. This experiment, performed with Isd11 bound to Nfs1, 
showed that the ANS fluorescence signal for the Nfs1-Isd11 complex is quenched by 
35.0 ± 7.0 %, as compared to the signal from Nfs1 (Figure 2.5). Signal quenching can 
be attributed to Isd11 displacing the ANS binding surface, or structural changes in local 
environment of the ANS binding site(s). A previous study using Circular Dichroism (CD) 
and Tryptophan fluorescence spectroscopies suggested that the Nfs1-Isd11 complex 
has substantially rearranged structural elements as opposed to Nfs1231. Therefore ANS 
fluorescence results would be consistent with Isd11 inducing a conformational change 
on Nfs1, maybe pushing the protein to rearrange its structure profoundly and adopt a 
compact fold.  
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Figure 2.5: ANS fluorescence spectra for purified Nfs1 and for the Nfs1-Isd11 
complex. Solid and dashed lines represent Nfs1 and Nfs1-Isd11, respectively.  
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2.4.5 Yeast Nfs1-Isd11 binds the substrate L-cysteine with millimolar affinity 
Due to the presence of bound pyridoxal-5’-phosphate cofactor, UV-visible 
spectra of purified Nfs1 and Nfs1-Isd11 complex contain a characteristic PLP spectral 
feature at 420 nm215. This feature is attributed to the protonated internal aldimine 
formed between PLP and the yeast Nfs1 Lysine residue (K299) at the enzyme’s 
substrate-binding site. Upon addition of the substrate L-cysteine, intensity of this feature 
diminishes while a new spectral feature appears at ~340 nm218,236. This new feature is 
attributed to the L-cysteine-PLP ketimine adduct that will undergo a nucleophilic attack 
from a catalytic cysteine residue (C421) to form a persulfide intermediate231,237. 
Because these spectral features represent reaction intermediates before and after 
substrate binding, both are useful to determine substrate binding kinetics for the Nfs1-
Isd11 complex. However, as observed, these features are also sensitive to persulfide 
formation on the protein238,239 and therefore they do not correlate directly to substrate 
binding. To isolate the spectral changes associated only with L-cysteine binding on 
Nfs1-Isd11, we developed a mutant Nfs1-Isd11 complex carrying C421A mutation in 
Nfs1. The Nfs1(C421A)-Isd11 complex is incapable of making the nucleophilic attack; 
hence the reaction is anticipated to stall after substrate binding with no acidic labile 
sulfide being formed (Figure S2.3). We verified by CD spectroscopy and DSC that the 
Nfs1(C421A)-Isd11 complex is not significantly different in secondary structure and 
stability as compared to the wild type complex (Figures S2.1 and S2.2, Table S2.1). A 
quantitative titration of L-cysteine into the Nfs1(C421A)-Isd11 sample was monitored at 
340 nm (Figure 2.6-A) to measure ketimine intermediate formation. These data 
indicated a substrate binding affinity (or Kd) of 0.76 ± 0.14 mM (Figure 2.6-B). A similar 
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affinity, with a Kd in the millimolar range, has been reported for several bacterial 
cysteine desulfurases219,237. 
2.4.6 Nfs1-Isd11 is a moderately efficient enzyme 
Michaelis-Menten kinetics was calculated to determine the catalytic efficiency of 
the Nfs1-Isd11 complex following an acid labile sulfide detection assay. Under these 
assay conditions, the Nfs1-Isd11 complex exhibited Michaelis-Menten kinetics with a 
Michaelis constant (KM) of 0.49 ± 0.07 mM for L-cysteine, a kcat of 13.1 ± 0.4 min-1, and 
a catalytic efficiency (kcat/KM) of 456 ± 263 M-1s-1 (Figure 2.7). The calculated Michaelis 
constant (KM) for yeast Nfs1-Isd11 complex was in close agreement with published KM 
values of 0.34 mM and 0.43 mM for human system207,230. However, the reported KM 
value for the bacterial cysteine desulfurase IscS (an enzyme that is functional in the 
absence of Isd11) is approximately a hundred fold lesser (KM = 0.0027 mM) than the 
values reported for eukaryotic homologs112. On the other hand catalytic efficiency (kcat/ 
KM) follows the trend of a gradual decrease from E. coli IscS (~52,000 M-1s-1)112 to yeast 
Nfs1-Isd11 complex (~460 M-1s-1; our result) to human NFS1-ISD11 (~100 M-1s-1)207.  
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Figure 2.6: Titration of L-cysteine to Nfs1(C421A)-Isd11 monitored by UV-visible 
spectroscopy. A: Consecutive spectra were collected after each addition of L-cysteine. 
Lines represent the following concentrations: bold solid: 0 mM, bold dashed: 0.010 mM, 
bold dotted: 0.035 mM, bold dash-dot: 0.084 mM, bold dash-dash-dot-dot: 0.183 mM, 
thin solid: 0.430 mM, thin dashed: 0.919 mM, thin dotted: 1.901 mM, thin dash-dot: 
4.346 mM, thin dash-dash-dot-dot: 9.200 mM. Arrows indicate the direction of change of 
spectral features upon consecutive addition of L-cysteine. B: Plot shows the change in 
absorbance at 340 nm as a function of L-cysteine concentration. Solid black line 
indicates the best-fit simulation obtained using DynaFit curve fitting software.  
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Figure 2.7: Rate of persulfide formation by Nfs1-Isd11 complex shown as a 
function of L-cysteine concentration. Solid black line indicates the best-fit curve.  
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2.4.7 Nfs1-Isd11 complex undergoes a conformational change during L-cysteine 
binding 
We have modeled the structure of Nfs1 to help provide a structural 
understanding of our results. Since three-dimensional structures of an eukaryotic 
cysteine desulfurase is not yet available, the published X-ray crystal structure of the 
bacterial cysteine desulfurase served as primary references for modeling the yeast 
structure. IscS, the cysteine desulfurase within ISC pathway of E. coli, exhibits the 
highest sequence identity to Nfs1; the two ortholog sequences share a 57% sequence 
identity and a 74% sequence similarity. We therefore selected the E. coli IscS223 
structure as the template to model the Nfs1 structure. Sequence alignments between E. 
coli IscS and yeast Nfs1 shows an overhanging group of 98 amino acids at the N-
terminal region of yeast Nfs1 (Figure 2.8-A). The first 33 amino acids of this yeast 
specific region is the mitochondrial targeting sequence (MTS) that facilitates import of 
the Nfs1 precursor protein into the mitochondria220. This sequence gets cleaved by the 
mitochondrial processing peptidase (MPP) following import240. Three additional amino 
acids are removed from the nascent yeast N-terminus by the Icp55 peptidase to 
produce the mature Nfs1 molecule240. The first 62 amino acids of mature mitochondrial 
Nfs1 does not overlap with IscS, and the function of this overhang region is still 
unknown, and this region could not be modeled. Of the region of sequence overlap, the 
modeled Nfs1 homodimer was shown to be very similar to the E. coli IscS structure. The 
yeast structure retained most secondary structural elements of IscS (Figure 2.8-B) 
during the modeling. Each substrate-binding site (including the PLP cofactor binding 
site) incorporates residues from both monomers, and PLP could be modeled as being 
 78	
attached to the K299 residue on each monomer via formation of an internal aldimine 
(Figure 2.8-C). The location of the substrate-binding site in the modeled structure is 
found buried beneath the dimer interface, suggesting the requirement of a 
conformational change on Nfs1 in order to bind L-cysteine in this pocket. The distance 
between catalytic cysteine residue C421 and PLP is over 15 Å, as calculated from the 
β-SH group of C421 to the aldehyde group on C4 of PLP. In the current state, this 
distance would be too far for a successful nucleophilic attack from the thiol group of 421 
to the Cys-ketimine PLP adduct to occur. Therefore, a second conformational change 
on Nfs1 would also be required to bring the catalytic C421 to the substrate-binding site 
to promote persulfide formation.  
ANS was used to attempt to detect any change in Nfs1 fold upon substrate 
binding. The ANS fluorescence signal for Nfs1(C421A)-Isd11 was monitored after 
addition of L-cysteine. As previously outlined, Nfs1(C421A)-Isd11 allows us to isolate 
the substrate-binding step from persulfide formation step, and to monitor structural 
perturbations caused only by L-cysteine binding on the enzyme, albeit in a perturbed 
(mutant) state. Following substrate addition, the fluorescence signal of Nfs1(C421A)-
Isd11 was only quenched by 8.9 ± 0.8 % when L-cysteine was added, however the 
emission maxima was shifted from 480 nm to 470 nm (Figure 2.9-A). A blue shift in the 
fluorescence indicates the polarity of the ANS binding environment on Nfs1(C421A)-
Isd11 decreased upon substrate binding. This result would be consistent with L-cysteine 
binding to Nfs1(C421A)-Isd11 as a result of a protein conformational change. 
Tryptophan fluorescence spectroscopy was also used to monitor a 
conformational change on Nfs1 resulting from substrate binding. Each Nfs1 monomer 
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contains three tryptophan residues that emit an intrinsic fluorescence signal, while Isd11 
does not contain a tryptophan. As a result, changes in tryptophan fluorescence during 
this experiment reflect changes in the tryptophan local environment within Nfs1. The 
tryptophan fluorescence signal for Nfs1(C421A)-Isd11 simultaneously reduced during 
the continuous L-cysteine titration. Consecutive addition of L-cysteine to Nfs1(C421A)-
Isd11 resulted in a quench in fluorescence intensity at 340 nm (Figure 2.9-B). A best-fit 
curve for changes in the fluorescence intensity vs. L-cysteine concentration yielded a Kd 
of 0.46 ± 0.08 mM, in close agreement with the Kd value we determined using UV-
visible spectroscopy for substrate binding. This further confirms that the overall change 
in tryptophan fluorescence was due to a conformational change in Nfs1 caused by 
substrate binding. With this result it could be concluded that a change in protein fold 
facilitates L-cysteine binding to Nfs1-Isd11.  
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Figure 2.8: Homology modeling of Nfs1. A: Clustal Omega alignment between yeast 
Nfs1 and E. coli IscS sequences. Asterisks represent, 1: MPP cleavage site, 2: Icp55 
cleavage site, 3: PLP binding Lys299 residue, and 4: catalytic Cys421 residue. B: Nfs1 
homodimer model based on IscS x-ray crystal structure (PDB: 1P3W). Small domain 
and large domain of each monomer are shown in magenta and yellow, respectively. C: 
Substrate/PLP binding region of Nfs1 homodimer. Residues constituting the 
substrate/PLP binding site are depicted as surfaces to emphasize the pocket nature of 
the site. PLP bound to the site is shown in magenta and K299 residue which forms a 
Schiff base with PLP is shown in yellow. Residues from the two dimers are colored in 
cyan and green. The catalytic C421 residue is shown in red.   
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Figure 2.9: Change in ANS and tryptophan fluorescence intensities of 
Nfs1(C421A)-Isd11 upon addition of L-cysteine. A: Change in ANS fluorescence of 
Nfs1(C421A)-Isd11 after addition of 20 equivalents of L-cysteine. Solid and dashed 
lines represent spectra before and after addition of substrate, respectively. B: Titration 
of L-cysteine to Nfs1(C421A)-Isd11 monitored with tryptophan fluorescence signal. 
Lines represent the following concentrations: bold solid: 0 mM, bold dashed: 0.010 mM, 
bold dotted: 0.035 mM, bold dash-dot: 0.084 mM, bold dash-dash-dot-dot: 0.183 mM, 
thin solid: 0.430 mM, thin dashed: 0.919 mM, thin dotted: 1.901 mM, thin dash-dot: 
4.346 mM, thin dash-dash-dot-dot: 9.200 mM. Solid downward arrow indicates the 
direction of change of spectral feature at 340 nm upon consecutive addition of L-
cysteine.  
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2.5 Discussion 
Given the indispensable roles of Fe-S clusters in biology, it is no wonder the 
activity of proteins driving the assembly process are so highly synchronized and very 
tightly regulated.  While every protein within the ISC apparatus works together in an 
orchestrated manner to drive Fe-S cluster assembly, it is the biophysical characteristics 
of each molecule that dictates their unique role in the process. Therefore, real insight in 
the bioassembly process can be gained by studying each molecule separately, followed 
by investigating how the proteins interact and work together to accomplish the final goal 
of Fe-S cofactor production. This report explores, in great detail, two of the four ISC 
proteins from the yeast system (Nfs1 and Isd11) to understand their role in generating 
the activated sulfur (via the persulfide) that is utilized during Fe-S cluster formation. 
Since Isd11 is essential only in eukaryotic Fe-S cluster assembly, having an atomic 
level understanding of Isd11 and Nfs1 alone provides fundamentals for revealing the 
coordination details that promote activation of the protein complex from the inert starting 
materials. Our goal in this report was to elucidate how cooperativity between yeast Nfs1 
and Isd11 allows these proteins to work together to provide the sulfur substrate required 
for Fe-S cluster assembly within the ISC pathway.  
Details related to the Nfs1-Isd11 complex obtained from this study provide an 
enhanced understanding of how the cysteine desulfurase reaction is accomplished 
when these proteins are coordinated, in contrast to being in their inactive homogeneous 
states. Here we present a molecular picture of the yeast Nfs1-Isd11 where the individual 
units alone are thermodynamically unstable, however when combined they form a 
complex that is highly soluble. Within this Nfs1-Isd11complex, Nfs1 exists as a 
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homodimer while coordinating with 2 Isd11 molecules per Nfs1 monomer in a 
quaternary structure of (Nfs1-Isd112)2 when combined. This quaternary structure is 
similar in stoichiometry to that reported in other eukaryotic systems213,229,235, and in the 
Nfs1-Isd11 subunit structure of our co-expressed Nfs1/Isd11/Isu1/Yfh1 complex [Dzul 
(2016) et al. Metallomics (in press)]. Our results do not match the observation by Terali 
et al.231 suggesting a Nfs1:Isd11 ratio of 1:1 and a quaternary structure of a (Nfs1-
Isd11)3 heterohexamer, possibly due to differences in overexpression characteristics, 
subtle differences in our protein amino acid constructs, or slight variations in solution 
conditions between the studies. It is interesting that this stoichiometry is preserved 
when we co-express yeast Nfs1-Isd11 with Isu1 and Yfh1. This Nfs1/Isd11/Isu1/Yfh1 
complex shows relatively high cysteine desulfurase activity (~6 fold higher than Nfs1-
Isd11 alone) and high correlated Fe-S cluster assembly activity ((~3 fold higher than 
Nfs1-Isd11 alone). With the observation of Nfs1 and Isd11 aggregating in the absence 
of complexation, it was apparent that these two proteins have a mutual stabilization 
effect on each other and thermal stabilities of Nfs1 and Nfs1-Isd11 complex assessed 
using DSC confirmed this fact. Over 40 % of the residues for both Nfs1 and Isd11 are 
hydrophobic, which is probably linked to the inherent insoluble nature of these two 
proteins by themselves. Since complexation relieves any insolubility it is reasonable to 
hypothesize that Isd11 may bind via hydrophobic interactions to minimize solvent 
exposure of hydrophobic patches on both Nfs1 and Isd11. This notion is further 
confirmed by ANS fluorescence spectroscopy, which shows exclusion of ANS from 
binding to Nfs1 during complexation with Isd11. It is possible that the entire complex 
becomes tightly folded encapsulating the hydrophobic regions within the inner core, 
 84	
making ANS inaccessible to the complex. Reported CD and Tryptophan fluorescence 
data also suggested substantial structural rearrangement during complexation providing 
additional proof for this hypothesis231. Therefore it is clear that association between 
Nfs1 and Isd11 provides mutual stabilization and a soluble complex.  
UV-visible spectroscopy is the best method to measure substrate-binding affinity 
of the Nfs1-Isd11 complex. As a consequence of the PLP cofactor being bound to Nfs1, 
reaction intermediates formed upon substrate binding created distinct spectral features 
that could be used to determine substrate-binding kinetics as the reaction progresses as 
previously reported218,237,239,241. Upon L-cysteine addition to Nfs1-Isd11, an absorption 
feature at 420 nm diminished while a new feature gradually appeared at 340 nm 
representing a mixture of reaction intermediates (i.e. internal aldimine and persulfide) 
rather than a single intermediate. The Nfs1(C421A)-Isd11 mutant complex allowed 
monitoring of spectral changes associated only with substrate binding. In addition, this 
mutant confirmed the spectral feature at 340 nm only represents L-cysteine-PLP 
ketimine adduct, the product directly consequential to substrate addition. Our Kd for 
Nfs1(C421A)-Isd11 complex was consistent with the affinities reported for bacterial 
cysteine desulfurases219,237. Given the pronounced differences between prokaryotes 
and eukaryotes (i.e., the presence of Isd11), it can be suggested that Isd11 has minimal 
effect on substrate binding on eukaryotic Nfs1. A previous study reported that Isd11 
only took part in persulfide formation step and had no contribution towards substrate 
binding in the Nfs1-Isd11116. Therefore Isd11’s role in the eukaryotic cysteine 
desulfurase complex is not directly linked to substrate binding to Nfs1. 
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Characterization of the kinetics of the yeast cysteine desulfurase enzyme is 
essential in order to assess activity parameters affected by the evolution of cysteine 
desulfurases from bacteria to humans. The most used assay to study cysteine 
desulfurase activity is a colorimetric detection system that quantifies the acid labile 
sulfide produced during catalysis242,218. This assay has been applied to study cysteine 
desulfurase activity in several different systems112,207,230. In this assay, a colorimetric 
measurement of methylene blue formed in proportion to the amount of persulfide 
produced allows straightforward quantitation of the same using a standard curve 
developed with inorganic sulfide. Although previous studies have quantified the amount 
of methylene blue produced by measuring the spectral intensity at 650 nm, we 
measured the absorbance at 750 nm, which is the second intense absorption maxima 
for methylene blue. This feature showed the lowest variation (< 5 % of the total signal at 
the highest L-cysteine concentration) for the blank reactions performed with varied L-
cysteine concentrations similar to the actual experiment, and therefore had minutest 
effect on the readings. Michaelis-Menten parameters calculated for the yeast Nfs1-
Isd11 complex from this report suggest that the yeast system falls between bacterial 
and human systems in the scale of evolution. The Michaelis constant (KM) for yeast 
Nfs1-Isd11 closely resembles that of the human homolog207,230, but largely deviates 
from that seen for the E. coli IscS112, which is a hundred fold lesser than eukaryotes. An 
increase in KM coupled to increasing complexity of the organism may indicate that 
cysteine desulfurases have evolved to function near physiological L-cysteine 
concentration of ~ 0.1 mM207. KM values near substrate concentrations allow enzymes 
to catalyze at a rate of Vmax/2 and thereby regulate turn over based on substrate 
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availability that is often adjusted to meet cellular demands. On the other hand, catalytic 
efficiency (Kcat/KM) of the yeast Nfs1-Isd11 complex falls between bacterial and human 
systems, in a series where catalytic efficiency decreases with increasing complexity of 
organisms. Catalytic efficiency is a measure of enzymatic function at low substrate 
concentrations and apparently it has been compromised in eukaryotic cysteine 
desulfurases as opposed to IscS. Such a compromise may indicate an extra level of 
regulation summoned to control the cysteine desulfurase reaction in eukaryotes. 
Interestingly, Isd11 is only present in eukaryotes and complexation with Isd11 has an 
activating effect on Nfs1. Given that IscS turns over at maximum velocity (when [S] >>> 
KM, V=Vmax) and exhibits high catalytic efficiency, it is possible that additional regulation 
was needed for cysteine desulfurase reaction within the mitochondria to eliminate the 
formation of toxic levels of sulfides.  
Although the function of eukaryotic Nfs1-Isd11 complex in Fe-S cluster 
biogenesis is established, structural details on the complex are lacking. Therefore a 
modeled structure for yeast Nfs1 developed from the published structure of the bacterial 
orthologs222,223 will have to suffice for now. The SWISS-MODEL homology modeling 
workspace243 was used with the E. coli IscS crystal structure to model Nfs1. However, 
IscS may not be the ideal template since prokaryotic systems do not utilize Isd11. In 
addition, the first 62 residues in Nfs1 N-terminus were absent from IscS, so the modeled 
structure lacked that region. A previous attempt to model Nfs1 using a different 
homology modeling platform yielded a structure without the flexible loop of 10 residues 
harboring catalytic cysteine residue (C421) due to lack of corresponding segment on 
IscS231. However our structure modeled with SWISS MODEL contained this missing 
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segment. Therefore, we were able to measure the distance between the catalytic 
cysteine and PLP, and predict that a conformational change is required for catalysis. 
Another conformational change was also predicted for L-cysteine binding, as it was 
apparent that the substrate-binding site was occluded in the model. Confirming this 
hypothesis, ANS and tryptophan fluorescence experiments showed a conformational 
change during substrate binding. Since Isd11 does not seem to be involved in the 
substrate binding (as seen with UV-visible spectroscopy experiments) but only alters 
catalytic activity it is likely that the second conformational change is facilitated by Isd11.  
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2.6 Supplementary Material 
	
 
Figure S2.1: Circular dichroism spectra of purified Nfs1-Isd11 and Nfs1(C421A)-
Isd11 protein complexes. Solid and dotted lines represent Nfs1-Isd11 and 
Nfs1(C421A)-Isd11, respectively. Experiment was carried out at 25 °C in 5 mM 
phosphate buffer at pH 7.5 supplemented with 100 NaF. Spectra were collected in the 
far-UV region (180-260 nm) with a JASCO J-1500 CD Spectrometer using 0.5 µM 
protein samples with 1 mm pathlength cuvette. Each displayed spectra represent a 
smoothed average of spectra from three independent experiments and in each 
experiment ten individual spectra were collected. Buffer scan was subtracted from the 
averaged spectra to accomplish baseline correction. Simulation of averaged spectra 
obtained using CDPro Analysis software, which used CONTIN as the method and 
SP29, SP37, SP43, SMP50, and SMP56 as reference databases yielded the amount of 
secondary structural elements present in each individual protein as listed in Table S2.1.  
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Table S2.1: Secondary structural elements by percentage for Nfs1-Isd11 and 
Nfs1(C421A)-Isd11 protein complexes from circular dichroism.  
 
Secondary structural element Nfs1-Isd11  Nfs1(C421A)-Isd11 
Helix 33.2 ± 2.6 38.5 ± 2.7 
Strand 18.8 ± 2.9 13.9 ± 1.4 
Turn 20.4 ± 0.5 20.7 ± 0.7 
Undetermined 27.7 ± 0.3 26.9 ± 0.7 
RMSD 0.14 0.15 
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Figure S2.2: Differential Scanning Calorimetric thermal profiles of purified Nfs1-
Isd11 and Nfs1(C421A)-Isd11 protein complexes. Solid and dotted lines represent 
Nfs1-Isd11 and Nfs1(C421A)-Isd11, respectively.  
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Figure S2.3: Persulfide forming activity of Nfs1-Isd11 compared to Nfs1(C421A)-
Isd11. Columns A and B represents Nfs1-Isd11 and Nfs1(C421A)-Isd11, respectively. 
Amount of sulfide formed by 15 µM protein is measured using the acid labile sulfide 
detection assay as described in the main article in a buffer containing 20 mM HEPES, 
and 300 mM NaCl at pH 7.5.  
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CHAPTER 3 
EFFECT OF YEAST FRATAXIN “YFH1”ON THE STRUCTURE AND FUNCTION OF 
THE NFS1-ISD11 COMPLEX 
3.0 Prelude 
This chapter describes my work studying the effect of yeast frataxin homolog 
Yfh1 on the structure and function of yeast cysteine desulfurase “Nfs1-Isd11” complex. 
The function of frataxin within Fe-S cluster biogenesis has been a longstanding 
discussion beginning with the discovery that its loss of function causes Friedreich’s 
ataxia. Presently, frataxin is viewed more as a regulator of cluster assembly than as an 
essential iron delivery protein. Involvement of frataxin in altering sulfur mobilization and 
cluster assembly in both prokaryotes and mammalian cells has been studied 
extensively over the past years, as described later in this chapter. But less attention has 
been paid towards investigating these events in yeast besides the radiolabeling 
experiments showing Yfh1 directly stimulating cysteine desulfurase by exposing binding 
sites to facilitate substrate binding116. The objective of my work was to fill in the gaps in 
knowledge of the Yfh1/Nfs1-Isd11 interaction and the effect of Yfh1 on cysteine 
desulfurase activity. Isothermal titration calorimetry and surface plasmon resonance 
studies were proposed to determine the binding affinity of Yfh1 to Nfs1-Isd11. UV-visible 
spectroscopy and acid labile sulfide detection assays were used to monitor the effect of 
Yfh1 on L-cysteine binding affinity and catalytic activity of Nfs1-Isd11 complex 
respectively. Finally, differential scanning calorimetry detected changes in thermal 
stability upon Yfh1 binding to the complex. My results presented below suggest that 
Yfh1 has minimal effect on Nfs1-Isd11 structure and function by itself but might be 
synergistic with other factors, such as Isu1. 
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3.1 Introduction 
Frataxin was first discovered two decades ago as the protein encoded by the 
gene X25 located in the critical region of the FRDA locus of Friedreich’s ataxia (FRDA) 
patients. Most patients were homozygous for an unstable GAA triplet repeat expansion 
in the first intron of this gene188. Since then, a plethora of studies performed pertaining 
to characterizing the structure and function of frataxin, not only in humans but also in 
other organisms, has been tremendously useful in understanding the relation of frataxin 
to the pathophysiology of FRDA. Initial studies on the yeast frataxin homolog protein 
(Yfh1) encoded by the YFH1 gene reported involvement of this protein in iron 
homeostasis and mitochondrial function. Loss of Yfh1 function lead to the accumulation 
of iron within the mitochondria244,245, deficiency in function of specific mitochondrial 
proteins (including cytochrome c oxidase), and hypersensitivity to H2O2, iron and 
copper245. The frataxin gene is of nuclear origin, and the protein was found localized to 
the mitochondria246-248 and predominantly expressed in tissues with high metabolic 
demand247. In the search for frataxin’s function within the cellular milieu, several 
hypotheses have been postulated and tested. A few postulates of frataxin’s function 
include 1) regulation of mitochondrial iron efflux249, 2) employment of early antioxidant 
defenses to prevent oxidative damage in the cell250, 3) activation of mitochondrial 
energy conversion and oxidative phosphorylation251, and 4) serve as an iron chaperone 
for proteins such as ferrochelatase252-256. Frataxin’s function, in relation to Fe-S clusters, 
was discovered only when Fe-S proteins such as mitochondrial respiratory complexes I, 
II, and III, and aconitase showed reduced activity with the deletion of frataxin gene257-
259. A decrease in Fe-S cluster protein maturation in ∆yfh1 yeast strains260,261, reduction 
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in mitochondrial Fe-S protein activities and Fe-S cluster association with the cytosolic 
iron regulatory protein 1 (IRP1) in frataxin-depleted HeLa cells262 indicated that frataxin 
is crucial for Fe-S protein biogenesis. Phylogenetic studies further confirmed the 
evolutionary lineage of the frataxin gene to be directly involved in Fe-S cluster protein 
assembly263. Frataxin’s mechanism of action within Fe-S cluster synthesis has been 
extensively investigated in various systems in the past decade and multiple studies 
provided evidence for frataxin’s function as an iron donor for Fe-S cluster assembly, as 
well as a regulatory protein altering the function of other protein partners of the 
assembly process. Such evidence is discussed in detail in the following sections. 
3.2 Frataxin’s function in Fe-S cluster assembly 
3.2.1 Iron binding ability and iron chaperone function of frataxin 
In relation to frataxin’s proposed function as an iron donor, its ability to bind iron 
has been tested in several studies. Affinities of all frataxin orthologs towards iron have 
shown to be weak, within the micromolar range. Human frataxin’s (FXN) ability to bind 
6-7 iron atoms with an affinity of Kd ~ 10-55 µM was quantified by iron-dependent 
fluorescence measurements and ITC119. Similarly, bacterial frataxin (CyaY) 
demonstrated binding of two ferrous ions per monomer with a Kd of 4 µM264. A more 
comprehensive study on monomeric Yfh1 characterized its iron binding properties and 
provided a detailed description of bound iron and the protein’s metal-binding sites. 
Monomeric Yfh1 was capable of binding two Fe2+ atoms in the high spin state with 
micromolar affinities (Kd1 ~ 3 µM and Kd2 ~ 2 µM) at the two independent sites. The 
coordination geometry of the iron binding sites was determined as six-coordinate with 
Fe-O/N based ligands attributed to the residues within the acidic patches on the 
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protein206. Weak micromolar affinities towards iron have been considered important for 
frataxin’s function as an iron chaperone within the cell. 
Structural studies provided a framework for mapping the key residues involved in 
iron binding. Both solution and crystal structures are available for the bacterial, yeast, 
and human frataxin orthologs252,265-269 and these proteins are extremely similar. All 
frataxins in common have an α-β sandwich structure motif with two terminal α-helices in 
one plane and five antiparallel β-strands constructing a second plane, which are 
intersected by a sixth β-strand120. Although frataxin has mostly been characterized as 
an iron binding protein, it somewhat lacks structural features of a typical iron binding 
protein, such as hydrophilic iron binding pockets or cavities and typical iron chelating 
residues (histidines and/or cysteines)265,270. Iron binding in all frataxins has been 
confined to a patch of acidic residues mostly comprising of conserved aspartates and 
glutamates (negatively charged carboxylate side chains serve as iron binding ligands) of 
N-terminal region of these proteins. These residues are located in the α1 and β1 
secondary structural elements. NMR chemical shift perturbation experiments on 
CyaY269  and Yfh1252 identified amino acid residues which underwent substantial 
chemical shift changes upon titration of iron. 
Requirement for oligomerization for iron loading to frataxin has also been studied 
extensively. Yfh1’s ability to self assemble into spherical multimers in the presence of 
iron and to sequester iron in a bioavailable form have also been reported271,272. Similarly 
human frataxin is capable of making an iron-binding stable homopolymer273 while 
bacterial frataxin CyaY behaves similar to Yfh1 and forms aggregates with iron loading 
capacity274. Hence oligomerization was considered an important property of all frataxins 
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and suggested an iron storage function. However the physiological relevance of higher 
order multimers was questioned at that time due to the non-conserved nature of 
aggregation between species274 and in due course iron-induced oligomerization and 
iron storage in Yfh1 was found dispensable for heme and Fe-S cluster assembly in 
vivo275,276. Therefore, frataxin’s function as an iron chaperone was deemed redundant. 
In summary, these studies indicated that although weak binding affinity towards 
iron and iron-dependent oligomerization predicted frataxin’s function as an iron 
chaperone, this function is not a critical function in cells. 
3.2.2 Frataxin interacts with other key proteins in Fe-S cluster assembly pathway 
De novo synthesis of Fe-S clusters is a complex process that involves multiple 
proteins3,175. Since frataxin was found to be essential for this process, initial studies 
attempted to identify its individual interaction partners within the cell. Direct interactions 
between frataxin and the respective scaffold protein within the Fe-S assembly 
machinery in human, yeast and bacterial systems have been reported many times, 
postulating frataxin’s function as an iron donor for the process119,277-282. In eukaryotes, 
this interaction is iron dependent, its Kd is nanomolar119,282 and requires frataxin 
oligomerization283. Isu1 binding residues on yeast Yfh1 have been located to the β–
sheet adjacent to the acidic iron binding ridge280-282. Similarly, direct interactions with 
ISD11 have also been identified defining ISD11 as a mediator for frataxin to interact 
with other cluster assembly components284. The interaction between frataxin and 
cysteine desulfurase has been demonstrated in a different context: frataxin as a 
regulator of cysteine desulfurase activity and of sulfur delivery. Pull-down assays 
confirmed bacterial frataxin CyaY interacting with cysteine desulfurase IscS208,279 and 
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NMR experiments mapped CyaY residues involved in the interaction in to an iron 
binding region208 comprising of α1, β1, and α1β1 loop285. Modeled structures identified 
CyaY bound at a site near the IscS dimer interface and the stoichiometry of CyaY:IscS 
was reported as 1:1 (from ITC, SAXS and NMR) with a Kd of 18.5 µM (from ITC)285. This 
lower affinity CyaY-IscS complex could not be isolated by gel filtration 
chromatography286. Similarly in the human system, no SDF (NFS1-ISD11-FXN) 
complex was observed from gel filtration chromatography and frataxin had no direct 
effect on cysteine desulfurase activity as well207. Characterization of these individual 
interactions added a new level of knowledge towards understanding frataxin function, 
yet the quest to understand frataxin’s function continues. 
Besides the direct interactions with each individual component, frataxin’s 
involvement in core Fe-S assembly complex (consisting of all four components, cysteine 
desulfurase (S) and its accessory protein (D), scaffold (U), and frataxin (F): SDUF 
complex) has been in the limelight in the past few years. Evidence of mammalian 
frataxin binding to the preformed SDU complex207,229,235,283 and mutations/other variants 
of frataxin binding weakly to the same287,288 suggested frataxin’s involvement in the core 
assembly complex. The role of frataxin in the SDUF complex has been studied 
extensively, and the most common hypothesis is that frataxin stimulates cluster 
assembly by enhancing sulfur delivery. The next section reviews this hypothesis. 
3.2.3 Frataxin as a regulator of Fe-S cluster synthesis through controlling 
cysteine desulfurase activity 
In the search for frataxin’s function within the Fe-S cluster assembly process, 
much evidence is directed towards defining it as a regulator for cysteine desulfurase 
 99	
activity (i.e. sulfur delivery). Formation of a multiprotein complex between human NFS1, 
ISD11, ISU2 and FXN enhanced catalytic efficiency and the KM for cysteine desulfurase 
activity within the quad complex dramatically in an ISU2-dependent manner, as 
compared to the NFS1-ISD11 (SD) complex alone. Addition of one equivalent of ferrous 
iron further stimulated cysteine desulfurase activity of this complex207. This notion was 
further confirmed when frataxin mutants/variants showed decreased binding affinities to 
the SDU complex, diminished Fe-S cluster synthesis, and lowered cysteine desulfurase 
activities of the SDUF complex287,288. In dissecting the mechanism of activation by 
frataxin, it was found that FXN stabilized a confirmation of the SDU complex that 
accelerated the formation of persulfide on NFS1. Simultaneously to that, FXN also 
facilitated inter-protein sulfur transfer between NFS1 and residue C104 of ISCU2, 
leading to acceleration of cluster assembly289. Studies on the yeast system suggested 
that Yfh1 directly and specifically enhances cysteine binding to Nfs1 by exposing its 
substrate-binding sites116. Notably, in the murine system, FXN enhanced the cysteine 
desulfurase activity of the SDU complex but the impact of iron on the stimulatory effect 
was only minimal and not specific to iron. The same study also reported that iron entry 
into the SDUF complex is contingent upon activation of cysteine desulfurase by FXN; 
hence suggesting a concerted mechanism for iron and sulfur entry. Assembly of a 4Fe-
4S cluster was observed in both SDU and SDUF complexes but cluster transfer was 
only efficient in the presence of FXN235. Controversially to all of the above, a novel study 
showed that FXN is not required for persulfide formation on NFS1, but it specifically 
enhances sulfur transfer from NFS1 to ISCU, thus increasing the rate of sulfide 
production in the SDUF complex in a global scale. FXN also stimulated sulfide release 
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from NFS1 by enhancing the reduction of persulfide on NFS1 by thiols such as DTT, 
although it is not relevant or efficient for Fe-S cluster synthesis290.  
On the other hand, bacterial frataxin CyaY is suggested as an iron-dependent 
inhibitor of 2Fe-2S cluster formation through binding to cysteine desulfurase IscS208 by 
directly inhibiting cysteine desulfurase activity291. In an experiment in which human and 
prokaryotic cluster assembly components were interchanged, CyaY could functionally 
replace FXN and activate human cysteine desulfurase while FXN failed to activate 
bacterial IscS. Therefore the inhibitory effect was determined by the identity of the 
cysteine desulfurase, not frataxin292. 
Taken together, these studies support the model that frataxin is a regulator of Fe-
S cluster synthesis in all organisms. Eukaryotic frataxin most probably facilitates sulfur 
transfer from the cysteine desulfurase to the scaffold protein. The observed stimulation 
of cysteine desulfurase activity on the SDUF complex could either be a direct 
repercussion of frataxin on the cysteine desulfurase enzyme, or a global scale effect 
observed due to enhanced sulfur transfer. Therefore the explicit function of frataxin in 
mammalian Fe-S cluster synthesis still remains elusive. In contrast prokaryotic frataxin 
is an inhibitor of cluster formation via decreasing cysteine desulfurase activity. The 
functional discrepancy of frataxin between eukaryotic and prokaryotic systems is 
surprising yet interesting and requires careful rationalization through further 
investigations.  
My goal in this report was to fill in the gaps in knowledge of the Yfh1/Nfs1-Isd11 
interaction and the effect of Yfh1 on structure and function of Nfs1-Isd11 in the yeast 
system. Experiments outlined below were carried out in such context. 
 101	
3.3 Experimental methods 
3.3.1 Bacterial expression and isolation of proteins 
3.3.1.1 Expression of yeast Fe-S cluster synthesis proteins 
Expression of Nfs1 (and C421A)-Isd11: pST39 co-expression vectors containing 
Δ1-33 Nfs1-6xHis-Isd11 or Δ1-36 Nfs1(C421A)-6xHis-Isd11 were transformed into BL21 
(DE3) cells. In both these constructs Nfs1 lacks mitochondrial targeting sequence but 
Isd11 remains full length. Starter cultures were made by inoculating a transformed 
colony in Luria Bertani (LB) broth supplemented with 100 µg/ml ampicillin. These 
cultures were incubated in a rotating shaker for 16 hours (overnight) at 230 rpm and 37 
°C. Starting OD of the growth cultures (1 L) supplemented with 100 µg/ml ampicillin 
were set to 0.075 by adding appropriate amount of starter culture and the cells were 
grown until cell density reached 0.4 OD600. Growth temperature was then switched to 18 
°C and cells were induced at 0.7 OD600 using of 0.8 mM IPTG supplemented with 10 µM 
PLP. Cells grew for 18 hours and then they were harvested by centrifugation at 15900 x 
g for 30 min. If not lysed immediately, cell pellets were flash frozen and stored at -80 °C 
for future use. 
Expression of Nfs1: pET21b vector containing Δ1-33 Nfs1-6xHis was 
transformed into BL21 (DE3) codon plus cells. Starter cultures and growth cultures (1 L) 
were treated as mentioned above except they were supplemented with 34 µg/ml 
chloramphenicol in addition to 100 µg/ml ampicillin. Cells were grown at 37 °C until cell 
density reached 0.4-0.5 OD600. Growth temperature was then switched to 25 °C and 
cells were induced at 0.7 OD600 with of 1 mM IPTG, supplemented with 10 µM PLP. 
Cells were continued to grow at 25 °C for 3 hours before harvesting, again by 
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centrifugation. If not lysed immediately, cell pellets were flash frozen and stored at -80 
°C for future use. 
Expression of Yfh1 and Yfh1-6xHis: Mature full length Yfh1 was expressed as 
described previously252. Briefly pET11a vector containing Δ1-52 Yfh1 or Δ1-52 Yfh1-
6xHis was transformed into BL21 (DE3) Star cells. Starter cultures and growth cultures 
(1 L) were treated as mentioned above and were supplemented with 100 µg/ml 
ampicillin. Cells were grown at 37 °C until cell density reached 0.8 OD600 and were 
induced with 1 mM IPTG. Cells were continued to grow at 37 °C for 6 hours before 
harvesting by centrifugation. If not lysed immediately, cell pellets were flash frozen and 
stored at -80 °C for future use. 
3.3.1.2 Purification of yeast Fe-S cluster synthesis proteins 
Purification of Nfs1, Yfh1-6xHis, Nfs1-Isd11, and Nfs1(C421A)-Isd11 proteins: 
Frozen cell pellets were resuspended in pH 7.5 lysis buffer containing 50 mM Sodium 
Phosphate, 150 mM NaCl for Yfh1-6xHis, Nfs1-Isd11, and Nfs1(C421A)-Isd11 
complexes/300 mM NaCl for Nfs1 alone, 5% Glycerol, 20 mM Imidazole, and 5 mM β–
ME (4 ml/g of cells). In addition, cOmplete™ EDTA-free protease inhibitor cocktail 
(Roche), lysozyme (10 mg/ml), and DNAse (10 µg/ml) supplemented with 5 mM MgCl2 
were also included in the lysis buffer. Protein purification was performed at 4 °C. Cell 
suspensions were incubated at 4 °C for 30 min while stirring at a slow pace before 
passing through the Emulsiflex cell homogenizer three times for cell lysing. Cell lysates 
were then centrifuged at 53000 x g for 1 hour. Crude soluble fractions were filtered 
(0.20 µm) before passing through Ni affinity columns. Nfs1-Isd11 soluble fraction was 
passed through His-Trap HP 5 ml Ni column (GE Healthcare) using an AKTA FPLC 
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chromatography system (Amersham Biosciences/GE Healthcare); Yfh1-6xHis, Nfs1 or 
Nfs1(C421A)-Isd11 soluble fractions were passed separately through pre-equilibrated 
high density Ni-NTA Agarose Beads (GoldBio) manually packed in bench-top columns. 
Ni columns were first washed with 20 column volumes of binding buffer to eliminate any 
residual unbound proteins. Bound proteins were then eluted by flowing an imidazole 
gradient of 20-500 mM across the columns and fractions containing Yfh1-6xHis, Nfs1, 
Nfs1-Isd11, and Nfs1(C421A)-Isd11 complexes were identified using SDS-PAGE. 
Active fractions were pooled and concentrated to ~ 1 ml using 10 kDa molecular weight 
cutoff Amicon centrifugal filter devices (Millipore). Nfs1 containing protein preparations 
were incubated with excess PLP to ensure 100 % loading of PLP to all Nfs1 units. 
Similarly, Yfh1-6xHis protein preparation was incubated with 5 mM EDTA to ensure 
removal of any bound iron. Concentrated Nfs1, Nfs1-Isd11, and Nfs1(C421A)-Isd11 
proteins and Yfh1-6xHis were passed through HiPrep 16/60 Sephacryl S-200 HR and 
HiLoad 16/600 Superdex-75 size exclusion columns (both GE Healthcare) respectively 
to further remove impurities and to transfer to pH 7.5 final buffer comprising of 20 mM 
HEPES, 150 mM NaCl for Yfh1-6xHis, Nfs1-Isd11, and Nfs1(C421A)-Isd11 
complexes/300 mM NaCl for Nfs1 alone, and 5mM β–ME. Fractions containing Nfs1, 
Nfs1-Isd11, and Nfs1(C421A)-Isd11 complexes were pooled and concentrated to store 
at -80 °C in aliquots until further use in experiments. Yfh1-6xHis fractions were 
concentrated and stored under oxygen depleted nitrogen atmosphere at 4 °C and was 
used within two weeks of isolation to ensure protein integrity. All purified proteins were 
>90% pure (Figure 3.1). 
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Purification of Yfh1: The mature form of Yfh1 was purified as described 
previously252. Briefly frozen cell pellets were resuspended in pH 8.0 lysis buffer 
containing 25 mM Tris HCl, 10 mM EDTA, and 5 mM β–ME (4 ml/g of cells). In addition, 
cOmplete™ EDTA-free protease inhibitor cocktail (Roche), lysozyme (10 mg/ml), and 
DNAse (10 µg/ml) supplemented with 5 mM MgCl2 were also added to the cell 
suspension. Protein purification was performed at 4 °C. Cell suspensions were 
incubated at 4 °C for 30 min while stirring at a slow pace before passing through the 
Emulsiflex cell homogenizer three times for cell lysing. Cell lysates were then 
centrifuged at 53300 x g for 1 hour. Crude soluble fractions were filtered (0.20 µm) and 
subjected to two ammonium sulfate precipitation steps: (1) contaminating proteins 
precipitated by incubating with 40% ammonium sulfate for 20 min and centrifugation at 
15900 x g for 20 min and (2) Yfh1 precipitation from resulting supernatant by incubating 
with 60% ammonium sulfate for one hour and centrifugation at 15900 x g for 20 min. 
Resulting Yfh1 pellet was resuspended in a minimal volume of lysis buffer before 
dialyzing twice for 3 hours each in 2 L of the same buffer to remove any ammonium 
sulfate. Then the protein mixture was passed through HiLoad 26/10 Q-Sepharose 
column (Amersham Biosciences/GE Healthcare) pre-equilibrated with pH 8.0 buffer 
containing 25 mM Tris HCl, 10 mM EDTA, and 5 mM β–ME and eluted using an 
increasing 1 M NaCl gradient. Fractions containing Yfh1 were identified using SDS-
PAGE, pooled, and dialyzed as before to remove any salt. Further purification of Yfh1 
involved passing through pre-equilibrated HiLoad 26/10 Phenyl-Sepharose column 
(Amersham Biosciences/GE Healthcare) and eluting with a decreasing 1 M ammonium 
sulfate gradient at pH 8.0. Solid ammonium sulfate was added to the protein mixture 
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prior loading to the column to make the starting ammonium sulfate concentration 1 M. 
Fractions containing Yfh1 identified by SDS-PAGE were concentrated to 1 ml, before 
treating with 5 mM EDTA at pH 8.0 for 30 min. Metal-free protein was then loaded on to 
pre-equilibrated HiLoad 16/600 Superdex-75 size exclusion column (GE Healthcare) for 
further purification and buffer exchange to final 20 mM HEPES, 150 mM NaCl, and 5 
mM β–ME pH 7.5 buffer. Pure Yfh1 (>90%) (Figure 3.1) was concentrated using a 10 
kDa molecular weight cutoff Amicon centrifugal filter device (Millipore) and was stored 
under oxygen depleted nitrogen atmosphere at 4 °C. Purified frataxin was used within 
two weeks of isolation to ensure protein integrity. 
3.3.2 Isothermal Titration Calorimetry 
ITC experiments were executed to determine the Yfh1 binding affinity to the 
Nfs1-Isd11 complex, as well as the maximum Yfh1/Nfs1-Isd11 stoichiometry. Titrations 
were carried out at 30 °C on a TA instruments Nano-ITC calorimeter under anaerobic 
conditions. Concentrated Yfh1 and Nfs1-Isd11 proteins were diluted to 500 µM and 25 
µM respectively in degassed pH 7.5 buffer containing 20 m HEPES, 150 mM NaCl, and 
5 mM β–ME. Twenty fold excess Yfh1 was loaded on to the syringe while 950 µl of 
Nfs1-Isd11 remained in the cell stirring at 200 rpm. A total of forty 5 µl injections of Yfh1 
were titrated consecutively at 300 s intervals to achieve the thermal titration profile. The 
TA Instruments NanoAnalyze software package was used to analyze the titration profile 
and identify the best-fit values for the dissociation constant, stoichiometry, and heat of 
enthalpy change for the Yfh1/Nfs1-Isd11 interaction. 
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3.3.3 In vitro pull-down assay 
A Ni-NTA agarose affinity pull-down assay was performed to observe any 
complex formation between Yfh1 and Nfs1-Isd11 proteins. Purified Nfs1-Isd11 (-6xHis 
tag on Nfs1) was incubated with 100 µl of high density Nickel-NTA Agarose Beads 
(GoldBio) pre-washed with Milli-Q water and equilibrated with 20 mM HEPES, 150 mM 
NaCl, and 5 mM β-ME pH 7.5 buffer, within a BioRad Micro Bio-Spin column. Maximum 
binding of Nfs1-Isd11 to the resin was allowed by end-to-end mixing on a rotating 
platform for 30 min at 25 °C. The sample was spun at 295 x g for 1 min using a tabletop 
centrifuge to remove the flow through from the column and subsequent washes with the 
same buffer removed any unbound protein. Beads saturated with bound Nfs1-Isd11 
were then treated with four-times molar excess of Yfh1 for 30 min on the rotating 
platform at 25 °C to allow maximum binding. Beads were extensively washed with buffer 
as before until no protein was detected in the collected washes, monitored using the 
Advanced protein detection solution. After a single 20 mM imidazole wash, bound 
proteins were eluted with 500 mM imidazole buffer and subsequently detected with 
SDS-PAGE. 
3.3.4 Differential Scanning Calorimetry 
Changes in the thermal stability of Nfs1, or the Nfs1-Isd11 complex, upon 
addition of Yfh1-6xHis were assessed using differential scanning calorimetry (DSC). 
Purified and concentrated proteins were mixed and incubated at 25 °C for 10 min to 
achieve respective stoichiometrically proportioned mixtures (~0.5-3 mg/ml). Samples 
were prepared in 20 mM HEPES, 300 mM NaCl, 5 mM β-ME at pH 7.5 buffer, degassed 
to remove dissolved air. Protein samples were loaded in the sample cell of a TA 
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Instruments Nano-DSC calorimeter; the reference cell was filled with matched buffer. 
The total volume for the capillary cell is 0.3 ml, however an excess of solution (~0.6 ml) 
is used for loading to prevent trapping air bubbles. Both capillary cells were manually 
pressurized to maintain a constant pressure of 3 atm during the scan. Each protein 
sample was scanned at a rate of 1 °C/min from 10 °C to 90 °C, and the melting curves 
for Nfs1:Yfh1 (1:2) and Nfs1-Isd11:Yfh1 (1:2) were assessed to identify differences in 
thermal stability of Nfs1 and Nfs1-Isd11 during complexation with Isd11. Experiments 
were done in duplicate using independently isolated proteins to ensure data 
reproducibility. Thermal profiles were simulated using the TA instruments NanoAnalyze 
software package to identify the best-fit values for melting temperatures (Tm). 
3.3.5 UV-visible spectroscopy 
UV-visible spectroscopy was used to identify if the affinity of Nfs1(C421A)-Isd11 
to L-cysteine is altered in the presence of Yfh1-6xHis. In this experiment, 50 µM purified 
Nfs1(C421A)-Isd11 was incubated with 100 µM Yfh1-6xHis (in 1:2 molar ratio) at 25 °C 
for 10 min. Samples were prepared in 20 mM HEPES and 300 mM NaCl at pH 7.5 and 
the protein mixture was then titrated consecutively with freshly made L-cysteine. Protein 
samples were carefully mixed and incubated for 10 min after each addition of L-
cysteine; spectra were measured at a 1.0 nm scan pitch using a Shimadzu UV-1800 
Spectrophotometer. Each addition was timed 1 min after the start of spectra acquisition 
to maintain consistency between data points. All spectra were collected at 25 °C under 
anaerobic conditions and corrected for dilution. Experiments were performed in 
duplicate using independently prepared protein samples to ensure spectral 
reproducibility. The change in spectral intensity at 340 nm was plotted against 
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respective L-cysteine concentrations to calculate the binding affinity of Nfs1(C421A)-
Isd11 to L-cysteine in the presence or absence of Yfh1-6xHis. Best-fit simulation to data 
was obtained using DynaFit curve fitting software227.  
3.3.6 Cysteine desulfurase activity assay 
An acid labile sulfide detection assay was performed to measure the activity of 
Nfs1-Isd11 complex in the presence or absence of Yfh1-6xHis. In this assay, Fe3+ with 
sulfide liberated from the enzyme aids the conversion of N, N-dimethyl-p-
phenylenediamine sulfate (DPD) to methylene blue. The characteristic blue color, i.e. 
the visible absorption feature at ~750 nm was used to quantify sulfide production along 
with the use of a calibration curve for signal intensity prepared with a series of known 
sodium sulfide concentrations. The purified Nfs1-Isd11 complex (12 µM concentration) 
was incubated with 1 mM L-cysteine in the absence or presence of stoichiometric Yfh1-
6xHis (1:2). An assay mixture contained 100 mM HEPES (pH 7.5), 150 mM NaCl, 50 
µM PLP, and distilled water, and the total reaction volume was 100 µl. Each reaction 
was prepared by first mixing the assay components together in an eppendorf tube 
covered with rubber septa caps (Sigma-Aldrich-Z565717) to prevent air escaping. 
Respective L-cysteine amounts were then introduced to each tube using a gas-tight 
Hamilton syringe. After a 5 min incubation at 30 °C, the reaction was stopped by adding 
100 µl of 20 mM DPD in 7.2 N HCl and 30 mM FeCl3 in 1.2 N HCl. This was also 
performed using a gas-tight Hamilton syringe and each addition was timed 45 s apart to 
maintain the consistency between each reaction. Distilled water was added up to 800 µl. 
Each tube was then vortexed for 10 s before incubating for 20 min at 30 °C for efficient 
color development. All tubes were spun at 14000 x g for 2 min to remove protein 
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precipitation before measuring the absorbance. Absorbance was measured at 750 nm 
using a 1 ml cuvette on a Varian Cary-50 Bio UV-Visible Spectrophotometer. The 
amount of persulfide liberated at each concentration was determined using the standard 
curve. Measurements were collected in triplicate, averaged, and corrected for dilution. 
3.4 Results 
3.4.1 Purified proteins are > 95% pure 
All proteins purified by following respective protocols listed above were > 95 % 
pure. Nfs1 was present as a homodimer, the typical oligomerization state attributable to 
cysteine desulfurase enzymes (data shown in chapter 2). Nfs1-Isd11 and Nfs1(C421A)-
Isd11 were heteromeric complexes comprising of Nfs1 (wild type or mutant) 
homodimers and 4 Isd11 units in each complex (data shown in chapter 2). Yfh1 
(with/without -6xHis tag) was present in its monomeric form as observed with size 
exclusion chromatography (data not shown). 
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Figure 3.1: SDS-PAGE gel of purified proteins. Lanes represent 1: molecular weight 
marker, 2: purified yeast Nfs1-Isd11 complex, 3: Nfs1(C421A)-Isd11 complex, 4: Yfh1, 
and 5: Yfh1-6xHis.   
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3.4.2 ITC experiments suggest a possible interaction between Nfs1-Isd11 
complex and Yfh1 
To provide evidence that Nfs1-Isd11 and Yfh1 physically interact during Fe-S 
cluster synthesis, and to quantify the interaction, isothermal titration calorimetry was 
performed. Titration of Yfh1 into Nfs1-Isd11 yielded the raw binding isotherm (Figure 
3.2-A) that could be simulated to obtain the best-fit binding isotherm (Figure 3.2-B) and 
corresponding binding parameters. The Kd, stoichiometry, and enthalpy for the 
interaction were 7.4 ± 3.2 µM, 1.5 ± 0.1, and -4.9 ± 0.7 kJ/mol respectively. Detection of 
a binding event with ITC suggested a physical interaction of Yfh1 with Nfs1-Isd11 under 
these experimental conditions. Weak binding affinity in the micromolar range was 
consistent with a previously published micromolar Kd for the interaction between 
bacterial orthologs IscS and CyaY285. Stoichiometry of 1.5 ± 0.1 indicated that 
approximately 2 Yfh1 units associate with Nfs1-Isd11 complex, in agreement with the 
1:1 Nfs1:Yfh1 (per Nfs1 monomer) stoichiometry observed in SDUF quaternary 
complexes in several systems229,235. Although this result suggested a physical 
interaction between Nfs1-Isd11 and Yfh1, it was also questionable due to few concerns. 
The Nfs1-Isd11 complex was unstable under these experimental conditions and 
precipitation of protein was observed during continuous stirring of Nfs1-Isd11 within the 
cell, regardless of measures taken to prevent precipitation (i.e. decreased stirring 
speed, addition of stabilizers such as glycerol). Protein precipitation created a shifted 
but stable baseline with minimal noise. Due to these reasons, reproduction of these 
results was impossible. Therefore the validity of ITC results was subjected to skepticism 
and the interaction observed here could be an outcome of aggregation during 
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experiment and be superficial. Therefore, more evidence to strengthen the validity of 
these results is required. 
3.4.3 In vitro pull-down assay indicates no interaction between Nfs1-Isd11 and 
Yfh1 
To ascertain the existence of an interaction between Yfh1 and Nfs1-Isd11, an in 
vitro Ni-affinity pull-down assay was performed. Nfs1-Isd11 bound to the resin could not 
retain any Yfh1 upon incubation, as Yfh1 readily eluted with the subsequent washes 
(Lanes 5-7, Figure 3.3). No Yfh1 was found bound to Nfs1-Isd11 when eluted with 
imidazole (Lanes 12-14, Figure 3.3). Even though a weak interaction with micromolar 
affinity was observed between Yfh1 and Nfs1-Isd11 with ITC under similar conditions, 
the same interaction was not observed with pull-down assay. This indicated that an 
interaction was unlikely under these experimental conditions, and ITC results were 
indeed superficial. An interaction between human orthologs NFS1-ISD11 and YFH1 
was also not detected in a previous study207. Hence, results from ITC and pull-down 
assay may suggest that an interaction between Nfs1-Isd11 and Yfh1 is mostly not a 
tight interaction, but rather they could be transient/weak and impossible to detect within 
the sensitivity limits of these techniques.  
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Figure 3.2: Raw isothermal titration calorimetry data (A) and binding isotherm 
data (B) for Yfh1 titration into Nfs1-Isd11 complex. Solid black line in panel B 
indicates best-fit simulation to binding isotherm data obtained using fitting programs.   
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Figure 3.3: Poly-histidine tag pull-down assay for Nfs1-Isd11 interaction with 
Yfh1. Flow through and washes were collected after addition of each protein and 
separated on SDS-PAGE along with elution fractions to identify binding partners. Lanes 
labels read: 1-molecular weight marker, 2-Nfs1-Isd11 flow-through, 3, 4-two consecutive 
washes after Nfs1-Isd11 binding to the resin, 5-Yfh1 flow-through, 6-11- consecutive 
washes after Yfh1 addition, 12- 20 mM imidazole wash, and 13-15 consecutive elutions 
with 500 mM imidazole.  
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3.4.4 Association of Yfh1 with Nfs1/Nfs1-Isd11 does not affect the stability of the 
proteins 
It is also likely that the association between Nfs1-Isd11 and Yfh1 is transient, and 
that this flexibility is essential to achieve certain functional goals during the Fe-S cluster 
assembly process. It is possible that the binding partners alter each other’s stability via 
such an interaction (similar to the effect Isd11 has on Nfs1, discussed in chapter 2). 
Such an effect was monitored by comparing the thermal profiles of Nfs1 and the Nfs1-
Isd11 complex in the presence and absence of Yfh1 using Differential Scanning 
Calorimetry (DSC). Thermal profiles of neither Nfs1 (top panel-Figure 3.4) nor Nfs1-
Isd11 (bottom panel-Figure 3.4) were substantially affected by incubation with Yfh1 
(Table 3.1). Therefore it is likely that either Nfs1-Isd11 and Yfh1 does not interact in Fe-
S cluster biosynthesis machinery, or their transient interaction has minor structural 
perturbations on both partners.  
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Figure 3.4: Differential Scanning Calorimetric thermal profiles for purified Nfs1 
and Nfs1-Isd11 complex in the presence or absence of Yfh1. Letters represent 
thermograms of: A-Nfs1 only, B and E-Yfh1 only, C-Nfs1 with Yfh1 (1:2), D-Nfs1-Isd11 
only, and F-Nfs1-Isd11 with Yfh1 (1:2). Solid black and gray lines represent raw data 
and sum of best-fit simulations respectively. Dashed lines represent simulated peaks 
corresponding to domains and/or individual unfolding events in each structure. Melting 
temperatures for simulated peaks are depicted in Table 3.1. B, C, E, and F thermal 
profiles are offset for clarity.   
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Table 3.1: Melting temperatures (°C) for each domain/unfolding event obtained from 
Differential Scanning Calorimetry data for Nfs1 and Nfs1-Isd11 in the absence/presence 
of Yfh1. Melting temperatures related to Yfh1 in each case are shown in italics. 
Protein(s) Domain/unfolding event 
Melting Temperature 
(°C) 
Nfs1 1 39.1 ± 0.6 
 2 42.0 ± 0.2 
 
Nfs1+Yfh1 (1:2) 1 39.2 ± 0.2 
 2 41.7 ± 0.2 
 3 53.2 ± 0.2 
 
Yfh1 only - 53.1 ± 0.2 
 
Nfs1-Isd11 1 56.9 ± 0.8 
 2 60.3 ± 0.4 
 3 62.1 ± 0.4 
 
Nfs1-Isd11+Yfh1 (1:2) 1 56.4 ± 0.1 
 2 59.8 ± 0.4 
 3 61.7 ± 0.1 
 4 51.9 ± 0.1 
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3.4.5 Yfh1 does not alter substrate binding affinity of Nfs1-Isd11 
In order to determine any functional relationship between Nfs1-Isd11 and Yfh1, 
UV-visible spectroscopy was utilized to monitor any changes in substrate binding affinity 
of Nfs1-Isd11 in the presence of Yfh1. As described in the previous chapter, the C421A 
mutant of Nfs1 was used for this assay to isolate the substrate-binding step from 
catalytic step of the enzyme. Titration of L-cysteine to the Nfs1(C421A)-Isd11 construct 
incubated with and without Yfh1 yielded binding curves that are not distinctly different 
from each other (Figure 3.5). Best-fit simulations for binding data revealed Kd values of 
0.76 ± 0.13 mM and 0.78 ± 0.14 mM in the absence and presence of Yfh1, respectively. 
The almost identical substrate binding affinities, regardless of the presence of Yfh1, 
agrees along with the prediction that Nfs1-Isd11 and Yfh1 may not interact or interact 
transiently to alter a different function other than substrate binding in Fe-S cluster 
biosynthesis machinery. 
3.4.6 Effect of Yfh1 on cysteine desulfurase activity of Nfs1-Isd11 is minimal 
In order to determine if a transient interaction with Yfh1 may alter cysteine 
desulfurase activity of Nfs1-Isd11 complex, an acid labile sulfide assay was performed.  
This assay was used to compare the rates of sulfide liberation in the absence and 
presence of Yfh1. The rate of acid labile sulfide formation within first five minutes of the 
reaction was not significantly altered by the presence of Yfh1 (only a slight 
enhancement of 16% was observed: Figure 3.6). Similarly, in the human system, 
frataxin had no direct effect on cysteine desulfurase activity of the human complex207. 
Therefore it is likely that Yfh1 may not interact with Nfs1-Isd11 in Fe-S cluster 
biosynthesis machinery in a functional point of view.   
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Figure 3.5: Titration of L-cysteine to Nfs1(C421A)-Isd11 in the presence/absence 
of Yfh1 monitored by UV-visible spectroscopy. Black and white markers represent 
the change in absorbance at 340 nm at each L-cysteine concentration in the absence 
and presence of Yfh1, respectively. Solid and dashed lines indicate the respective best-
fit simulations obtained using DynaFit curve fitting software.   
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Figure 3.6: Persulfide forming activity of Nfs1-Isd11 in the presence/absence of 
Yfh1.  
 121	
3.5 Discussion 
The exact function of frataxin within mitochondrial Fe-S cluster biogenesis has 
been a longstanding question since the protein was discovered to be defective in 
Friedreich’s ataxia, a neurodegenerative disorder affecting 1/30,000 Caucasians. 
Although initial in vitro studies provided evidence to ascertain the protein’s function as 
an iron chaperone delivering Fe for the cluster assembly machinery, later studies 
proved additional functions were also likely. In recent years, frataxin has been identified 
as a regulator of Fe-S cluster assembly. Evidence was presented to prove that frataxin 
achieves this by enhancing cysteine desulfurase activity and sulfur delivery of the core 
assembly complex207,235,289. Much of the mechanism of this effect was elucidated in the 
human and murine systems, but studies on yeast orthologs are lacking. The objective of 
my research was to identify an interaction between Yfh1 and the yeast Nfs1-Isd11 
complex, and then to study the effect of Yfh1 on the structure and function of this 
system. In such a context, it was proposed that we isolate the necessary proteins and 
utilize techniques such as ITC, pull-down assays, and DSC to identify any interaction. In 
addition, we planned to use our UV-visible assay and activity assay to study any 
possible effect. This chapter describes experimental details and results pertaining to 
those projected studies.  
The expression and purification of all proteins required for these experiments 
were straightforward, since we have already established protocols and our lab is 
equipped with required instruments. All isolated proteins were > 90 % pure (Figure 3.1). 
Some of the initial experiments used Yfh1 with no additional tag, but later a 6xHis 
tagged version of Yfh1 became available for use with an easier, less time-consuming 
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and resource-consuming isolation protocol. Therefore later experiments used Yfh1-
Hisx6. There is no detectable difference in the structure and function of these two Yfh1 
variants, and this was confirmed by experiments performed by a fellow graduate student 
in the lab (Stephen Dzul). Therefore, results obtained with both versions are directly 
comparable. However, for clarity and integrity, each individual experiment was 
performed only with one version or the other. The use of the Nfs1(C421A)-Isd11 mutant 
complex for UV-visible spectroscopy studies was justified in chapter 2, and our CD, 
DSC, and activity assay experiments confirmed it is not significantly different from the 
wild type complex. 
ITC experiments were proposed to identify a possible interaction between Yfh1 
and Nfs1-Isd11 and elucidate physical parameters such as the dissociation constant 
and stoichiometry (Figure 3.2). These experiments were plagued with protein 
precipitation issues that caused us to question the validity of our ITC results. 
Continuous stirring during the experiments seemed to affect the stability of the Nfs1-
Isd11 complex, although it was more stable as a complex than its constitutive proteins 
were individually (chapter 2). Experimental conditions (i.e. stirring speed and buffer 
composition) were changed to prevent precipitation; nonetheless it could not be 
avoided. Despite protein precipitation, the shifted baseline was surprisingly stable and 
not noisy. Although after baseline correction, binding data for one experiment yielded 
probable binding parameters in the range of published values for the bacterial system, 
subsequent runs failed to reproduce this. Therefore, our results observed here are more 
likely to be an outcome of aggregation rather than actual interaction between Nfs1-
Isd11 and Yfh1. However the binding affinity obtained from this single experiment was 
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similar to the published binding affinity seen between the bacterial orthologs285, and the 
preliminary results reported by a previous lab member (Swati Rawat) for yeast proteins*. 
These preliminary results were obtained using a different ITC instrument and no 
precipitation has been documented for her experiment. Since ITC experiments were 
subjected to technical limitations, a less rigorous method, surface plasmon resonance 
(SPR) was proposed. SPR involves immobilizing a 6xHis-tagged protein on a Ni-affinity 
chip and passing the ligand protein over the bound molecule along with the solvent to 
allow maximum association. In the next step, dissociation is allowed by passing the 
ligand free solvent and the changes in SPR signal during association and dissociation 
steps are used to determine equilibrium binding constants. Yfh1 with no tag was passed 
with PBST (Phosphate Buffered Saline and Tween-20) buffer over Nfs1-Isd11 (-6xHis) 
complex immobilized on the sample channel as well as the empty reference channel. 
Interestingly, this technique was also subjected to technical limitations simply because 
Yfh1 unexpectedly started binding to the reference channel despite the absence of a 
6xHis-tag associated with it. Hence, no reference measurement could be made for 
accurate data analysis (data not shown). Association of Yfh1 with nickel ions is not 
novel, as reports show nickel serving as a mediator for Yfh1’s interaction with other 
cluster assembly components within humans, while other metals act as inhibitors284. 
Presumably, frataxin’s acidic ridge, proposed to serve as the iron-binding region, may 
facilitate interaction with nickel in this case. Therefore SPR was not capable of verifying 
the questionable results from ITC. An in vitro pull-down assay was performed using 
purified proteins as the last resort to observe a possible Yfh1 interaction with Nfs1-
																																								 																				*	Rawat, Swati, "Molecular Details Of The Mitochondrial Iron Sulfur Cluster Assembly Pathway" (2011). 
Wayne State University Dissertations. Paper 204.	
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Isd11. Nfs1-Isd11 was immobilized to Ni-NTA Agarose resin and subsequent washes 
removed any adventitiously bound protein before incubation with Yfh1. Yfh1 was used 
in excess (4 times) to ensure maximum and efficient association with the immobilized 
complex. Washes immediately after Yfh1 addition contained a significant amount of 
unbound Yfh1. Interestingly, the first few washes also contained a minute amount of 
Nfs1-Isd11, eluted with excess unbound Yfh1 (Figure 3.3). This could potentially be due 
to a displacement of some of the Nfs1-Isd11 complex from the resin by Yfh1 (given that 
Yfh1-Ni interaction was observed in SPR experiments too). This is likely however not 
due to Yfh1 pulling-down Nfs1-Isd11. No Yfh1 was present in subsequent elution 
fractions, indicating no stable association between Yfh1 and Nfs1-Isd11, at least under 
the assay conditions we used. Similarly, human NFS1-ISD11 and YFH1 showed no 
physical interaction in gel filtration chromatography207. In that context, ITC results could 
be confirmed superficial. Overall, these results suggested that a stable interaction 
between Nfs1-Isd11 complex and Yfh1 is unlikely. It is therefore likely that this 
interaction is transient under these experimental conditions. 
In the event of a transient binding interaction, it is possible that Yfh1 interacts 
with Nfs1-Isd11 to reach certain functional goals, even though the physical association 
is beyond the sensitivity limits of our experimental techniques. To identify if Yfh1 had 
any effect on stability, substrate binding affinity, and activity of Nfs1-Isd11, DSC, UV-
visible, and activity assay measurements were performed, respectively. DSC thermal 
profiles obtained for Nfs1 and Nfs1-Isd11 in the presence of Yfh1 were not significantly 
different from their individual thermal profiles (Figure 3.4). Melting temperatures 
obtained for individual denaturation events within each profile were not substantially 
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affected by Yfh1, indicating that it does not induce changes in protein fold on Nfs1 or 
Nfs1-Isd11 globally, or in the domains level of the proteins. Similarly, Yfh1 did not have 
any effect on the substrate binding affinity of Nfs1-Isd11 complex (Figure 3.5). In a 
previous study, Yfh1 was reported to enhance cysteine binding to Nfs1 by exposing 
substrate-binding sites to the exterior116. Therefore it is reasonable to expect a change 
in the substrate binding affinity in the presence of Yfh1. However, the opposite was 
observed. Yfh1 also had no significant effect on cysteine desulfurase activity of Nfs1-
Isd11 (Figure 3.6), similar to that seen in the human system207.  
With all these evidence, it is reasonable to assume that no stable physical 
interaction between Nfs1-Isd11 and Yfh1 exists in yeast Fe-S cluster biosynthesis 
machinery. No discrepancy in the structure and function of Nfs1-Isd11 in the presence 
of Yfh1 was measured by assessing the thermal stability, substrate binding affinity, and 
catalytic activity comparatively. This further supports a lack of any appreciable stable 
binding interaction. My results in this chapter add an extra level of comprehension on 
the role of eukaryotic frataxin on regulating the cysteine desulfurase. Since human 
orthologs show similar behavior207, it is possible to assume that eukaryotic frataxins 
have no dramatic effect on their respective cysteine desulfurases when viewed as an 
individual binding event. It is now logical to hypothesize that the effect of yeast frataxin 
on cysteine desulfurase activity is contingent on the presence of Isu1229. Altered activity 
by frataxin in the Nfs1-Isd11-Isu1-Yfh1 (SDUF) cluster synthesis complex was reported 
for other systems (discussed in section 3.2.3). The direction of research in such a 
context is therefore discussed in detail in a following chapter. 
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CHAPTER 4 
SOLUBILITY BARRIER PREVENTS STRUCTURAL AND FUNCTIONAL STUDIES 
ON ISD11 
4.0 Prelude  
This chapter describes my initial work on purifying Isd11, the functional partner of 
Nfs1 within yeast mitochondrial ISC biogenesis pathway. The objective of this study was 
to characterize the molecular features of Nfs1-Isd11 complex by isolating each protein 
separately and characterizing their interaction. Isothermal titration calorimetry was 
proposed to determine the binding affinity and stoichiometry of Nfs1 and Isd11, and 
nuclear magnetic resonance (NMR) spectroscopy, along with chemical shift 
perturbations assignments, was to be performed to elucidate the solution structure of 
Isd11 and to locate Isd11 residues involved in Nfs1-Isd11 interaction. Work presented 
below describes the strategies I employed to purify Isd11 to make protein available for 
the experiments suggested above. Isd11 purified partially from soluble fractions 
contained predominantly higher order species that were confirmed by western blot 
analysis to be our desired protein. Denatured Isd11 purified from insoluble fractions by 
urea denaturation failed to recover from urea efficiently in an attempt to refold protein to 
its native conformation. Therefore, due to its inherent insolubility and typical “orphan-
protein” like nature232, sufficient amounts of Isd11 could not be obtained with either 
methods employed. Details of the methods and some preliminary results obtained 
during the initial characterization are included in this chapter for general knowledge 
since the time and effort I spent working on this protein was significant. 
4.1 Introduction 
The accessory protein Isd11, first discovered a decade ago by two groups, was 
shown to be an 11 kDa protein essential for mitochondrial Fe-S cluster synthesis in 
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yeast113,233. Gene deletion experiments verified Isd11 (Iron Sulfur cluster biogenesis 
Desulfurase interacting protein) is present in all eukaryotic species but not in any 
prokaryote. Isd11 is classified in the LYR family of proteins due to the presence of a 
LYR/K amino acid residue segment near its N-terminus113,233. Cellular localization 
experiments and the absence of any predicted transmembrane segments confirmed 
that Isd11 is a mitochondrial matrix protein loosely associated with the inner 
membrane113,233. It does not contain a cleavable mitochondrial targeting sequence, and 
it is imported into mitochondria in a ∆Ψ-dependent manner233. In studies performed to 
search for the function of Isd11, cells depleted of Isd11 have shown reduced maturation 
of Fe-S clusters and decreased activity of Fe-S proteins such as aconitase and 
succinate dehydrogenase. Isd11 depleted cells further expressed iron accumulation 
characteristics. It is for both reasons that Isd11 was suggested to have a function linked 
to Fe-S cluster biogenesis and cellular iron homeostasis113,233. Yeast cysteine 
desulfurase Nfs1 forms a stable complex with Isd11 in vivo and in the absence of Isd11 
Nfs1 aggregates. Therefore Isd11 was also predicted to have a stabilizing effect on 
Nfs1 when the enzyme operates to provide sulfur component for the cluster synthesis. 
These initial studies also reported that Isd11 is not required for sulfide production 
activity by Nfs1 in vitro113,221,233, however Isd11 and complex formation with Nfs1 are 
needed for the maturation of Fe-S proteins in vivo, implying that Nfs1-Isd11 is the 
physiological cysteine desulfurase complex.  
A similar study in HeLa cells showed localization of human ISD11 to the 
mitochondria and nuclei, and formation of a complex with human cysteine desulfurase 
ISCS. Co-expression of ISCS with ISD11 in bacteria recovered ISCS from being 
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sequestered to inclusion bodies by facilitating correct folding and enhanced cysteine 
desulfurase activity. ISD11 deficiency caused a cytosolic iron deficiency phenotype and 
activated iron regulatory proteins IRP1 and IRP2 in cells, leading to the conclusion that 
ISD11 is important in maintaining cellular iron homeostasis in humans293. 
A number of studies that followed examined Isd11’s binding partners and 
attempted to understand the exact function of Isd11 within the Fe-S cluster biosynthesis 
pathway as well as understanding its role in maintaining cellular iron homeostasis. The 
findings of such studies are discussed below. 
4.1.1 Structure and oligomeric state of Isd11 
Isd11 lacks a characterized crystal or solution structure, likely due to the inherent 
insolubility of the protein that has been reported many times since its discovery. One 
study attempted to look at Isd11 three dimensionally using an ab-initio structure 
prediction server Robetta to build the best possible structure of Isd11. The model 
primarily consisted of α-helices, as predicted previously (with secondary structure 
prediction software)217. Docking experiments predicted the attachment of Isd11 to the 
Fe-S cluster assembly complex containing Isu1, Yfh1, and Nfs1234. A single far-UV 
circular dichroism (CD) study performed recently indicated that the protein’s structure 
was comprised of 57% α-helices and 10% β-sheets232 further confirming the α-helical 
nature of ISD11. 
This same study isolated human ISD11 from E. coli in the soluble form (by 
expressing in conjunction with a cleavable N-terminal GST tag)232. This protein was not 
found to be monomeric, but instead it existed as a heterogeneous mixture comprising of 
large and small oligomeric units of dimer-tetramer and monomer-dimer species 
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respectively. Ratios between oligomers in each species varied with the concentration 
and purified lifetime of Isd11, and therefore the oligomers were proposed to be in 
equilibrium. CD thermal denaturation profile for ISD11 revealed a relatively higher 
melting temperature of ~67 °C, but the integrity of this result is questionable due to the 
oligomeric nature of purified ISD11232. Besides these reports, no structural details are 
available for Isd11, and this hinders us from understanding its function better. 
4.1.2 Functional interactions of Isd11 in Fe-S cluster assembly 
In the search for the precise function of Isd11 during Fe-S cluster synthesis, 
numerous studies have discovered individual interacting partners on Isd11 as well as 
multiprotein complexes containing Isd11.  
One such study on human system reported that frataxin (FXN) interacts with 
ISD11 of the NFS1/ISCU complex and a knockdown of ISD11 creates frataxin 
deficiency like phenotypes, aconitase deficiency and cellular iron overload. Pull-down 
assays confirmed that I154F and W155R point mutations of FXN inhibit its interaction 
with ISD11. Therefore it was suggested that ISD11 serves as an adaptor between FXN 
and NFS1/ISCU complex284. This fact was further confirmed when the same FXN point 
mutations depicted above promoted a reduced affinity towards the SDU 
(NFS1/ISD11/ISCU) complex287. Similarly, the yeast Nfs1-Isd11 complex directly 
interacts with oligomeric yeast frataxin homolog (Yfh1) and the interaction is mediated 
at least in part by contact between Isd11 and Yfh1283. A modeled structure for yeast Fe-
S cluster assembly protein complex (including Yfh1, Nfs1, Isd11, and Isu) with two 
Isd11 proteins shows that Isd11 and Yfh1 are in close proximity, providing implications 
on Isd11’s involvement in mediating the Yfh1-Nfs1 interaction234. 
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Evidence for interactions of Isd11 with the scaffold protein Isu have only been 
reported once. This study utilized 15N TROSY-HSQC NMR experiments to show that the 
addition of unlabeled human ISD11 to labeled scaffold protein ISCU leads to no 
changes in NMR spectra, and this indicate that ISD11 does not interact directly with 
ISCU294. 
Interactions of Isd11 with its functional binding partner Nfs1 has also been 
studied, but again due to inherent instability of both proteins in the absence of complex 
formation (as described in chapter 2), the number of such studies is limited. The only 
reported binding data between the proteins is available for human ISD11, which binds to 
human NFS1 with a Kd of 100 nM, as measured by surface plasmon resonance (SPR) 
spectroscopy230. Eight ISD11 residues (F40, L63, R68, Q69, I72, Y76, L81, and E84) 
are critical for the NFS1-ISD11 interaction, and these were identified recently. Mutating 
them compromised the NFS1-ISD11 interaction and this led to reduced Fe-S cluster 
assembly and diminished mitochondrial respiration214.  
Existence of Isd11 within multiprotein complexes with other partners of the Fe-S 
cluster assembly machinery has been reported, along with their stoichiometry discussed 
in several systems, most of which are outlined in chapter two. 
4.1.3 Role of Isd11 in Fe-S cluster assembly 
Since its discovery, Isd11 was found associated with its functional partner 
cysteine desulfurase in all eukaryotic systems. Elucidating the purpose and role of such 
interaction is an area of interest within the Fe-S cluster assembly field. Proposed 
functions of Isd11 include activating catalytic function of cysteine desulfurase and 
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stabilizing cysteine desulfurase by preventing aggregation. These hypotheses have 
been tested in several studies over the past years.  
4.1.3.1 Isd11 prevents aggregation of Nfs1 
The effect of Isd11 preventing Nfs1 aggregation was reported in the two initial 
studies within yeast. In one report, isolated mitochondria depleted of Isd11 contained 
higher order aggregates of Nfs1 within the insoluble fraction, following incubation of the 
system at 37 °C. Moreover, in lysed mitochondria, Nfs1 was prone to proteolytic 
degradation by endogenous proteases and also showed a lack of association with 
mitochondrial membranes in the absence of Isd11233. Similarly, the other study reported 
the presence of Nfs1 within the pellet when mitochondria were isolated from heat-
shocked conditional Isd11 mutant strains. During prolonged incubation at non-
permissive temperatures, Nfs1 readily degraded113. Both studies concluded that Isd11 
functions as a stabilizer for Nfs1 in vivo.   
An additional study suggested that Isd11 binds to Nfs1 in its oligomerization 
surface in the three-dimensional modeled structure for yeast Fe-S cluster assembly 
protein complex, and thereby prevents the aggregation seen in the previous 
examples234. More recently, eight human ISD11 residues were identified as important 
for the NFS1-ISD11 interaction, and they were also marked as being essential in 
preventing aggregation of NFS1 in vitro214.  
Chapter two of this dissertation describes the work performed to elucidate the 
biophysical basis of the stability imparted by Isd11 onto yeast Nfs1. Instability of Nfs1, 
when expressed and purified not in complex with Isd11, was again observed in vitro. 
The hypotheses that the Nfs1-Isd11 co-complex must possess higher thermal stability 
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than the proteins alone, and that complex formation stabilizes Nfs1 by binding and 
inducing a more compact and stable fold in Nfs1 were tested using differential scanning 
calorimetry and fluorescence spectroscopy respectively. The SD complex was over 20 
°C more stable than Nfs1 alone and a conformational change on Nfs1 induced by Isd11 
binding was suggested to alter the fold of the enzyme. Therefore my work provides 
insight into how Isd11 stabilizes Nfs1. 
4.1.3.2 Isd11 activates cysteine desulfurase 
Although initial studies proposed that Isd11 complexation with Nfs1 is only 
essential for maturation of Fe-S proteins in vivo but not in vitro, recent studies have 
proved otherwise213,224. It was discovered that the assays previously utilized to measure 
sulfide production did not clearly eliminate other sources of sulfide within the assay 
mixture, hence providing false positive results224. A recent study utilized a novel 
approach to prove that Nfs1 by itself was inactive, but that Isd11 was capable of 
activating the cysteine desulfurase function within isolated mitochondria as well as with 
purified proteins. A carefully designed radiolabeling experiment, which separated the 
substrate-binding step of Nfs1 from its persulfide forming step, revealed that Nfs1 is 
capable of binding its substrate cysteine even in the absence of Isd11, but persulfide 
formation is strictly dependent on the presence of Isd11. It was suggested that Isd11 
binding to Nfs1 induces a conformational change that brings the catalytic cysteine 
residue and bound substrate in close proximity for persulfide formation116,224.  
4.1.4 Other functions of Isd11 in cellular milieu 
Since it was shown that Isd11 enhances the cysteine desulfurase reaction by 
associating with Nfs1, the role of this protein was also deemed important for other 
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pathways that Nfs1 serves as the sulfur donor. One study reported that yeast Isd11 is 
essential for tRNA thiolation in addition to its function in Fe-S cluster assembly within 
the flagellate Trypanosome brucei system. Isd11 forms a stable complex with Nfs1 and 
aids in sulfur delivery to drive tRNA thiolation in both cytoplasm and mitochondria295.  
4.1.5 Isd11 and human diseases 
So far, the number of diseases associated with defective Isd11 is limited to one. 
A mutation in the LYRM4 gene encoding ISD11 in humans causes combined oxidative 
phosphorylation deficiency (COXPD), a disease in which respiratory complexes I, II, and 
III and several other Fe-S proteins are deficient in muscle and liver213. Consequentially 
due to defective oxidative phosphorylation, patients develop neonatal lactic acidosis, 
respiratory distress and hypotonia296. A recent study showed that the R68L mutation 
that causes COXPD impairs the ability of ISD11 to form a stable complex with NFS1214. 
Given the importance of Isd11 in activating cysteine desulfurase during cluster 
assembly, it is no wonder if more diseases associated with Isd11 are discovered in the 
future.  
4.2 Experimental methods 
4.2.1 Bacterial expression and isolation of Isd11 
4.2.1.1 Purification of Isd11 from soluble fraction of the cell lysate 
Isd11-6xHis was expressed and purified from the soluble fraction as described 
previously, only with slight modifications to the protocol225. Briefly, the pET21b vector 
containing Isd11 with a C-terminal 6xHis tag was transformed into BL21 (DE3) codon 
plus cells to express Isd11-6xHis. Starter cultures were made by inoculating a 
transformed colony in LB broth supplemented with 100 µg/ml ampicillin and 34 µg/ml 
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chloramphenicol, and this was incubated in a rotating shaker overnight at 200 rpm and 
37 °C. Growth cultures (200 ml) were supplemented with 100 µg/ml ampicillin and 34 
µg/ml chloramphenicol, and the starter culture was diluted in LB in 1:40 ratio. Cells were 
grown at 37 °C in LB broth until the cell density reached 0.6 OD600; then the shaker 
temperature was switched to 25 °C. After a 10 min incubation at the lower temperature, 
cells were supplemented with 0.5 M filtered sorbitol and induced with 0.2 mM IPTG after 
incubating for 15 min. Cells were allowed to grow at 25 °C for 72 hours before 
harvesting by centrifugation. This protocol yielded a significant amount of 
overexpressed Isd11 within soluble fraction, as opposed to the regular 3-hour induction 
at 37 °C protocol. Cell pellets were resuspended in lysis buffer containing 50 mM Tris 
HCl (pH 8.0), 10 % glycerol, and 1 mM PMSF. Cells were lysed by six rounds of 
sonication (20 s each round and 2 min intervals while samples are kept on ice). Lysate 
was spun at 12100 x g for 30 min at 4 °C and the supernatant was mixed with His-select 
Ni affinity resin (600 µl resin, Sigma P6611, pre-washed with water and lysis buffer) for 
3 hours at 4 °C on a rocking platform to allow end-to-end mixing. After removing 
unbound protein, the resin was further washed with 50 mM Tris HCl (pH 8.0), 10 % 
glycerol, 10 mM imidazole, and 1 mM PMSF at wash buffer to eliminate any residual 
unbound protein. Bound protein was then eluted using elution buffer containing 50 mM 
Tris HCl (pH 8.0), 10 % glycerol, 400 mM imidazole, and 1 mM PMSF. Fractions 
containing soluble Isd11 were identified using SDS-PAGE. All buffers used were made 
fresh by mixing suitable stock solutions as needed and fresh Ni affinity resin was used 
each time. 
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4.2.1.2 Purification of Isd11 from insoluble fraction of the cell lysate 
Expression and purification of Isd11-6xHis from insoluble fractions followed a 
deviated protocol from the one above225. Briefly, same protocol as above was followed 
to start growth cultures. Cells were grown at 37 °C in LB broth until the cell density 
reached 0.7-0.8 OD600. Cells were then induced with 0.5 mM IPTG. Cells were allowed 
to grow at 37 °C for 3 hours before harvesting by centrifugation. When cells were grown 
under these conditions, the majority of overexpressed Isd11 was found in bacterial 
inclusion bodies due to lack of solubility. Cell pellets were resuspended in lysis buffer 
containing 50 mM Tris HCl (pH 8.0), and 1 mM PMSF. Cells were lysed by six rounds of 
sonication (20 s each round and 2 min intervals while samples are kept on ice). Lysate 
was spun at 12100 x g for 30 min at 4 °C and crude soluble fraction was removed. 
Pellet containing insoluble Isd11 was dissolved with a denaturing buffer containing 50 
mM Tris HCl (pH 8.0), 8 M urea, and 1 mM PMSF, and the resulting suspension was 
spun at 65000 x g at 20 °C for 30 min. Supernatant was mixed with His-select Ni affinity 
resin (600 µl resin, Sigma P6611, pre-washed with water and denaturing buffer) for 3 
hours at room temperature on a rocking platform to allow end-to-end mixing. After 
removing unbound protein, the resin was further washed with denaturing buffer to 
eliminate any residual unbound protein. Bound protein was then eluted using 50 mM 
Tris HCl (pH 8.0), 8 M urea, 400 mM imidazole, and 1 mM PMSF buffer. Fractions 
containing denatured Isd11, identified using SDS-PAGE were pooled and stored at 
room temperature until further use. All buffers used were made fresh by mixing suitable 
stock solutions as needed and fresh Ni affinity resin was used each time. 
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4.2.2 Western blot 
In preparation for western blot analysis, samples containing purified Isd11 were 
subjected to SDS-PAGE. Samples were run on a 4-20 % gel (Bio-Rad Mini-PROTEAN-
TGX) at 120 V to allow separation of proteins. Nitrocellulose membrane (0.2 µm) was 
cut to overlap with the dimensions of the gel and then pre-soaked in transfer buffer 
containing 25 mM Tris, 192 mM glycine, 20 % methanol, and 0.1 % SDS. This was 
done along with fiber pads and filter papers required to make the transfer sandwich. The 
SDS-PAGE gel was also pre-soaked in transfer buffer for 15 min. Transfer cassette was 
assembled so as to sandwich the gel and nitrocellulose membrane between filter paper 
and fiber pads on both sides without introducing air bubbles; this was done to allow 
smooth transfer of proteins to the membrane. Protein transfer was performed overnight 
at 22 V in the cold room (4 °C) under stirring conditions. Membrane was washed with 
TBST buffer (20 mM Tris, 150 mM NaCl, 0.1 % Tween-20 at pH 7.5) for 5-10 min on a 
rocking platform. Efficiency of protein transfer was checked by staining the membrane 
with Ponceau Red solution (0.2 % Ponceau S dye, 3 % trichloroacetic acid, and 3 % 
sulfosalicylic acid) for 5 min. Background stain was removed by thoroughly washing with 
water. Once the bands were visualized for successful transfer, Ponceau Red stain was 
completely removed by washing with water and TBST buffer. Membrane was blocked 
using blocking solution containing 5 % (w/v) skim milk powder in TBST buffer for 30 
min. The membrane was then treated with primary antibody (anti-Isd11 rabbit antiserum 
in blocking solution, 1:500 dilution) for 3 hours on a rocking platform. Membrane was 
further washed three times (10 min each) with TBST buffer to remove unbound primary 
antibody before incubating with the secondary antibody solution (Bio-Rad anti-rabbit 
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HRP conjugated antibody, 1:10,000 dilution) for one hour at room temperature. 
Unbound secondary antibodies were removed by washing with TBST buffer three times, 
10 min each. Isd11 was identified by incubating the membrane for 5 min with Bio-Rad 
Clarity Western ECL Substrate and detecting chemiluminescence with a digital imager. 
Urea solubilized Isd11 served as the positive control for the experiment. 
4.2.3 Protein refolding 
This section describes techniques I used in the attempt to refold urea denatured 
Isd11 isolated from bacterial inclusion bodies. All methods were unsuccessful towards 
yielding soluble monomeric Isd11. Typical results provided protein aggregates that 
precipitated out of solution. Only one method, using a liquid chromatography desalting 
column could recover soluble protein, but this method did not yield sufficient protein to 
perform any of the proposed experiments.   
4.2.3.1 Sequential dialysis 
Purified urea-denatured Isd11 was dialyzed into a series of buffers with 
decreasing urea concentrations and then finally into urea free buffer. Isolated protein 
was originally placed in 50 mM Tris HCl (pH 8.0), 8 M urea, 400 mM imidazole, and 1 
mM PMSF buffer. Protein samples were placed in Slide-A-Lyzer dialysis cassettes 
(ThermoFisher Scientific) and dialyzed into 500 ml of buffer containing 50 mM Tris HCl 
(pH 8.0), 6 M urea, 100 mM NaCl, 10 % glycerol, and 1 mM PMSF for 3 hours at room 
temperature while stirring (buffer: protein ratio was maintained at 250:1). Subsequent 
buffers had the same composition except the urea concentration was gradually lowered 
to 4 M, 2 M, 1 M, and 0 M. Cassettes were checked visually for precipitation after each 
dialysis step and any precipitation was removed by spinning down at 14000 x g for 10 
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min before proceeding to the next buffer. Fresh cassettes were used in any incidents of 
visible precipitation. Protein concentrations at each step were measured using the 
Advance Assay to evaluate the amount of protein recovered. 
4.2.3.2 Spin chromatography desalting column 
In a second method, purified urea-denatured Isd11 in 50 mM Tris HCl (pH 8.0), 8 
M urea, 400 mM imidazole, and 1 mM PMSF buffer was desalted to gradually remove 
urea. Isolated protein samples (75 µl) were placed in a Micro Bio-Spin 6 
chromatography column (Bio-Rad), which consists of a special grade polyacrylamide 
gel designed to desalt proteins. Desalting was carried out by following the manufacturer 
instructions. Fresh buffer containing 50 mM Tris HCl (pH 8.0), 6 M urea, 100 mM NaCl, 
10 % glycerol, and 1 mM PMSF buffer was applied to the column pre-equilibrated with 
the same buffer before spinning at 1030 x g for 4 min using a microcentrifuge. Flow 
through was collected and subsequent buffers were applied, which had 6 M, 4 M, 3 M, 2 
M, 1 M, and 0 M urea concentrations. Fresh columns were used for each dialysis step. 
Protein concentrations at each step were measured using Advance Assay to evaluate 
the amount of protein recovered in each step. 
4.2.3.3 Refolding by immobilizing on a nickel chelating column 
Cells containing Isd11 were grown using the protocol at section 4.2.1.2. 
“Purification of Isd11 from insoluble fraction”. The same protocol was followed to 
separate the supernatant containing urea solubilized Isd11 by centrifugation at 65000 x 
g for 30 min at 20 °C. The supernatant was then diluted (1:3) with a buffer comprised of 
100 mM Tris HCl (pH 8.0), 0.5 M NaCl, 10 % glycerol, 1 mM PMSF, and 0.5 M arginine 
for the final urea concentration in the supernatant to reach 2 M. His-select Ni affinity 
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resin (600 µl resin, Sigma P6611) was pre-washed with the above buffer before 
applying the supernatant to the resin. Isd11 was allowed to bind to the resin by end-to-
end mixing on a rocking platform for 3 hours at 4 °C. The flow through was collected 
and the column was washed with a buffer containing 100 mM Tris HCl (pH 8.0), 0.5 M 
NaCl, 10 % glycerol, 1 mM PMSF, 0.2 M sucrose, and 0.5 M arginine. To remove non-
specifically bound protein, the column was further washed with the same buffer 
although with 10 mM imidazole added. Isd11 bound to the column was eluted by using 
0.4 M imidazole buffer with all the additional components outlined above.  
4.2.3.4 Liquid chromatography desalting column 
Purified urea-denatured Isd11 was passed through HiTrap Desalting column (GE 
Healthcare) attached (5 ml) to an AKTA FPLC system (GE Healthcare) as a means to 
allow refolding by removing denaturant. The column was pre-equilibrated with 50 mM 
Tris HCl (pH 8.0), 10 % glycerol, 250 mM NaCl, and 1 mM PMSF buffer before applying 
the denatured Isd11 (1.5 ml of sample made by diluting 1:1 with the same running 
buffer). The column was then run at 1 ml/min flow rate. Fractions containing refolded 
protein were identified from the chromatogram and SDS-PAGE gel, and they were spun 
down at 14000 x g for 5 min to remove any precipitate present. Pooled fractions were 
concentrated using 10 kDa Amicon centrifugal filter devices. Isd11 concentrations 
before and after passing through the column were measured using Advanced Assay® 
for protein detection to calculate the yield after desalting and protein was stored at -80 
°C for further use. 
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4.2.4 Circular dichroism 
Circular dichroism spectra were collected to check the integrity of Isd11 structure 
following refolding. CD data of a 40 µM Isd11 sample in 1 mM sodium phosphate buffer 
(pH 8.0) were collected at room temperature using the Applied Photophysics π* 180 CD 
instrument with a 0.2 mm quartz CD cell. Eight independent scans were collected over a 
wavelength range of 190-260 nm. Buffer baseline was subtracted from averaged 
spectra to obtain baseline correction and spectral simulations by CDNN software of 
Applied Photophysics suggested secondary structural elements for refolded Isd11. 
4.3 Results 
4.3.1 Bacterial expression and isolation of Isd11 
4.3.1.1 Isd11 purified from soluble fraction of the cell lysate 
Our purification protocol to isolate Isd11 from the soluble fraction of bacterial cell 
lysate yielded a small amount of monomeric Isd11 (yield of total purified protein was 
~150 µg per 1 liter of bacterial cells), but also contained higher order oligomeric 
structures as well (Figure 4.1, lanes 9 and 10). This observation is in agreement with 
the results published recently saying Isd11 purified from soluble fraction is polydisperse 
and comprised of a heterogeneous mixture of oligomers232. This protocol did not yield 
sufficient amounts of Isd11 (mg quantities) required to perform my suggested 
experiments. Even if the yield was substantial, due to the heterogeneous nature of 
purified Isd11, use of such protein in further experiments was questionable. Scaling up 
preparation was not an option, as it increased the amount of impurities in isolated 
protein samples (data not shown).   
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Figure 4.1: SDS-PAGE for purification of Isd11 from soluble fraction of cell lysate. 
Lane labels read: 1-molecular weight marker, 2-cells pre-induction, 3-cells post-
induction, 4-cell lysate, 5-supernatant, 6-pellet, 7- flow through, 8-unbound wash, 9-
elute 1, and 10-elute 2.   
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4.3.1.2 Isd11 purified from insoluble fraction of the cell lysate 
Our purification protocol to isolate Isd11 from the insoluble fraction of bacterial 
cell lysate yielded ~100 % pure (yield of purified protein was ~5 mg per 1 liter of 
bacteria cells) monomeric Isd11 (Figure 4.2). This protocol could yield sufficient 
amounts of Isd11 (mg quantities) required to perform suggested experiments, but since 
Isd11 was present in its denatured form dissolved in 8 M urea, refolding techniques 
were attempted to refold Isd11 as described below.   
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Figure 4.2: SDS-PAGE for purification of Isd11 from insoluble fraction of cell 
lysate. Lane labels read: 1-molecular weight marker, 2-cells post-induction, 3-cell 
lysate, 4-supernatant, 5-inclusion bodies pellet, 6-solubilized inclusion bodies, 7-flow 
through, 8-unbound wash, 9-elute 1, 10-elute 2, and 11-elute 3.   
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4.3.2 Western blot 
In order to confirm the oligomers present in the Isd11 preparation from soluble 
fraction of cell lysate are indeed oligomers of Isd11, a western blot was performed 
against Isd11. The higher order oligomers and monomers of Isd11 transferred to the 
membrane, expressed chemiluminescence signals upon detection (Figure 4.3), 
indicating that Isd11 isolated from soluble fraction most certainly forms oligomeric 
structures. This observation further confirms the results above from SDS-PAGE 
analysis, which immediately followed purification and results published recently saying 
Isd11 purified from soluble fraction comprised of a heterogeneous mixture of 
oligomers232. 
4.3.3 Protein refolding 
4.3.3.1 Sequential dialysis 
In the attempt to refold urea denatured Isd11 isolated from bacterial inclusion 
bodies using the sequential dialysis method, Isd11 continuously aggregated and fell out 
of the solution as the urea concentration was gradually lowered. No precipitation was 
observed when transferred to 6 M urea, but there onwards protein levels gradually 
decreased, as measured with Advanced Assay® reagent (Table 4.1). The minimum 
concentration of urea required to detect a significant amount of Isd11 remaining in 
solution was 2 M and no protein could be detected thereafter.   
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Figure 4.3: Western blot for Isd11 purified from soluble fraction. Lane labels read: 
1-urea denatured Isd11 (positive control), 2 and 3-Isd11 from soluble fraction.   
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Table 4.1: Protein concentrations measured in each dialysis buffer in the sequential 
dialysis method to refold urea denatured Isd11. 
Urea concentration in 
dialysis buffer 
Isd11 concentration remaining 
after each step 
Precipitation observed 
8 M 309 µM - 
6 M - No 
4 M 134 µM Yes 
2 M 56 µM Yes 
1 M Not detected No 
0 M Not detected No 
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4.3.3.2 Spin chromatography desalting column 
With the use of Micro Bio-Spin 6 chromatography columns, Isd11 levels 
continuously decreased as measured with Advanced Assay® reagent (Table 4.2) when 
the protein was transferred to lower urea concentrations. The minimum concentration of 
urea required to detect a significant amount of Isd11 remaining in solution was 3 M and 
no protein could be detected thereafter. 
4.3.3.3 Refolding by immobilizing on a nickel chelating column 
In the attempt to refold urea denatured Isd11 while being immobilized to the 
nickel affinity column, Isd11 eluted as a suspension with white precipitate from the 
column. The suspension was spun down to remove any precipitated protein and the 
amount of protein remaining in the supernatant was measured using Advanced Assay® 
reagent. No remaining protein was detected. 
4.3.3.4 Liquid chromatography desalting column 
We used a HiTrap Desalting column to elute Isd11 out with the refolding buffer, 
and monitored the buffer exchange process using conductivity measurements (Figure 
4.4). An SDS-PAGE gel of the peak fractions revealed the presence of ~97% pure 
monomeric Isd11 (Figure 4.5). Most fractions contained visible white precipitate, 
indicating some level of oligomerization, but once the precipitate was removed only the 
monomeric species remained in the soluble fraction. Isd11 concentrations measured 
before and after passing through the column showed that ~90 % of protein present in 
urea media is lost due to aggregation during refolding (Table 4.3).   
 149	
Table 4.2: Protein concentrations measured in each dialysis buffer in the spin 
chromatography desalting method to refold urea denatured Isd11. 
 
Urea concentration in 
dialysis buffer 
Isd11 concentration remaining 
after each step 
8 M 309 µM 
6 M 314 µM 
4 M 310 µM 
3 M 186 µM 
2 M Not detected 
1 M Not detected 
0 M Not detected 
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Figure 4.4: Desalting chromatogram for urea denatured Isd11. UV intensity and 
conductivity are depicted as a solid line and a dashed line respectively. Refolded Isd11 
elutes out with the new buffer in the void volume of the column. Buffer containing urea 
elutes later.   
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Figure 4.5: SDS-PAGE of Isd11 containing fractions from desalting column. Lanes 
1 to 6-fractions containing Isd11, 7-molecular weight marker.   
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Table 4.3: Isd11 concentrations measured before and after passing through HiTrap 
desalting column. 
Attempt Concentration before column Concentration after 
column 
% Recovery 
1 222 µM 22 µM 10.0 
2 208 µM 21 µM 10.1 
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4.3.4 Circular dichroism (CD) of refolded Isd11 
CD spectra of refolded Isd11 suggested the secondary structure was primarily 
helical (Figure 4.6). Spectral simulations for eight individual scans estimated the 
percentage of each secondary structural element in Isd11 as depicted in Table 4.4. 
Having a greater percentage of ordered structural elements, as opposed to random 
coils, suggested that Isd11 may have refolded to its native structure. But, due to 
heterogeneity of Isd11 purified from the soluble fraction, a direct comparison of refolded 
Isd11 versus soluble Isd11 was not feasible. To make a comparison, no CD structure 
analysis results have been published previously for the yeast Isd11 either. 
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Figure 4.6: Circular dichroism spectra of refolded Isd11. CD data of a 40 μM Isd11 
sample in 1 mM sodium phosphate buffer (pH 8.0) were collected at room temperature. 
This spectrum represents the average of eight spectra.   
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Table 4.4: Secondary structure elements of refolded Isd11 determined by far-UV CD. 
Secondary structural elements % 
α-helices 26.20 (± 0.12) 
Antiparallel β-sheets 17.90 (±0.50) 
Parallel β-sheets 8.52 (±0.13) 
β-turns  17.90 (± 0.08) 
Random coils 29.51 (±0.59) 
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4.4 Discussion 
Since its discovery, Isd11 has been suggested to function within the eukaryotic 
mitochondrial Fe-S cluster biogenesis pathway by primarily associating with the 
cysteine desulfurase Nfs1 and promoting Nfs1 activation towards persulfide formation. 
Functional association between Nfs1 and Isd11 within a complex has been reported, but 
no attempts were made to elucidate the characteristics of the interaction. Such 
information can help explain how Isd11 exerts its modulating effect on Nfs1 
stability/activity. Moreover it would also provide insight into the need to have Isd11 
exclusively in eukaryotic species, as it is required to aid cysteine desulfurase activity in 
eukaryotes but prokaryotic cysteine is perfectly self sufficient. In such context, it was 
proposed to isolate the two partner proteins (Nfs1 and Isd11) separately and 
characterize the interaction between them by NMR and ITC. This chapter described the 
efforts made to isolate Isd11 individually. Despite the number of methods employed, 
sufficient amounts of protein could not be yielded to perform experiments due to 
inherent insolubility and/or instability of Isd11 in the absence of Nfs1. Hence the project 
is currently stalled until a better method of isolating pure homogeneous Isd11 can be 
determined.  
The observed oligomeric nature of purified Isd11 lead to the conclusion that 
Isd11 could be present as a heterogeneous mixture of oligomers under non-denaturing 
conditions. Higher order oligomers were present when Isd11 was isolated from the 
soluble fraction of the cell lysate, in close agreement with the polydisperse nature of 
Isd11 under reported recently non-denaturing conditions232. Oligomerization is 
inevitable, even when denatured Isd11 is refolded by transferring to non-denaturing 
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conditions, which further confirms the tendency of Isd11 to cluster when forced to exist 
in the absence of its binding partner, Nfs1. This nature could very well be attributed to 
the “complex-orphan protein” like behavior of Isd11 that was proposed recently by 
another group232. Complex-orphan proteins are difficult to produce in the absence of its 
native binding partner and/or cofactor, as they tend to aggregate although they may not 
necessarily be unstable/defective in a thermodynamic standpoint286. Therefore it is 
possible that the aggregated state of Isd11 may also be functionally significant, although 
it may not represent its true physiological oligomeric state. This nature is also seen for 
other proteins involved in Fe-S cluster biogenesis such as IscU286 and Isu1 (by 
experience from ongoing projects our lab). As mentioned in Chapter 2 and reported in 
previous publications113,214,233,234, the fact that Isd11 prevents the aggregation of Nfs1 by 
binding to its oligomerization surface can be postulated in reverse in this context: Nfs1 
prevents aggregation of Isd11 as well. Therefore, the Nfs1-Isd11 interaction could 
primarily be functional in activating cysteine desulfurase activity as a complex, and 
secondarily as a mutual relationship in maintaining protein stability for efficient catalysis. 
The fact that Isd11 oligomers could be observed in the denaturing SDS-PAGE is 
surprising, knowing that SDS denatures proteins and disrupts their interactions. But 
given the nature of intermolecular interactions, SDS may not necessarily denature all 
secondary structures and completely disrupt all interactions, especially the stronger 
ones. The fact that Nfs1-Isd11 is soluble and stable as a complex but the two proteins 
aggregate in the absence of each other suggests the interaction interface between 
these two proteins could predominantly be hydrophobic. Covering up hydrophobic 
regions of both proteins by complexation could very well stabilize them as a single 
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functional unit. If such notion is correct, oligomerization of Isd11 in the absence of Nfs1 
could be an attempt to hide exposed hydrophobic patches in an enclosed environment. 
Based on the affinity of the interactions between units in the oligomer, it is possible that 
SDS is not capable of disrupting them completely; hence oligomers can be visualized 
even in denaturing SDS-PAGE gels. Western blots performed against Isd11 further 
confirmed these oligomers as comprising of Isd11. 
Various methods were employed in the attempt to refold denatured Isd11 
isolated from bacterial inclusion bodies. Sequential dialysis allowed the gradual 
decrease of urea in the protein’s environment, which is essential to drive correct 
refolding of Isd11 by populating folding intermediates that will most likely aggregate if a 
direct dilution is performed. Moreover, refolding using any desalting chromatography 
column with a porous resin provides a favorable pace at which Isd11 could interact with 
the renaturant, that allows slow folding kinetics and physical separation of refolding 
intermediates preventing aggregation. Similarly, nickel-chelating columns provide a 
matrix for unfolded protein to attach during refolding and thereby prevent unwanted 
intermolecular interactions leading to aggregation. Chemical additives such as L-
arginine and sucrose are also commonly used as refolding aiding agents297. In 
sequential dialysis lesser protein was detected even at 4 M urea compared to spin 
desalting column, which gave higher protein at 3 M urea. Therefore it is apparent that 
Isd11 prefers the assistance of a porous environment in refolding. But even with the use 
of a spin desalting column, no Isd11 was remaining in the final non-denaturing buffer 
probably because applying centrifugal forces to elute Isd11 must not have provided 
sufficient time for refolding. Immobilization on nickel chelating column yielded no 
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refolded protein, probably due to incompatibility of Isd11 and chemical additives used. 
Clearly the best method to refold Isd11 was the use of liquid chromatography desalting 
column because it allowed recovery of at least 10 % protein in the non-denaturing buffer 
while other methods failed to recover any. The porous resin environment and controlled 
flow rate must have provided better conditions to refold Isd11. Overall, none of the 
techniques were able to recover Isd11 from the denaturing conditions, and therefore 
failed to provide sufficient amounts to perform experiments.  
Structural details of Isd11 are scarce, and a potentially easy technique to obtain 
a crude estimation of its secondary structure constituents is using circular dichroism. It 
is also a perfect measurement to observe if Isd11 isolated from insoluble fraction has 
refolded to its native structure upon removal of urea by comparison with native Isd11 
isolated from the soluble fraction. Unfortunately, due to the oligomeric nature of Isd11 in 
the soluble fraction (as described in section 4.3.1.1.), a direct comparison could not be 
performed. Having a greater percentage of ordered structural elements, as opposed to 
random coils, suggested that Isd11 may have refolded to its native structure. But, as 
mentioned above, the certainty of this fact could not be verified. Although this result 
agrees with the secondary structure prediction studies217 and ab-initio protein modeling 
attempts234 that suggest yeast Isd11 structure as primarily helical, it is deviated farther 
from the results obtained for human ISD11 in a recent far-UV circular dichroism (CD) 
study. That study confirmed a higher α-helical content for ISD11, 57% and 10% β-
sheets232. Human ISD11 and yeast Isd11 shares ~60 % sequence similarity. This may 
suggest that the ratios of structural elements we see for refolded yeast Isd11 could be 
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superficial due to improper folding and yeast Isd11 could be more helical than we 
observed. 
In conclusion, all results point towards the notion that complex formation between 
Nfs1 and Isd11 is mutual necessity to maintain the structure of both partners as much 
as it is important functionally. Individual proteins are unstable and the efforts to study 
them separately may not provide physiologically relevant information as much as for the 
complex. Therefore the opportunity to understand the reason behind the requirement for 
the presence of Isd11 for cysteine desulfurase activity in eukaryotes relies on the 
attempts to obtain the crystal structure of this complex. Significant effort has been made 
towards that goal in our lab. 
4.5 Acknowledgements 
This research was supported by T32 HL120822 (DPB) and NIH RO1-DK068139 
and NIH RO1-GM107542 (TLS). Special acknowledgement goes towards Dr. Debkumar 
Pain and Dr. Alok Pandey (Rutgers New Jersey Medical School) for training and 
guidance provided in protein isolation procedures and western blot and Dr. Andrew 
Dancis (University of Pennsylvania) for providing Isd11-Hisx6 plasmid and bacterial cell 
lines. 
  
 161	
CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
5.0 Prelude 
A number of human disorders show direct correlations to disrupted iron 
homeostasis within the body. Among them are the most common neurodegenerative 
disorders (Alzheimer’s, Parkinson’s, Friedreich’s Ataxia and Huntington’s), all of which 
are complicated due to iron induced oxidative damage of nerve cells that is caused by 
iron accumulation in the central nervous system. Pertaining to the growing occurrence 
and devastating burden associated with these diseases, the emphasis towards 
understanding the pathophysiology related to the role of iron homeostasis within these 
disorders becomes more and more important every day. As the second most prominent 
class of iron cofactor within the body, Fe-S clusters play an essential role in helping the 
body maintain proper iron homeostasis. In the case of Friedreich’s ataxia, caused by a 
deficiency in the protein frataxin that is indispensable during Fe-S cluster assembly, the 
impact of iron homeostasis related to the disorder is directly obvious. Friedreich’s ataxia 
and other disorders associated with defective Fe-S cluster assembly accentuate the 
need to unravel the structural and functional aspects of this fundamental biochemical 
pathway. Effective disease treatment has been hampered by the lack of a molecular 
level understanding for the individual roles key proteins play in Fe-complex formation. 
The work described in this dissertation attempts to diminish this knowledge gap by 
providing a comprehensive biophysical characterization of the key proteins involved in 
sulfur mobilization during the yeast mitochondrial Fe-S cluster synthesis process. The 
role of the accessory protein “Isd11” within the catalytic activity of the cysteine 
desulfurase “Nfs1” has been assessed in a detailed manner for the first time as a part of 
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this work. Our results will lay the groundwork for understanding a possible regulatory 
function of Isd11 and possibly help identify the evolutionary requirement for its activating 
function on Nfs1 in eukaryotes only. The effect of Yfh1 on sulfur mobilization by the 
Nfs1-Isd11 complex has also been evaluated in detail. Our results suggest that frataxin 
impacts cluster assembly mostly at the level of the assembled complex rather than at 
the individual protein level. This information adds an extra level of understanding for the 
regulatory role of Yfh1 within the yeast mitochondrial Fe-S cluster assembly pathway. 
This work, therefore, provides novel and significant insight into how the cluster 
assembly proteins function, and sets the groundwork for which additional experiments 
that need to be designed to further unravel the mechanistic details of sulfur mobilization 
during Fe-S cluster bioassembly. These molecular level details will assist in future drug 
design strategies directed at treating the disease states outlined above. In addition, this 
chapter concludes the dissertation by summarizing the final outcomes of the previous 
three chapters and also by providing potential routes the project can take. Some 
preliminary work performed in relation to our future objectives is included in this chapter. 
5.1 Summarization of dissertation and conclusions 
5.1.1 Molecular characterization of yeast Nfs1-Isd11 complex 
Although several studies have provided details regarding how the Nfs1-Isd11 
complex functions from a biochemical point of view, many of the biophysical details of 
how the complex functions are lacking. Chapter 2 provided findings regarding a 
comprehensive in vitro biophysical characterization of the yeast Nfs1-Isd11 protein pair. 
Successful purification of these proteins was followed by experiments that were 
performed to unveil basic properties of the complex. Co-expressing Nfs1 with Isd11 led 
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to formation of a stable complex and prevented Nfs1 aggregation, indicating Isd11 
coordination to Nfs1 contributed to the stability and solubility of the enzyme. Additional 
studies confirmed the precise molecular weight and stoichiometry of the proteins within 
the complex, and also provided the exact oligomeric arrangement of the proteins in our 
overexpressed complex. Subsequent experiments attempted to rationalize the 
requirement for Isd11 within yeast Nfs1 Fe-S cluster biosynthesis. Biophysical studies 
revealed that Isd11 imparts a high thermodynamic stability on Nfs1, most likely by 
altering the structure of Nfs1 in a manner that is not yet clear. Our measurements 
testing the substrate binding affinity of Nfs1 suggested Isd11 likely does not exert a 
direct effect on altering Nfs1’s substrate binding affinity. Subsequent activity 
measurements however proved that Isd11 alters the catalytic activity of eukaryotic Nfs1. 
Kinetic parameters, such as KM and catalytic efficiency, were significantly altered during 
the emergence of Isd11 in eukaryotes in the evolutionary lineage compared to 
prokaryotes. Homology modeling was used to generate a structure framework for us to 
predict yeast Nfs1 biophysical properties. The modeled structure suggested that 
conformational changes would be required for substrate binding and persulfide 
formation; these results were supported by our Fluorescence experiments. Taken 
together, the second chapter of this dissertation supports the idea that cooperativity 
between Nfs1 and Isd11 is essential to bring about the full functional outcome of 
cysteine desulfurase complex in yeast. Isd11 alters the catalytic activity of Nfs1 in 
addition to functioning as a stabilizer for the protein. Having this multifaceted level of 
control within eukaryotes may be a safeguard established by evolution to eliminate 
unwanted product formation within higher developed organisms. 
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5.1.2 The transient effect of frataxin on Nfs1-Isd11 activity 
Recently, frataxin was identified as a regulator of the cysteine desulfurase within 
the ISC Fe-S cluster biosynthetic pathway. This function however has not been 
completely clarified at a molecular level in any eukaryotic system. Experiments in 
Chapter 3 were designed to test the hypothesis that Yfh1 interacts directly with the 
Nfs1-Isd11 complex to regulate the complex’s activity. In addition, this chapter tested 
the effect of Yfh1 on the structure and activity of the complex. Isothermal titration 
calorimetry was used to explore for a stable physical interaction between proteins, 
however our work was limited in its outcome due to protein aggregation issues. Pull-
down assays were used as an alternative method to explore inter-protein interactions, 
and our results suggested a transient but not stable interaction between Yfh1 and the 
complex. Additional biophysical experiments tested the ability of Yfh1 to alter the 
thermal stability, substrate binding affinity and catalytic activity of Nfs1-Isd11 in order to 
determine if we could detect any evidence of this transient interaction, however no 
impact of Yfh1 was identified. Therefore, it is plausible that an interaction between Yfh1 
and Nfs1-Isd11 does not exist, or that this interaction is not stable enough to be 
measured under the conditions we explored. In alignment with similar results observed 
with human orthologs, it is reasonable to assume that eukaryotic frataxin interacts with 
the cysteine desulfurase only when it is part of the complete cluster assembly complex 
that also include Isu1 along with Nfs1 and Isd11. 
5.1.3 Challenges in expression and purification of Isd11 
In an effort to study the functional association between molecules within the 
Nfs1-Isd11 complex, it was proposed that we isolate the two proteins individually. 
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Chapter 4 described the attempts we made towards this directive, and how we 
rationalize our inability to isolate Isd11 separately. All failed attempts pointed towards 
the notion that complex formation between Nfs1 and Isd11 is a mutual necessity in 
order to maintain the structure and functionality of both partners. Our differential 
scanning experiments described in Chapter 2 supported this idea.  
5.2 Future directions 
Although the Fe-S cluster biogenesis pathway has been under investigation for 
several decades, many questions regarding how the molecules within the pathway 
operate together remain unanswered. While genetics and cellular studies on the yeast 
cluster assembly system are well understood, little is known about the molecular 
aspects of how the proteins work together during Fe-S cofactor assembly. Given its 
reduced complexity, the yeast model system serves as a bridge between the 
prokaryotic and eukaryotic cluster assembly systems. The yeast system therefore 
provides a unique opportunity to explore the fine details of how proteins within the Fe-S 
cluster assembly pathway interact. Sulfur mobilization, which is used during de novo Fe-
S cluster assembly, contains specific gaps in our knowledge of how the proteins work 
together to operate, and as a result there are several questions that need to be 
addressed in this area. I performed several preliminary new experiments in this context, 
and the results I have obtained during these exploratory but yet to be completed 
experiments are provided below. 
5.2.1 Elucidation of x-ray crystal structure of Nfs1-Isd11 
Not having exact structural details for the structure of Nfs1-Isd11 has hindered 
our progress in understanding how these proteins function. Some of the specific 
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questions that still remain unanswered include: 1) What are the molecular details 
regarding the interaction between Nfs1 and Isd11?, 2) What is the location and 
proximity of the PLP-bound active site relative to the catalytic cysteine residue?, and 3) 
What are the structural rearrangements that drive chemistry related to the substrate 
bound cysteine?. In order to address this knowledge gap, we have attempted to 
crystallize the yeast Nfs1-Isd11 complex. In-house crystal screens were set for purified 
Nfs1-Isd11 with Qiagen NeXtal Tubes JCSG Core Suites I-IV using the sitting drop 
method. These crystal trays were set at temperatures of 4 and 25 °C. Screens are 
currently being monitored for visible crystals and once suitable hits are obtained, more 
elaborate screens will be developed to find the best crystallization condition(s) to obtain 
suitable diffracting crystals. Crystal diffraction and structure elucidation procedures are 
being done in collaboration with Dr. Amy Rosenzweig’s laboratory at Northwestern 
University.  
5.2.2 Role of Acyl Carrier Protein in cysteine desulfuration and Fe-S cluster 
assembly 
Most recently, the Acyl Carrier Protein (ACP) involved in mitochondrial fatty acid 
synthesis was identified to be an essential component of the yeast Fe-S cluster 
assembly complex210. This study reported the role of ACP in Fe-S cluster biogenesis as 
functioning to stabilize the Nfs1-Isd11 complex, because Nfs1 and Isd11 were found as 
insoluble aggregates in yeast ACP knockdown strains. This work is supported by the 
fact that Nfs1 and Isd11, expressed and isolated from bacteria, require ACP. As we 
observed, purified yeast Nfs1-Isd11 always carries a single impurity of ~18 kDa that we 
could not separate from our constituent proteins (Chapter 2, Figure 2.1). We actually 
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identified this protein by mass spectrometry several years ago as potentially being the 
E. coli Acyl Carrier Protein (data not shown). In the absence of the yeast ACP ortholog, 
recombinant Nfs1 and Isd11 do associate with the E. coli ACP during our preps, and 
this indicates the significance of the protein in in helping form the Fe-S cluster assembly 
complex. Our next step in trying to elucidate the function of ACP will be to assess its 
effect on the activity of our in vitro cysteine desulfurase-Isd11 complex. Interestingly, 
activity measurements on purified yeast Nfs1-Isd11 performed to date have already 
been completed in the presence of bacterial ACP (although we have not quantified the 
stoichiometry), as a result of the protein’s tendency to co-purify with Nfs1-Isd11 at high 
quantities. If the bacterial ACP is associated with the yeast Nfs1-Isd11 in the correct 
stoichiometry, or if it fully complements the capabilities of the yeast ACP ortholog are 
questions that still need to be addressed. To test if increasing the expression of E. coli 
ACP will have any stimulatory effect on yeast cysteine desulfurase activity, auto-
induction methods were tested during bacterial cell growth in an attempt to coordinate 
yeast protein expression with the enhanced expression of bacterial ACP. Unfortunately 
there was no significant difference in bacterial ACP levels observed by using auto-
induction as opposed to growth under IPTG inducible conditions. Therefore, we will try 
co-expressing yeast ACP with yeast Nfs1-Isd11 directly in E. coli using a co-
transformed plasmid vector. In this manner, we will try to coordinate yeast ACP 
expression with the expression of the complex. Additional strategies, such as a ΔACP 
E. coli expression strain, will also be utilized to eliminate the expression of E. coli ACP. 
This should allow us to obtain an ACP free complex that we can use for side-by-side 
comparison of protein activity.  
 168	
 
5.2.3 Elucidation of cysteine desulfurase mechanism of Nfs1-Isd11 
At present, the molecular details of the cysteine desulfurase reaction mechanism 
have been identified in detail in only a small number of systems; the best of which is in 
the bacterial systems219,237,238,298. Reaction mechanisms followed by different cysteine 
desulfurase orthologs during their catalytic activity vary only slightly. The resting state of 
all the PLP containing cysteine desulfurases consist of a functional internal aldimine 
formed between PLP and an active site lysine residue. The incoming cysteine substrate 
forms an external Cys aldimine with the PLP cofactor at the active site, which in turn 
gets deprotonated to form a Cys quinonoid intermediate. The subsequent protonation at 
the α-C4 atomic position converts this intermediate to a Cys ketimine adduct, which 
then undergoes nucleophilic attack by the deprotonated catalytic cysteine residue. The 
end result is an enzyme bound persulfide and an Ala enamine. Thereafter, the alanine 
gets released and the persulfide gets transferred to a sulfur acceptor216 (Figure 5.1). 
However, eukaryotic cysteine desulfuration requires the accessory protein Isd11 for 
activity, and therefore Isd11 plays a direct or an indirect role in this enzymatic reaction 
mechanism. Having a complete characterization of the eukaryotic cysteine desulfurase 
reaction mechanism will allow for a direct comparison between the prokaryotic and 
eukaryotic sulfur mobilization mechanisms, something that may be possible since the 
bacterial reaction mechanism has already been solved. Obtaining this information will 
therefore provide direct answers regarding why Nfs1 has evolved to catalyze the 
persulfide product with an aid of a second protein Isd11, in contrast to the bacterial 
protein, which did not.  
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In order to begin to elucidate the mechanism of Nfs1-Isd11, we have expressed 
and purified two mutant forms of Nfs1 and we will use these to monitor the fate of three 
separate intermediates formed during the reaction mechanism. As mentioned in 
Chapter 2, monitoring the characteristic 420 nm UV-vis signal from wild type Nfs1-Isd11 
revealed that it is a compound signal representing both internal aldimine (between K299 
and PLP) and persulfide formation (on C421). As the reaction progresses, the 
consumption of the aldimine species upon substrate binding causes a diminution in the 
420 nm signal, while persulfide formation causes an increase in the signal (Figure 5.2-
A). Our Nfs1(C421A)-Isd11 mutant, in which the catalytic cysteine residue essential for 
persulfide formation is mutated, was incapable of performing the nucleophilic attack 
leading to persulfide formation. Therefore, the reaction stalled at the Cys ketimine stage 
(Figure 5.2-B). The decrease in the 420 nm signal observed for this mutant only 
represents the consumption of internal aldimine leading to Cys ketimine formation, 
eliminating the signal for the production of a persulfide. In contrast, my Nfs1(K299A)-
Isd11 mutant was not expected to make a progression upon substrate addition, as this 
mutant was incapable of binding PLP in the active site; this Lys-299 residue forms the 
internal aldimine with PLP at the resting state of the enzyme. However our studies 
showed that the Nfs1(K299A)-Isd11 complex was still capable of accommodating PLP 
in the active site, this interaction is likely facilitated by interactions with amino acids in 
the active site vicinity. Interestingly as a result of the K299A mutation, the signal around 
420 nm from the internal aldimine was only slightly viable (only a low intensity peak at 
405 nm was present, Figure 5.2-C). Upon substrate addition, this signal steadily 
increased, indicating persulfide formation, which was masked before by the internal 
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aldimine signal (Figure 5.3-A, and B). In addition, the increasing L-cysteine 
concentration caused a red shift in the data that was observed from 405 nm to 424 nm. 
A previous report attributes the red shift to an increase in the pKa of an acidic group on 
PLP due to persulfide formation238, supporting the identity of the red shift we observed 
for the Nfs1(K299A)-Isd11 complex. Therefore, the Nfs1(K299A)-Isd11 complex can be 
used to observe the fate of the persulfide intermediate in the second half of the reaction. 
On the other hand, in the wild type and mutant complexes, the signal at 340 nm might 
represent a single intermediate, which is likely the Cys ketimine (Figure 5.2-A/B, and 
Figure 5.3-B). Having the capability to monitor three separate reaction intermediates 
during the reaction process will allow for the explicit design of stopped flow 
spectrophotometric experiments that could be performed using isotope labeled 
substrate (deuterated L-cysteine and H2O) to help elucidate the complete reaction 
mechanism.  
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Figure 5.1: Proposed chemical mechanism for the cysteine desulfurase reaction 
[by Behshad (2009) et al. for bacterial cysteine desulfurases237].  
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Figure 5.2: Absorbance measurements for three variants of yeast Nfs1-Isd11. 
Absorbance change measured over time at 340 nm (white circles) and 420 nm (black 
circles) for (A) Nfs1-Isd11 wild type and (B) Nfs1(C421A)-Isd11 protein complexes upon 
addition of 20 molar excess L-cysteine. (C) Absorption profiles of Nfs1(C421A)-Isd11 
(dashed line) and Nfs1(K299A)-Isd11 (solid line) protein complexes for comparison.  
 173	
 
 
Figure 5.3: Titration of L-cysteine to Nfs1(K299A)-Isd11 monitored by UV-visible 
spectroscopy. (A) Consecutive spectra were collected after each addition of L-
cysteine. Lines represent the following concentrations: bold solid: 0 mM, bold dashed: 
0.010 mM, bold dotted: 0.035 mM, bold dash-dot: 0.084 mM, bold dash-dash-dot-dot: 
0.183 mM, thin solid: 0.430 mM, thin dashed: 0.919 mM, thin dotted: 1.901 mM, thin 
dash-dot: 4.346 mM, thin dash-dash-dot-dot: 9.200 mM. (B) Plots show the change in 
absorbance for Nfs1(K299A)-Isd11 at 340 nm (white circles) and 420 nm (black circles) 
as a function of L-cysteine concentration.  
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5.2.4 Effect of frataxin on the cysteine desulfurase activity of Nfs1/Isd11/Isu1/Yfh1 
complex 
As discussed in Chapter 3, Yfh1 showed no direct interaction with or effect on the 
stability, substrate binding affinity, and activity of the Nfs1-Isd11 complex alone. These 
results suggest the effect of frataxin on this complex is transient and/or contingent upon 
other factors. However, the effect of Yfh1 on the Fe-S cluster assembly activity in the 
Nfs1/Isd11/Isu1/Yfh1 complex has been established*. To test the hypothesis that Yfh1’s 
ability to alter cluster assembly within the Nfs1/Isd11/Isu1/Yfh1 complex occurs by 
altering the cysteine desulfurase function, I completed some initial preliminary 
experiments. Yfh1’s ability to alter substrate binding affinity of Nfs1-Isd11 within a 
reconstituted Nfs1/Isd11/Isu1/Yfh1 complex was tested first. The Nfs1/Isd11/Isu1/Yfh1 
quad complex was reconstituted by combining individually purified Nfs1-Isd11 (mutant 
or wild type), Yfh1 and Isu1 proteins together at a 1:2:1:1 stoichiometric ratio. This ratio 
was shown by others and us to match that identified in vivo213,229,235. Using the protocol 
outlined in Chapters 2 and 3, UV-visible spectroscopy was used to study the substrate 
binding affinity of reconstituted Nfs1(C421A)/Isd11/Isu1/Yfh1 complex. The absorbance 
at 340 nm was monitored upon consecutive titration of L-cysteine to this quad complex. 
The identical experiment was performed using the as purified Nfs1(C421A)/Isd11 
complex alone as a control for comparison for possible alteration in substrate binding 
affinity within the quad complex. Titration of L-cysteine to reconstituted 
Nfs1(C421A)/Isd11/Isu1/Yfh1 complex or the as purified Nfs1(C421A)/Isd11 yielded the 
binding curves that are not distinctly different from each other (Figure 5.4). Best-fit 
																																								 																				*	Stephen Dzul’s (2016) PhD dissertation “Insights into de novo Fe-S cluster biogenesis via the eukaryotic 
Fe-S cluster pathway (ISC) in vitro”.	
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simulations for binding data revealed Kd values of 0.58 ± 0.13 mM and 0.55 ± 0.14 mM 
for Nfs1(C421A)/Isd11/Isu1/Yfh1 and Nfs1(C421A)/Isd11, respectively. However from 
these results, no direct conclusion could be made regarding the effect Yfh1 had on 
substrate binding affinity of Nfs1(C421A)/Isd11 within the reconstituted 
Nfs1(C421A)/Isd11/Isu1/Yfh1 complex, due to two reasons: 1) During reconstitution, as 
soon as purified Isu1 was added to the Nfs1(C421A)/Isd11/Yfh1 reaction mixture, 
protein precipitation was visible and this continued through the entire experiment. No 
precipitation was observed when the experiment was carried out with just the 
Nfs1(C421A)/Isd11/Yfh1 complex (as outlined in Chapter 3), indicating Isu1 is likely 
causative of aggregation. Wild type yeast Isu1 alone is unstable and prone to 
aggregation, even at the slightest perturbation of conditions, during and/or after 
purification (data not shown). Therefore, the similarity of the binding affinity data of 
Nfs1(C421A)/Isd11 and Nfs1(C421A)/Isd11/Isu1/Yfh1 may have caused by the poor 
solubility of Isu1 during reconstitution; 2) The absorbance values recorded for the 
reconstituted quad complex were higher than those only for Nfs1(C421A)/Isd11 
complex by a same amount at each point, even after correcting for dilution (Figure 5.4). 
This too is an indication of the effect of poor solubility of Isu1 on the reading following 
reconstitution since neither Yfh1 nor Isu1 alone absorb at 340 nm or 420 nm. Therefore 
this experiment needs to be repeated using an alternative strategy to avoid Isu1 
precipitation during the reaction, as reconstitution of separately purified proteins is not 
the best approach. Nfs1/Isd11/Isu1/Yfh1 quad complex has been co-expressed and co-
purified in our lab for several years with high purity and stability. Therefore, it would be 
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beneficial to repeat this experiment with a co-expressed and co-purified 
Nfs1(C421A)/Isd11/Isu1/Yfh1 quad complex.  
Similarly, acid labile sulfide production activity within the reconstituted 
Nfs1/Isd11/Isu1/Yfh1 was tested, as described above. However, no significant 
enhancement in the persulfide formation activity within the Nfs1-Isd11/Isu1/Yfh1 
complex was observed compared to the Nfs1/Isd11 complex (Figure 5.5). As mentioned 
above, validity of this result is questionable due to aggregation of Isu1 during the assay, 
and therefore this experiment should be repeated with the co-purified 
Nfs1/Isd11/Isu1/Yfh1 quad complex, which exists as a more stable. 
To summarize, experiments proposed to help elucidate the structure and the 
reaction mechanism of yeast Nfs1-Isd11 complex will greatly contribute towards closing 
the knowledge gap regarding the sulfur mobilization step within de novo Fe-S cluster 
assembly. The experiments that we proposed in order to study the effect of possible 
regulators of the sulfur mobilization process (such as, ACP and Yfh1) will provide 
comprehensive information on how cluster assembly if achieved on a global scale within 
the regulated environment of the mitochondria. Taken together, these experiments will 
produce a wealth of information that would contribute towards a better understanding of 
the molecular details of the Fe-S cluster assembly process. This in turn will aid in 
accentuating the drug design process for those diseases associated with cluster 
assembly.  
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Figure 5.4: Absorbance change measured at 340 nm for Nfs1(C421A)/Isd11 (white 
circles), and Nfs1(C421A)/Isd11/Yfh1/Isu1 reconstituted complex (black circles) 
upon addition of substrate L-cysteine. Substrate was incubated for 10 min after each 
addition and spectra were measured at 25 °C.  
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Figure 5.5: Persulfide forming activity of Nfs1-Isd11 and reconstituted 
Nfs1/Isd11/Yfh1/Isu1 complex measured by acid labile sulfide detection assay.  
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 ABSTRACT 
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Degree: Doctor of Philosophy 
Disrupted iron homeostasis within the human body materializes as various 
disorders. Pathophysiology of many of them relates to iron induced oxidative damage to 
key cellular components caused by iron accumulation within the tissues. Pertaining to 
the growing occurrence, cost of patient care and devastating burden associated with 
these diseases, the call for understanding the role of iron homeostasis within these 
disorders becomes inevitable. Being an abundant iron containing cofactor, the role of 
Fe-S clusters in cellular iron homeostasis is indisputable in the case of Friedreich’s 
ataxia, a disease caused by a deficiency in the protein frataxin that is indispensable 
during Fe-S cluster assembly. Friedreich’s ataxia and similar disorders associated with 
defective Fe-S cluster assembly accentuate the need to unravel the structural and 
functional aspects of this fundamental biochemical pathway. Effective disease treatment 
has been hampered by the lack of a molecular level understanding of the individual 
roles of the key proteins in Fe-S cluster formation.  
The work presented within this dissertation diminish this knowledge gap 
significantly by providing a comprehensive biophysical characterization of the key 
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proteins involved in the sulfur mobilization step during the yeast mitochondrial Fe-S 
cluster synthesis process. The role of the accessory protein “Isd11” within the catalytic 
role of the cysteine desulfurase “Nfs1” in delivering sulfane sulfur for cluster assembly 
has been studied. The effect of Yfh1 on sulfur mobilization by the Nfs1-Isd11 complex 
has also been evaluated in detail. Our results suggest a possible regulatory function of 
Isd11 and possibly rationalize the evolutionary requirement for its role as an additional 
cofactor introduced in eukaryotes. Frataxin’s effect on cluster assembly was evident to 
materialize the most at the overall assembled complex level rather than at the individual 
protein level. This work, therefore, provides novel and significant insight into how the 
cluster assembly proteins function, and sets the groundwork for which additional 
experiments that need to be designed to further unravel the mechanistic details of sulfur 
mobilization during Fe-S cluster bioassembly. These molecular level details will assist in 
future drug design strategies directed at treating the diseases outlined above.   
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